Author index

January 1	pages	1-380	**March 1**	pages	1665-2076	**May 1**	pages	3341-3758
January 15	pages	381-786	**March 15**	pages	2077-2448	**May 15**	pages	3759-4226
February 1	pages	787-1202	**April 1**	pages	2449-2900	**June 1**	pages	4227-4646
February 15	pages	1203-1664	**April 15**	pages	2901-3340	**June 15**	pages	4647-5142

Abbate, G., 3106
Abbitt, K. B., 921
Abe, K., 1477
Abraham, R. S., 3801
Abramovich, C., 4529
Abrams, T. J., 3188, 3597
Abruzzo, L. V., 4903
Abu-Libdeh, B., 3492
Acha-Orbea, H., 3550
Ackerstein, A., 441
Adachi, K., 1185
Adams, G. B., 45
Adelmeijer, J., 1864
Adkins, D., 2067, 5092
Aggarwal, B. B., 1053
Agrawal, S., 3164
Agricola, B. A., 2199
Agut, H., 52
Ahlke, E., 2529
Ahmed, M. R., 1558
Ahr, B., 399
Ahrens, K. P., 1977
Aiach, M., 1833
Aigner, E., 4148
Aird, W. C., 3765, 3940
Aitken, A., 4828
Aiyagari, A. L., 2250
Aizawa, H., 5014
Ajdic, J., 4423
Ajtai, K., 4380
Ajzenberg, N., 4363
Akagi, K., 1934
Akashi, K., 383, 903
Akatsuka, Y., 1460
Aker, M., 441, 4437
Akiba, H., 3741
Akin, C., 4660
Akiyama, M., 703, 1530, 2762
Akman, H. O., 2253
Aktas, B., 3948
Al-Ali, H.-K., 1941, 2152
Alavi, A., 3875
Albelda, S. M., 2816, 3977
Alberich Jordà, M., 1336
Alberta, J. A., 2570
Albertson, D. G., 3109, 4539
Albitar, M., 1692, 2507
Albrecht, D., 2617
Alcoser, P., 1718
Aldape, K., 466
Aldinucci, D., 376
Aleksic, N., 1243
Alexander, S. W., 2473
Alexandridis, P., 2637
Algara, P., 4042
Ali, M., 921
Aliberti, J., 305, 961
Alitalo, K., 168
Alitalo, R., 168
Alizadeh, A. A., 433, 3109
Allain, J.-P., 370, 2419
Allay, E. R., 2175
Alleyne, M., 2563
Allman, D., 1950
Allmer, C., 3801
Almasy, L., 163
Alon, R., 4437
Alonzo, T. A., 3398
Alpdogan, O., 2440
Alt, F. W., 2159
Alter, B. P., 822, 2072
Altes, H. K., 1891
Altman, J. D., 1024
Altomonte, M., 4644
Alvarez-Mon, M., 3424
Álvaro, T., 681
Alving, B. M., 31
Alyea, E. P., 363
Amadio, C., 4850
Amadori, S., 2125
Amar, A., 441
Ambrosetti, A., 2489
Ambrosino, D. M., 831
Ambrozak, D. R., 2711
Ambruso, D. R., 454
Amendola, G., 3857
Ameri, A., 1871
Amico, D., 4589
Amin, M. A., 3960
Amiral, J., 4850
Amrolia, P. J., 1007
Anaissie, E., 3849
Anaissie, E. J., 2542
Anasetti, C., 1620, 2043
Anderson, H., 3840
Anderson, K. C., 703, 1530, 2377, 2762, 3606, 4055
Anderson, K. L., 3265
Anderson, K. P., 4757
Anderson, R. J., 3174
Andersson, G., 4305
Ando, K., 2905
André, P., 4789
Andreakos, E., 983
Andréasson, B., 783
Andreeff, M., 3413
Andrew, M., 4273
Andrews, R. G., 4209
Anegon, I., 3325
Anether, G., 4561
Ang, S., 1591
Angelisová, P., 1874
Angerhaus, D., 1845
Anjo, A., 2973
Anokwa, M., 2419
Ansorge, W., 3690
Anstee, D. J., 1790, 4180
Antin, J. H., 363, 831
Antonissen, C., 2584
Antsaklis, A. I., 3444
Aoki, Y., 1535
Aoun, P., 2363
Aplan, P. D., 4529
Appelbaum, F. R., 2521, 3628
Apperley, J., 5084
Arai, K., 4733
Arai, M., 3485
Araki, K., 3501
Arber, D. A., 4701
Arceci, R. J., 3398, 4298
Arese, P., 722
Arevalo, J., 112
Arguin, C., 292
Arieh, S.-B., 2858
Arlettaz, L., 3198
Arlinghaus, R., 97, 690
Arman-Kalcek, G., 1759
Armitage, J. O., 2363, 2476
Armstrong, M., 415
Armstrong, S. A., 1270
Arnaout, M. A., 894, 4033
Arnoulet, C., 1277
Arnout, J., 157
Arnulf, B., 4576
Arosio, P., 1996
Arrighi, J.-F., 1727
Arruda, V., 3338
Arruda, V. R., 2963
Arthur, D. C., 4944
Arya, R., 101
Asada, R., 2924
Asano, S., 4711
Asazuma, N., 3469
Aschan, J., 469
Ashihara, E., 3334
Asnafi, V., 2693
Asosingh, K., 3136
Asou, N., 2074
Asselta, R., 173
Aster, R. H., 937, 1655
Astier, A. L., 1118
Ataga, K. I., 3281
Atchison, M. L., 1950
Atta, J., 85
Attanasio, C., 1851
Aubin É., 1660
Auclair, D., 3606
Auerbach, A. D., 1249
Augery-Bourget, Y., 2575
Ault, P., 4714
Aumann, V., 1845
Aurora, V., 2250
Autran, B., 1891
Avet-Loiseau, H., 1570, 4975, 4998
Avishai, O., 4783
Avril, S., 4070
Axworthy, D., 2340
Ayyoub, M., 4643
Azuma, E., 1185
Azuma, H., 532

Bäandrup, U., 4632
Baars, J. W., 2144
Baas, M.-J., 3477
Baba, M., 3581
Babbage, G., 4975
Baccarani, M., 3827
Bach, S., 4775
Bachelot-Loza, C., 1833, 4363
Bachi, A., 1038
Bachleitner-Hofmann, T., 4990
Bächli, E. B., 3755
Bachmann, M. H., 640
Bacino, D., 992
Bader, P., 869, 1630
Badman, D. G., 15
Badros, A., 3849
Baer, M. R., 2940
Bagdi, E., 3590
Bagg, A., 3875
Baggio, G., 2955
Bagley, C. J., 1308
Bagot, M., 1203
Bagrintseva, K., 1494
Bahou, W. F., 2285, 3021
Bahram, S., 3316
Bailey, C., 2377
Bailey, D., 524
Bailey, R. J., 1981, 4569
Bain, C., 52
Baker, G., 3875
Bakker, A., 253
Balabanov, S., 375
Balcerzak, S. P., 425
Baldanti, F., 5053
Baldini, L., 2489
Ballantyne, C. M., 3257
Ballen, K., 373
Balthasar, J. P., 1659
Baltus, B., 134
Bánhegyi, G., 2381
Banker, D. E., 3628
Bar, I., 1898
Barber, D. L., 524
Barber, G. N., 2321
Barbui, A. M., 4589
Barbui, T., 1827, 3749
Bardenheuer, M., 1882
Bargou, R., 3568
Barjesteh van Waalwijk van Doorn-Khosrovani, S., 837
Barker, J. E., 325
Barker, J. N., 4233
Barlogie, B., 1128, 2374, 3849, 4005, 4982
Barnes, N. M., 3212
Barnet, M., 1727
Barragan, A., 2405
Barragán, M., 3674
Barré, B., 4070
Barrett, A. J., 71, 1752
Barron, L. L., 4903
Barry, T. S., 4944
Barth, T. F. E., 3681
Barthold, S. W., 3257
Bartholomew, A., 2999
Bartlett, E. J., 2727
Bartlett, N. L., 4285
Bartolovic, K., 375
Baruch, D., 4363
Baruch, D. I., 331, 2850
Basso, G., 202
Basso, K., 2914
Bast, B. J. E. G., 1653
Basu, R., 2496

Bataille, R., 1570, 4998
Batchelder, A. L., 2043
Batish, S. D., 1249
Battini, J.-L., 1913
Battistini, L., 4775
Battmer, K., 1566
Batuman, O. A., 2253
Baudet, S., 265
Baum, C., 1759, 2099
Baumann, H., 2940
Baumgartner, M., 1874
Baumgartner, M., 4990
Baxevanis, C. N., 3444
Baxter, E. J., 3391
Bayry, J., 758
Bazarbachi, A., 4576
Beaubier, N., 2521
Beaumont, N., 3316
Beckmann, R., 4180
Beelen, D. W., 446
Behm, F. G., 3862
Behre, G., 270, 655, 2074
Belch, A. R., 1520
Belcher, J. D., 3953
Beldjord, K., 2693
Belinchon-Romero, I., 2446
Bellantuono, I., 3560
Bellas, C., 681
Bellinger, D. A., 3924
Belloc, F., 2368
Bello-Fernández, C., 2184
Belloni, D., 186
Bellosillo, B., 2328, 3674
Belnoue, E., 4253
Bemelman, F., 2686
Bendriss-Vermare, N., 1015
Bendz, B., 4387
Benedetti, A., 2381
Benekli, M., 2940
Benichou, G., 4305
Benner, A., 2191
Ben-Nun, A., 4347
Bensa, J.-C., 949
Bensinger, W. I., 3319
Benson, K. F., 2898
Bensussan, A., 1203
Bentley, P., 2454
Bents, K., 3288
Benzakour, O., 4797
Beran, M., 3413
Berdel, W. E., 2775, 3164
Berdel, W., 64
Beretta, A., 4452
Berg, T., 259
Bergamaschi, G., 1996
Berger, C., 476
Berger, F., 4279
Berger, P. B., 3901
Berger, R., 1277
Berger, U., 375
Bergmeier, W., 4789
Bergmeister, H., 2886
Berguido, F. J., 2206
Berliner, N., 3460
Berlin-Frankfurt-Münster Relapse Study Group, 3835
Berman, B., 2401
Bernacki, R. J., 602
Bernard, A., 4836
Bernardi, G., 4775
Bernards, A., 3021
Bernasconi, N. L., 4500
Bernaudin, F., 2137
Berndt, M. C., 3469
Bernstein, A., 517
Bernstein, I. D., 1784, 3398
Bernstein, W., 2563
Berrebi, D., 729
Bertina, R. M., 4387
Bertolette, D., 498
Bertolini, G., 1827
Bertolino, P., 3338
Bertomoro, A., 151
Bertoncini, J., 560
Bertucci, F., 4998
Berwick, M., 1249
Bethge, W. A., 5068
Betts, M. R., 2711
Beutler, E., 1596
Beuzard, Y., 2412
Beverloo, H. B., 837, 2743
Bex, F., 4576
Bezombes, C., 1543
Bhagwat, S. V., 1818
Bhalla, K., 3236
Bhan, A. K., 2159
Bharadwaj, M., 3150
Bharadwaj, R. R., 1603
Bhardwaj, N., 3520
Bharti, A. C., 1053
Bhatia, R., 4701
Bhatia, S., 2015
Bi, W., 2521
Biard-Piechaczyk, M., 399
Biasin, M., 2514
Biasiotto, G., 1996
Bièche, I., 1833
Bienvenu, F., 4070
Bierer, B. E., 216
Bierman, P. J., 2363
Biesma, D. H., 2144
Biesta, P., 3058
Bigenzahn, S., 2886
Bignon, J., 3014
Bigouret, V., 3198
Bilhou-Naberra, C., 1277
Bilke, S., 2307
Billheimer, J. T., 58
Binder, B. R., 3042
Binet, J.-L., 265
BIOMED II Pathophysiology and Treatment of Aplastic Anaemia Study Group, 2833
Birkenmeier, C. S., 325
Birnbaum, D., 286, 4998
Bischof, J. C., 3953
Bisping, G., 2775
Biswas, P., 4452
Bitan, M., 5084
Bjerregaard, M. D., 4322
Björck, E., 4047
Björkholm, M., 3840
Bjorkman, P. J., 2008
Blackwell, A. D., 2008
Blaese, R. M., 2563
Blaha, P., 2886
Blair, E. J., 3416
Blake, N., 4290
Blanco, J. G., 3862
Blangero, J., 163
Blatt, J., 2137
Blau, C. A., 476
Blazar, B. R., 3714, 3741, 5076
Blennow, K., 3749
Blesa, D., 3109, 4539
Bloem, A. C., 1201
Blood, E., 4569
Bloom, S., 3337
Bloomfield, C. D., 425, 2521
Blum, W., 2067, 5092
Blume, K. G., 1620
Boasso, A., 2514
Bochinski, K., 97
Bochner, B. S., 5014
Bociek, R. G., 2363
Bodian, C., 929
Bodine, D. M., 325
Boeckh, M., 407, 3319, 4195, 5091
Boersma-Vreugdenhil, G. R., 1653
Bogner, C., 278
Böhmer, F. D., 3164
Boiocchi, M., 3818
Boise, L. H., 2321
Bojczuk, P. M., 1024
Bokemeyer, C., 375
Bökkerink, J. P. M., 3868
Bolognesi, A., 202
Bondurant, M., 2235
Bonifacino, J. S., 4402
Bonifer, C., 4393
Bonig, H., 4739
Bonini, C., 1290
Bonnefoy, A., 1375, 3969
Bonnefoy, J.-Y., 143
Bonnet, M.-L., 4583
Boon, D., 157
Boonstra, R., 1149
Bordignon, C., 1290
Boreham, C. A., 2483
Boreström, C., 3749
Borges, L., 1484
Borghi, M. O., 3495
Borgmann, A., 3835
Borjesson, D. L., 3257
Borneo, J., 4725
Bornstein, P., 3915
Borrebaeck, C. A. K., 2307
Borregaard, N., 4322
Borrell, M., 163
Borrello, I., 1645
Borsellino, G., 4775
Borst, E., 1201
Bos, H. J., 747
Bosch, F., 78
Bosga-Bouwer, A. G., 1149
Boshkov, L. K., 454
Bosisio, D., 3495
Bosly, A., 4279
Bosman, G. J. C. G. M., 747
Bosse, H., 2049
Bostrom, B. C., 3809
Boswell, P. D., 4708
Botelho, R. J., 2804
Bots, M. L., 1841
Böttinger, E. P., 4033
Bouabdallah, R., 4279
Bouchardy, I., 3492
Bouchet-Delbos, L., 729
Boudjerra, N., 1277
Bougie, D., 1655
Bouillet, P., 2393
Boulanger, E., 2693
Boulland, M.-L., 2756
Boullier, S., 3102
Boulton, E., 2349
Bouma, B. N., 4844
Bourhis, J., 4583
Bourin, P., 2609
Bouscary, D., 3436
Boussiotis, V. A., 998
Bouvier, M. E., 2043
Bovenschen, N., 3933
Bovia, F., 1727
Bovin, L. F., 1430
Bowden, R. A., 407
Bowen, D. T., 2770
Bower, M., 4000
Bowlin, P. R., 3953
Bowman, L. C., 1718
Boyaka, P. N., 807
Boyett, J. M., 3862
Braciale, T. J., 4916
Bradstock, K., 2314
Brady, C., 331
Braedel, S., 2810
Brambilla, D., 2401
Brandén, L., 4870
Branger, J., 4446
Brashem-Stein, C., 1784
Braudeau, C., 3325
Braun, M., 1469
Bräuninger, A., 1505
Braylan, R. C., 1977
Braziel, R. M., 815
Brechbiel, M. W., 5068
Breier, G., 886
Breitenbuecher, F., 2960
Brekalo, N. L., 2727
Bremer, E. G., 4013
Brenchley, J. M., 2711
Brendel, C., 259
Brennan, F. M., 983
Brenner, M. K., 1007, 1718, 2434
Breslin, S., 4285
Breslin, T., 2307
Bretscher, C., 2049
Breuer, W., 4172
Breuer-McHam, J., 2132
Breuss, J. M., 3042
Brichard, B., 2137
Bridges Jr, S. L., 1030
Bridon, J.-M., 1015
Brière, F., 1015
Briere, J., 4279
Brison, O., 541
Brittenham, G. M., 15, 5089
Brizard, A., 374
Brizard, F., 374
Brochstein, J. A., 2137
Brodsky, A. L., 2070
Broide, D. H., 863
Brossart, P., 977, 2810
Brouet, J.-C., 1891
Brown, B. D., 1257
Brown, B., 1734
Brown, E. J., 338, 4836
Brown, L. F., 560
Brown, L., 2314
Brown, M., 2563
Brown, R. A., 2067
Brown, T. J., 856
Broxmeyer, H. E., 1299, 4680
Bruce, L. J., 4180
Brück, P., 85
Bruckdorfer, K. R., 3174
Brugnara, C., 2412
Brummel, K. E., 372
Brümmendorf, T. H., 375
Brüne, B., 4847
Brune, M., 469
Bruner, G. R., 992
Bruneval, P., 758
Bruno, A., 2125
Bruno, S., 3514
Bruscoli, S., 729
Bryant, C. J., 3953
Bryceson, Y., 4909
Buccisano, F., 2125
Buchdunger, E., 664
Buchholz, D., 2426
Büchner, T., 64
Buchonnet, G., 4539

Buckley, S. M. K., 1359
Budde, U., 1845
Buet, D., 4583
Buffler, P. A., 4640
Buhot, C., 1351
Bühring, H.-J., 869
Buijt, I., 2144
Buijtenhuijs, P., 4844
Buil, A., 163
Buitenhuis, M., 134
Büller, H., 4823
Bumm, K., 1128, 3849
Bumm, T., 1941
Bunce, C. M., 3212
Buonocore, S., 1469
Burakoff, S. J., 3687
Burchert, A., 259
Burg, G., 1487
Burger, H.-J., 2381
Burger, P. C., 2661
Burgtorf, C., 2842
Burhop, S., 5061
Burnett, A. K., 624
Burney, S. N., 3281
Burny, W., 1351
Burrows, P. D., 1030
Burt, R. K., 2064
Busam, K. J., 1422
Buschle, M., 2184
Bush, T. S., 311
Buske, C., 1494, 4529
Bussel, J., 2268
Bustin, M., 2652
Butcher, E. C., 4775
Butt, C., 3037
Bux, J., 2591
Buzyn, A., 2693
Byrd, J. C., 6, 425, 4547

Cabantchik, Z. I., 4172
Cabral, L., 2321
Cahour, A., 52
Cai, D., 259
Cai, J., 1919
Cai, S.-R., 3924
Calderhead, D., 4305
Caleo, A., 4042
Caligaris-Cappio, F., 1262, 1962
Caligiuri, M. A., 425, 3052
Callander, N. S., 3778
Calmuntia, M. J., 4695
Calzada-Wack, J., 3181
Camacho, F. I., 681, 4042
Cambareri, B. A., 1308
Cammenga, J., 2206
Campàs, C., 3674
Campbell, J. J., 1677
Campo, E., 78, 2489, 3181, 4042
Candotti, D., 2419
Candotti, F., 2563
Cao, Y.-A., 640
Cao, Z., 498
Capanni, P., 202
Capecchi, P.-L., 2381
Capella, C., 2489
Caramia, M. D., 4775
Carballido, J. M., 2184
Carballido-Perrig, N., 2184
Carbone, A., 4115
Carbone, D. P., 4878
Carbonneil, C., 758
Carcelain, G., 1891
Carmel, R., 3302
Carmeliet, P., 560, 4823
Caron, G., 143
Carpentieri, D. F., 2473
Carr, D., 2070
Carreras, E., 3373
Carteaux, J.-P., 1419
Carter, C. S., 2563
Cartron, J. P., 338
Casado, F. J., 2328
Casasnovas, O., 1277
Casazza, J. P., 2711
Casella, I., 1316
Casonato, A., 151
Castaño, A., 681
Castel, V., 1611
Castelli, G., 1316
Castle, B. E., 3574
Castro, M. G., 3325
Castro, O., 1257
Cataland, S. R., 425
Catley, L., 2762
Catovsky, D., 4975
Cattaneo, M., 2446
Cattaneo, R., 2557
Cattini, M. G., 151
Cavalli, F., 2489
Cavallin-Ståhl, E., 3840, 4267
Cavill, I. A., 372
Cazenave, J.-P., 2426, 3477
Cazzaniga, S., 1290
Cazzola, M., 1996
Cella, M., 3052
Cerroni, L., 2335
Cesarman, E., 4115
Chabner, K. T., 45
Chadburn, A., 2932, 4115
Chaffanet, M., 286
Chaganti, R. S. K., 2914
Chagraoui, H., 2983
Chagraoui, J., 2973
Chai, J. G., 2704
Chait, P., 4273
Chakrabarti, S., 2071
Chamba, A., 3212
Champlin, R., 2132
Chan, H. T. C., 1045
Chan, K. K., 425
Chan, P. V., 3188
Chan, R. J., 1329
Chan, S., 2219
Chan, V., 791
Chan, W. C., 2363
Chandler, W. L., 4355
Chang, C.-Y., 2081
Chang, J.-G., 3205, 5086
Chang, S. P., 2300
Chang, S. H., 4625
Chang, W.-C., 1637
Chao, N., 5061
Chaperot, L., 949
Chapuis, B., 3198
Charbonnier, P., 143
Charbord, P., 2973
Chasis, J.-A., 1790, 4180, 5039
Chaudhary, P. M., 1956
Chauhan, D., 703, 1530, 2377, 3606, 4055
Chauncey, T., 1620
Chaux, P., 1351
Chelucci, C., 1316
Chen, A. I., 3741
Chen Barrett, Y., 58
Chen, C.-C., 4347
Chen, E., 4958
Chen, G., 226
Chen, H., 1409
Chen, J., 383
Chen, J., 524
Chen, L. B., 3606
Chen, L., 2514
Chen, L.-J., 2667
Chen, Q., 2405
Chen, W., 3229
Chen, X., 2721
Chen, Z., 5076
Cheng, D., 4088
Cheng, N. W., 3730
Cherrington, J. M., 3597
Cheson, B. D., 391
Chessells, J., 1713
Cheung, J., 4301
Chevailler, A., 758
Chew, A. J., 2963
Chi, A. W., 1071
Chi, E., 295
Chiarle, R., 1919
Chiba, H., 532
Chiba, S., 1777
Chiba, T., 1367
Chien, S., 2667
Chiorean, E. G., 3527
Chiriva-Internati, M., 955
Chiu, J.-J., 2667
Cho, M. J., 2646
Chodniewicz, D., 1181
Choi, S. J., 3778
Choi, Y. K., 1684
Chollet, C., 2368
Chomienne, C., 4033
Chott, A., 2335, 2547
Chou, M.-L., 2081
Choudhary, C., 3164
Chrétien, S., 3436
Christensen, R. L., 4708
Christensen, T., 91, 4632
Christensson, B., 1080
Christodoulou, J., 1205
Christofidou-Solomidou, M., 3977
Christopherson II, K. W., 801, 4680
Christopoulos, C. G., 1655
Chuah, M. K. L., 1734
Chuang, P. I., 295
Chuang, S.-S., 2547
Chui, D. H. K., 791
Chun, K. T., 1769
Chung, I.-J., 1324
Ciabini, D., 4775
Ciana, A., 3751
Ciccone, E., 3514
Ciccone, S. L. M., 1299
Ciceri, F., 1290
Ciciotte, S. L., 4402
Cifone, G., 585
Cinamon, G., 4437
Cines, D. B., 3977
Circosta, P., 1962
Ciudad, J., 4695
Cividin, M., 374
Clackson, T., 476
Claessens, Y.-E., 3436
Clapp, D. W., 1299, 1769, 1984
Clark, E. A., 4464
Clarke, G., 454
Cleary, H., 2349
Cleary, M. L., 633
Clerici, M., 2514
Climent, J., 4539
Clouston, A. D., 2033
Cobbs, C., 2999
Cockerill, P. N., 4393
Coffer, P. J., 134, 1439
Coffman, T. M., 2646
Cogger, V. C., 3338
Cohen, A., 5090
Cohen, A., 3373
Cohen, N., 729
Coiffier, B., 4279
Cole, A. M., 2388
Cole, C., 2349
Coligan, J. E., 2858
Colin, Y., 338
Colizzi, F., 4644
Collen, A., 1810
Collen, D., 1734, 2551
Coller, B. S., 929, 2268
Collins, K. F., 3309
Colombo, M. P., 568
Colomer, D., 78, 2328, 3674
Colomo, L., 78
Colonna, M., 3052, 3198
Comba, B., 2693
Combrié, R., 1400
Combs, D., 466
Comp, P. C., 576
Conboy, J. G., 4164
Conconi, A., 2489
Conlan, M., 2426
Conley, P. B., 1400, 1409
Connolly, G., 3150
Connors, M., 2711
Consogno, G., 1038
Constantin, G., 4775
Contag, C. H., 640
Conte, R., 202
Conti-Fine, B. M., 1038
Contini, P., 186
Cook, D. J., 3049
Cook, J. D., 3359
Cooke, K. R., 2877
Cooling, L. L. W., 711
Cools, J., 4660
Coombes, K. R., 4903
Cooper, K., 1718
Cooper, L. J. N., 1637
Cooper, L., 3150
Cooper, M. D., 1030
Cooper, M. A., 3052
Cooper, S., 4680
Copeland, N. G., 1934
Copie-Bergman, C., 2756
Coqueret, O., 4070
Corash, L., 2426
Corbacioglu, S., 3868
Corbin, A. S., 4611
Corcuff, E., 4887
Corey, L., 407, 4195
Corey, S. J., 2804
Corinti, S., 3985
Cornelissen, J. J., 2144, 4290
Cornely, O. A., 3365
Cornillet, P., 1277
Corral, J., 4224
Corrocher, R., 2412
Corsi, B., 1996
Cortelazzo, S., 2489
Cortes, J. E., 97, 3794
Cortes, J., 473, 1692, 3413, 4714
Cosset, F.-L., 2167
Costa, F. T. M., 5025
Cotta, C. V., 4342
Cotter, F., 1558
Cotter, M. J., 921
Cottrez, F., 4836
Couderc, J., 729
Coulocheri, S. A., 2898
Coulombel, L., 4313
Coupland, R., 1149
Coutelle, C., 1359
Couto, L. B., 2963

Cowland, J. B., 4322
Cox, M. C., 2125
Crable, S. C., 4757
Cragg, M. S., 1045
Craig, R., 2064
Cranmer, S. L., 3477
Crawford, J. H., 4408
Crawford, J. M., 2440
Craxton, A., 4464
Crean, C. D., 1118
Creekmore, S., 2294
Creer, M. H., 2054
Creutzig, U., 3868
Crispino, J. D., 4298
Cristillo, A. D., 216
Critchley, E., 3082
Croci, G., 2071
Cromley, D. A., 58
Cromwell, C. C., 4903
Croockewit, A. J., 2144
Crooks, G. M., 4201
Crosbie, G. V., 2314
Cross, N. C. P., 3391
Cross, N., 5084
Crotty, L. E., 2711
Crow, A. R., 1658, 3708
Crowley, J., 3849
Cukier, I. H., 1928
Cull, V. S., 2727
Cummings, R. D., 552
Cunningham, T., 407
Cunningham-Rundles, C., 1705
Cupit, L. D., 3021
Curatola, G., 2071
Curti, A., 568
Curtis, R. E., 2015
Cushman, M., 1243
Cwynarski, K., 3560

Da Costa, L., 318, 5039
Da Silva, N., 4033
Dabak, V., 4916
Daha, M. R., 1439
Dahl, G., 4640
Dahl, K. N., 1194
Dahlbäck, B., 2277
Dahm, A., 4387
Dahse, T., 1359
Dai, C., 1324
Dai, G., 425
Daley, G. Q., 2070
Daliphard, S., 1277
Dalla-Favera, R., 1505, 2914, 4115
Dallman, M. J., 1359
Daly, R. N., 58
Damaj, B., 4909
d'Amato, T. A., 4708
Damianaki, A., 2591
Damiani, D., 3827
Dammacco, F., 3818
Damon, L., 466
Danhauser-Riedl, S., 655
Daniel, S., 4131
Dankbar, B., 2775
Danloy, S., 3969
Dao, M. A., 112
Dardalhon, V., 2167
Dardik, R., 4783
Darley, R. L., 624
Dasilva, I., 3520
Dastugue, N., 1277
Dauzat, M., 4850
Davi, F., 265, 1277, 2693, 4598
David, A., 1851
Davidoff, A., 1718
Davies, S. M., 4233
Davies-Hill, T., 3181
Davis, A. R., 1905
Davis, E. M., 3188
Davis, K., 2426
Davis, R. E., 4944
Davis, Z., 4944, 4975
Dawson, M. A., 3319, 4209
Dazzi, F., 3560, 3722
de Beaumont, R., 1118
de Bruin-Versteeg, S., 1446
de Fornel, D., 194
De Franceschi, L., 2412
De Geest, B. R., 2551
de Grandmont, M. J., 3065
de Greef, G. E., 837
de Greef, G., 2426
De Groot, P. G., 1864, 4372
de Groot, R., 1446
de Jong, B., 1149
de la Hera, A., 3424
de Maistre, E., 1419
De Marchi, G., 3827
de Martin, R., 3042
De Palma, R., 3106
de Pauw, E. S. D., 358
De Raeve, H., 3136
De Re, V., 3818
de Saint Basile, G., 2736
De Stefano, P., 3857, 5053
de Thé, H., 4576
De Vita, S., 3827
De Vos, R., 3969
De Wit, D., 4894
de Witte, T., 5085
De Wolf-Peeters, C., 706
Deaglio, S., 2748
DeBaun, M. R., 415
Debili, N., 541
Debnam, E. S., 3316
Debré, P., 1891
Decaux, O., 4998
Déchaud, H., 4850
Decker, T., 278
Deckmyn, H., 782
DeCock, H. E. V., 3257
Degan, M., 4644
Deguchi, M., 4219
Dehoulle, C., 2756
Deininger, M., 1620
Deininger, M. W., 4611
Deininger, M. W. N., 1941, 2152, 4641
Dejoux, O., 4836
Dekovic, F., 351
del Cañizo, M. C., 4695
Del Poeta, G., 2125
Del Principe, M. I., 2125
Delabesse, E., 2693
Delaunay, J., 338, 4180
Delauzun, V., 399
Delehanty, L. L., 1744, 4333
Delia, D., 3622
Delic, J., 265, 4598
Dellian, M., 1970
Delneste, Y., 143
Delwel, R., 837, 1111, 1336
Demonté, D., 4894
Demotte, N., 1351
Demur, C., 1543
den Boer, M. L., 1270, 2743
DeNardo, G. L., 3641
Denecke, B., 259
Dent, P., 524, 3648
Denz, C., 1882
Desaymard, C., 2736
Deschemin, J.-C., 4253
Deschler, B., 3753
Desikan, R., 3849
Dessypris, E. N., 524
Desvard, F., 1833
Detmar, M., 560
Deutsch, E., 4583
Devaux, C., 399
Devereux, S., 779
Devine, S. M., 2067, 2999, 5092
Devizzi, L., 2489
Devlin, J., 101
Devoe, C. E., 3021
Dewald, G. W., 1981, 4569
Deyev, V. V., 2321
Dhall, G., 1919
Dhillon, A. P., 5090
Dho, S. H., 5033
Di Marco, B., 585
Di Santo, J. P., 4887
Diago, O., 849
Dibbelt, L., 4416
Dick, J. E., 517
Dickey, W. O., 454
Dictor, M., 4047
Diehl, V., 420, 1505, 4063
Dierks, H., 655
Dierlamm, J., 2335
Dietz, K., 375
Díez, A., 681
Dighiero, G., 4029
Dignani, M. C., 2542
Dimitroff, C. J., 602
Ding, S., 4816
Ding, Z., 3908
Ding, Z., 4245
Dini, G., 1611
Diomede, L., 3220
DiPersio, J. F., 2067
DiPersio, J., 5092
Dirschinger, R. J., 1494
Discher, D. E., 1194
Dispenzieri, A., 827, 1715, 2156, 2496
Djeu, J. Y., 236
Do, K., 2507
Dogan, A., 2547
Döhner, H., 2049
Doi, T., 4748
Dombkowski, D., 45
Dombrosky-Ferlan, P., 2804
Dömötör, E., 4797
Donaghy, H., 4505
Donahue, R. E., 2199
Donato, N., 1053
Donato, N. J., 690
Dong, H., 2514
Dong, H.-Y., 3509
Dong, R., 3560
Donkova, V., 758
Donohue, S. J., 2294
Donovan, K. A., 2557
Dörffler-Melly, J., 4823
Dörken, B., 3568
Dorsam, R. T., 3908
Dotti, G., 1007
Doty, R. T., 4492
Douek, D. C., 2294, 2711
Dougherty, J. P., 4347
Douki, J.-B., 5025
Douville, J., 5061
Down, J. D., 4305
Downey, G. P., 4245
Downing, J. R., 624
Downs, L., 3875
Drabek, D., 2842
Drabick, J. J., 4547
Drachtman, R., 2401
Dragoo, J., 119
Drake, C. J., 2215
Drayer, A. L., 1172
Drayson, M. T., 3212
Dreger, P., 2049
Drewke, E., 1845
Dreyfus, M., 4430
Dreyling, M., 699
Driessen, C., 420
Dring, A., 2770
Driscoll, M. C., 2401
Driscoll, T. A., 5061
Drouet, M., 2609
Druker, B. J., 4611
Drutskaya, L. N., 1477
Drysdale, J., 1996
Du, M.-Q., 2547, 4539
Du, X., 4423
Dubrez-Daloz, L., 194
Duchayne, E., 1277
Ducoroy, P., 194
Ducrey-Rundquist, O., 2167
Dudek, A. Z., 4687
Duga, S., 173
Dugray, A., 4583
Duhen, T., 1015
Dührsen, U., 2748
Düllmann, J., 2099
Dumas, G., 4029
Dummer, R., 1487
Dumortier, A., 2219
Dunbar, C. E., 71, 2199, 2563
Dunn, J. J., 2285
Dupont, A., 1833
Duraiswamy, J., 3150
Durante, W., 3901
Dürig, J., 2748
Dutartre, P., 194
Duvic, M., 2132
Dyer, M. J. S., 2547, 2756, 3109, 4539
Dylla, S. J., 3527
Dyson, J., 3722
Dzierzak, E., 2246
Dzik, S., 3756

Ebell, W., 3835, 3872
Ebihara, Y., 2990
Ebling, W., 58
Ebus, M. E. G., 1270
Eclache, V., 1277
Eder, M., 1566
Edinger, M., 640
Edwards, O. L., 1905
Egorin, M., 5010
Ehinger, M., 4047
Ehrlich, R., 2858
Eichbaum, Q., 3756
Eichler, P., 2617, 2955
Eichner, D. A., 363
Eigenthaler, M., 4423
Eiskjær, H., 4632
Ekblom, M., 877
Ekblom, P., 877
Ekstrand, B. C., 4285
El Ouriaghli, F., 1752
Elagib, K. E., 4333
Elenitoba-Johnson, K. S. J., 4903
Elfenbein, G. J., 771
El-Hemaidi, I., 779
Eliopoulos, A. G., 2591
Eliopoulos, G. D., 2591, 2898

Ellegaard, J., 91
Elliott, M., 2534
Ellis, J., 1603
Ellis, L. M., 4222
Elmaagacli, A. H., 446
El-Osta, A., 1656
El-Sabban, M. E., 4576
Elsässer, A., 655
Elstrom, R., 3875
Elzi, D. J., 454
Emile, J.-F., 4279
Emilie, D., 729
Enblad, G., 4047, 4952
Engel, C., 1630
Engert, A., 420
Enk, A. H., 4862
Enns, C. A., 2008
Enouf, J., 3220
Entwistle, A., 3560
Epling-Burnette, P. K., 3240
Epstein, A. L., 4853
Epstein, J., 351
Epstein, J., 3849
Erba, E., 4589
Erdlenbruch, B., 2001
Erdmann, G. R., 3809
Eriksson, B. I., 2617
Eriksson, I., 4047, 4952
Erkeland, S. J., 1111
Ermakova, O., 903
Erpelinck, C., 837
Ersöz, I., 375
Ertault-Daneshpouy, M., 2073
Ertem, M., 2137
Esteller, M., 2784
Estienne, M.-H., 2693
Etzioni, A., 4437
Eurocord Transplant Group, 2137
European Blood and Marrow Transplantation Acute Leukemia Working Party, 1611
Evans, J. P. M., 846
Evans, W. E., 3862
Eyrich, M., 1630

Fabbri, M., 186
Fabbro, D., 664
Faber, F., 1494
Fabre, J.-E., 1409
Fabris, F., 2955
Facchetti, F., 3052
Facchinetti, V., 1038
Fadeel, B., 1080
Faderl, S., 97, 473, 3413, 3794
Fagerberg, J., 4930
Fagioli, F., 1611
Fagioli, M., 3514
Faioni, E. M., 2446
Fairhurst, R. M., 3309
Fais, F., 3514
Falet, H., 4789
Falini, B., 78
Falkenhahn, M., 3690
Fallert, B. A., 1684
Fallon, R., 45
Falo Jr, L. D., 611
Fan, G.-H., 2115
Fan, Z., 4285
Fandrey, J., 4416
Fanin, R., 3827
Fanourakis, G., 2377, 4055
Farag, S. F., 425
Farcet, J.-P., 2756
Farin, F. M., 2896
Farndale, R. W., 4372
Farokhzad, O. C., 4033
Fassas, A., 3849
Fattorutto, M., 782
Fay, J. W., 2015
Fay, P. J., 4802
Feccia, T., 1316
Fegan, C., 2454
Fehniger, T. A., 3052
Fehse, B., 2099
Feigelson, S., 4437
Feijge, M. A. H., 3969
Feingold, J., 3868
Feldman, G. M., 1535
Feldmann, J., 2736
Feldmann, M., 983
Felsher, D. W., 2797
Fenaux, P., 1277
Fend, F., 3181
Feng, H., 245, 4485
Fenneteau, O., 1277
Ferenczi, K., 4033
Ferlito, F., 202
Fermand, J.-P., 1891
Fernandez, C., 265
Fernandez-Abellan, P., 2446
Fernández-Calvo, J., 4695
Ferraccioli, G., 3827
Ferrajoli, A., 3413, 3794, 4714
Ferrant, A., 1611
Ferrante, P., 2514
Ferrara, G. B., 202
Ferrara, J. L. M., 2033
Ferrara, J. L., 2877
Ferreira, G. C., 348
Ferreri, A. J. M., 2489
Ferrero, E., 186
Ferrero, M. E., 186
Feuer, G., 2321
Feunteun, J., 541, 4583
Feuring-Buske, M., 4529
Feusner, J., 4640
Février, M., 3102
Fibbe, W. E., 358
Fibbe, W. E., 2144
Fiegl, M., 4137
Field, E. H., 2024
Filatov, A. V., 1045
Files, B., 2401
Filippich, C., 2033
Filomenko, R., 1543
Finazzi, G., 3749
Findley, H. W., 1030
Finn, W. G., 2895
Fiorilli, A., 2071
Fischer, A., 2736
Fischer, K.-G., 3753
Fischer, R., 4063
Fischer, T., 2960
Fisher, D. R., 5068
Fisher, D. B., 425
Fisher, J., 624
Fiuza, C., 2652
Fixler, J., 318, 5039
Flake, A. W., 2963
Flamand, V., 1469
Flament, J., 2426
Flanders, K. C., 498
Flandrin, G., 1277
Flegel, W. A., 752
Fleischhack, G., 2529
Fleisher, T. A., 2563
Fleming, M. D., 2473
Fleming, P. A., 2215
Florena, A. M., 2464
Flores, T., 681
Florquin, S., 4823
Flower, R. J., 4140
Flowers, C. H., 3359
Flowers, M. E. D., 407, 3319
Flygare, J., 1284
Flynn, G., 4828
Flynn, S., 4472
Fogarty, P. F., 71
Foglieni, C., 186
Foley, P. L., 1071
Follows, G. A., 4393
Folsom, A. R., 1243
Fonseca, R., 827, 1715, 2496, 3801, 4569
Fontana, P., 1833
Fontcuberta, J., 163
Fontenay-Roupie, M., 3436
Fonteneau, J.-F., 3520
Foran, S., 3756
Forbes, J., 3699
Forlow, S. B., 739, 921
Forman, S. J., 1637, 4701
Forsblom, A.-M., 1080
Forster, K., 655, 664
Forsythe, A. M., 4225
Foussat, A., 729
Foxall, R. B., 45
Foxwell, B. M., 983
Fraga, M., 681
Franchi, A., 2125
Franchini, G., 2294, 4653
Franchini, S., 3784
Franco, V., 2464
Frank, R. D., 3940
Franke, C., 1941
Frankel, S. R., 425
Franklin, J., 4063
Fraser, R., 3338
Frassoni, F., 1611
Fredén, S., 4267
Freedman, A. S., 1118
Freedman, J., 1658, 3708
Freeman III, M. E., 4005
French, D. L., 2268
French, R. R., 1045
Frenette, P. S., 1705
Frew, M. E., 2770
Freytes, C. O., 2015
Frickhofen, N., 1236
Friedman, A. D., 3885
Friedrich, T., 1941, 4641
Friel, J., 1759
Frisaldi, E., 1962
Frisen, C., 3416
Fromes, Y., 3014
Fruehauf, S., 2191
Fry, T. J., 2294
Fu, P., 5061
Fucharoen, S., 791
Fuchida, S., 3334
Fuchs, E. J., 1645
Fuhler, G. M., 1172
Führer, A., 2748
Fuino, L., 3236
Fujimura, K., 2870
Fujimura, Y., 915, 2924
Fujioka, H., 3309
Fujioka, T., 1698
Fujisawa, H., 1801
Fujita, N., 3334
Fujiwara, H., 1752
Fujiwara, Y., 508
Fukudome, K., 4797
Fukushi, J., 2620
Fulceri, R., 2381
Fung-Weier, J., 2797
Furukawa, T., 3274
Furukawa, Y., 3074
Furukawa, Y., 2870
Furuyama, K., 1188, 4623

Gabayan, V., 2388
Gabbianelli, M., 1316, 2826
Gabig, T., 1118
Gabrilovich, D. I., 4878
Gadner, H., 3635
Gahl, W. A., 4402
Gaidano, G., 4115
Gaines, P., 3460
Galanaud, P., 729
Galanello, R., 5090
Galgani, S., 4775
Galili, U., 2318
Gallagher, P. G., 4625
Gallagher, R. E., 2521
Galli, M., 1827
Gallick, G., 690
Galm, O., 2784
Gamadia, L. E., 2686
Gamis, A. S., 4298
Gamm, H., 2960
Gane, P., 338
Ganeshaguru, K., 3174
Ganser, A., 1566
Ganz, T., 2388, 2461
Gao, C., 3924
Gao, L., 1007
Garabedian, E. K., 2563
Garand, R., 1277, 1570, 4975
García, J. F., 681
Garcia, S., 3102
García-Conde, J., 3109, 4042, 4539
Garcia-Manero, G., 97, 473, 1692, 3413, 3794, 4131
García-Sanz, R., 4695
Garnache, F., 1277
Garnier, F., 2137
Garrett, K. P., 576
Gartner, T. K., 2646
Gascard, P., 5039
Gascoyne, R. D., 4539
Gasperini, C., 4775
Gassmann, M., 348, 4416
Gassmann, W., 64
Gathy, K., 4958
Gattei, V., 376, 4644
Gaubatz, J. W., 3901
Gaulard, P., 2756, 4279
Gaussem, P., 1833
Gavins, F. N. E., 4140
Gaynon, P. S., 3809
Gazitt, Y., 4078, 4105
Gazzard, B., 4000, 4505
Ge, S., 4201
Ge, Y., 1551
Gee, A., 1718
Gee, S. L., 4164
Geginat, J., 4260
Gehrke, B., 85
Gehrke, S. G., 3288
Gelbart, T., 1596
Gemetzi, C., 2591
Gemignani, F., 104
Gentner, B., 2191
Georgakis, A., 4033
George, D., 4013
Georgii, A., 4063
Gera, J., 3126
Gerbing, R. B., 3398
Gerhard, B., 3142
Gerlach, A., 3872

German Aplastic Anemia Study Group, 1236
German Hodgkin Lymphoma Study Group (GHSG), 420
Gerna, G., 5053
Gerstenberger, E., 2652
Gertz, M. A., 827, 1715, 2496, 3801
Gervois, P. P., 545
Gessani, S., 4909
Gessner, A., 4457
Geuna, M., 1262, 1962
Geyer, S. M., 3801
Ghia, P., 1262, 1962
Ghiotto, F., 3514
Ghosh, S. K., 2321
Giachetti, C., 2419
Giampietro, P. F., 1249
Giannetti, A. M., 2008
Giannì, M., 3220
Giardina, S., 2294
Giardini, R., 2489
Giesecke, C., 289
Gil, J., 2328, 3674
Gilbert, G. E., 2628
Giles, F., 97, 473, 1692, 3794
Giles, F. J., 2507, 3413
Gill, D., 2314
Gillemans, N., 2842
Gillespy III, T., 4209
Gillies, S. D., 649
Gilliet, M., 1487, 3520
Gillijns, V., 1734
Gilliland, D. G., 1494, 3188, 4660
Gilvary, D. L., 236, 3240
Ginsburg, D., 4449
Ginsburg, H., 4189
Giordano, S., 1962
Giorgiani, G., 2137, 5053
Girard, J.-P., 38
Giraudier, S., 2983
Girolami, A., 151, 2955
Girolami, B., 2955
Girolomoni, G., 3985
Gisselbrecht, C., 4279
Gisselbrecht, S., 3436
Gits, J., 2584
Giuriato, S., 2797
Gkika, D. G., 3444
Glader, B., 2963
Gleason, L. A., 4708
Gleich, G. J., 1898
Glennie, M. J., 1045
Glennie, S., 3722
Glodek, A., 3784
Gloghini, A., 4115
Gluckman, E., 2137
Gnatenko, D. V., 2285
Gobbi, M., 202
Gobin, S. J. P., 3058
Goi, G., 2071
Goi, K., 3658
Golay, J., 4589
Gold, S., 3809
Goldberg, S. L., 781
Goldenring, J. R., 2115
Goldfarb, A. N., 1744, 4333
Goldman, J., 5084
Goldman, J. M., 1007, 2368, 3560
Goldman, M., 1469, 4894
Goldschmidt, M. H., 1950
Goldstein, S. C., 2015
Goltry, K., 5061
Goltsova, T., 1905
Gombart, A. F., 3265
Gombás, J., 4380
Gong, J. Z., 1919
Gongora, C., 961
Gonias, S. L., 1744
González de Buitrago, G., 38
Gonzalez, J., 2679
González, M., 4042
Gonzalez, S., 1637
González-Conejero, R., 4224
Goodall, A. H., 4372
Goodell, M. A., 2434
Goodman, R. B., 295
Goodnough, L. T., 2067, 5092
Gooley, T., 2043, 4195
Gordon, J., 3212
Goriely, S., 4894
Goronzy, J. J., 3543
Gosnell, W. L., 2300
Gospodarowicz, M. K., 2489
Goss, P. E., 4966
Gotch, F., 4000, 4505
Gotoh, M., 2870
Gottardi, D., 1262
Gottschalk, S., 1905
Goud, B., 2736
Gougeon, M.-L., 3102
Gough, M., 4209
Gough, P. J., 485
Govoni, G., 3699
Gozzini, A., 4615
Grabovsky, V., 4437
Grader-Beck, T., 998
Graf, T., 903, 1103, 2388
Grafakos, S., 2137
Grafton, G., 3212
Gramaglia, I., 5076
Graner, M. W., 245, 4485
Granger, D. N., 3977
Granjeaud, S., 4998
Grant, N., 4653
Grant, S., 3648
Granziero, L., 1962
Gratama, J. W., 4290
Gratwohl, A., 71, 3198
Graves, L. M., 4958
Gray, A. R., 2081
Gray, E., 4372
Gray, L. A., 2534
Gray, R., 4701
Green, R., 3750
Greenberg, A. S., 2440
Greenblatt, J. F., 4966
Greene, A., 71
Greene, M. E., 4298
Greene, M. H., 822, 2072
Greeve, J., 3574
Gregoli, P., 2235
Gregory, C. D., 3212
Greil, J., 1630
Greil, R., 4561
Greinacher, A., 2617
Greiner, T. C., 2363
Greipp, P. R., 827, 1715, 2496, 4569
Gressin, R., 949
Grever, M. R., 425, 4547
Grewal, S. S., 4233
Gries, M., 3568
Griffin, J. H., 4797
Grilley, B., 1718
Grillo-Lopez, A., 466
Grimbergen, J., 1810
Grimbergen, J. M., 3933
Grimes, S., 1558
Grimwade, D., 1558
Grinstein, S., 2804
Gris, J.-C., 4850
Grishin, A., 2804
Gritzapis, A. D., 3444
Grobbee, D. E., 1841
Groenen-Döpp, Y. A. M., 747
Gros, P., 3699
Grosse-Wilde, H., 446
Grossi, C. E., 3514
Grosveld, F., 2842
Gruber, F., 3042
Gruel, Y., 1419
Grünebach, F., 977
Grüner, S., 3948
Gschaidmeier, H., 85, 259, 375, 2960
Gu, J. J., 4958
Gu, X., 2377
Gu, Y.-C., 877
Guan, L., 3875
Guan, Y., 3142
Guan, Y., 1591, 3294
Guasch, G., 286
Guasparri, I., 1919
Guerriero, R., 1316
Guha, M., 3940
Guida, G., 1262
Guido, M., 5090
Guilhot, F., 374, 4583
Guillonneau, C., 3325
Guillot, C., 3325
Guinan, E. C., 831
Gulliksson, H., 2426
Gunkel, N., 3690
Günther, C., 2152
Gupta, A., 4446
Gupta, D., 2762
Gupta, P., 2243
Gurbuxani, S., 4298
Gutierrez, M., 4653
Gutiérrez, N., 4695
Gwynn, B., 4402
Gysin, J., 5025

Haas, O. A., 3635
Haas, O., 2184
Haaz, S., 351
Haberichter, S. L., 1384
Häberle, J., 1845
Habib, A., 1400
Hack, C. E., 4446
Hack, R., 837
Hackman, R. C., 4209
Hackstein, H., 4457
Hadaschik, B., 3288
Hadjur, S., 3877
Hadwiger, P., 3157
Haferlach, T., 64
Hafid-Medheb, K., 2575
Hagberg, H., 3840, 4267
Hagemeijer, A., 706
Haight, A. E., 1718
Haioun, C., 2756
Halbach, A., 1213
Halfmeyer, K., 2748
Hallek, M., 655, 664
Halstead, E. S., 1024
Hamada, H., 532
Hamaguchi, M., 1185
Hamblin, T., 1087
Hamblin, T. J., 4944
Hamlin, D. K., 5068
Hammer, J., 1038
Han, J., 970
Han, Y.-H., 5033
Han, Z. C., 4816
Hanada, S., 2990
Hanania, N., 2575
Hanawa, H., 2175
Handa, H., 3386
Handgretinger, R., 869, 1630
Haneline, L. S., 1299
Hanemaaijer, R., 1810
Hanenberg, H., 1249
Hankenson, K. D., 3915
Hankin, A., 3337
Hanna, K., 4273
Hänninen, A., 4022
Hans, C. P., 2363
Hansal, S. A., 4520
Hansen, R. J., 1659
Hansmann, K., 71
Hansmann, M.-L., 1505, 4063
Hansson, L., 4607, 4930
Hao, H., 4551
Hao, Q.-L., 4201
Harada, H., 673
Harada, N., 3029
Harada, S., 2924
Harada, Y., 673
Haralambieva, E., 1149
Harant, H., 3042
Harbord, M., 3337
Hargrave, D. R., 846
Hargrove, P. W., 2175
Harigae, H., 1188, 4623
Harlan, J. M., 295
Harley, J. B., 992
Harlow, L. A., 3960
Harnisch, B., 226
Harousseau, J.-L., 1570, 4998
Harrington, D., 4569
Harrington Jr., W. J., 2321
Harris, R. E., 2476
Harrison, C., 783
Harshaw, D. W., 3977
Hart, D. N. J., 2033, 2314
Hartmann, R., 3835
Hartmann, U., 375
Hartwig, J. H., 4789
Hasegawa, J., 4416
Hasegawa, T., 1164
Hasel, C., 3681
Hashimoto, K., 1094
Hashimoto, S., 3509
Hassenpflug, W., 1845
Hasson, H., 4452
Haug, J., 383
Haut, P. R., 2137
Havekes, L. M., 3933
Haverkate, F., 1841
Hawley, R. G., 4717, 4966
Hawley, T. S., 4717
Hayashi, N., 1460
Hayashi, S.-I., 2227
Hayashi, T., 703, 1530
Haylock, D. N., 856
Hayton, K., 3309
He, B., 58
He, R., 1572
He, X., 383
Hebbel, R. P., 3953
Hecht, T. T., 2294
Heck, S., 903
Heckbert, S. R., 1243
Hedin, N., 2340
Heemskerk, J. W. M., 3969
Heerema, N. A., 3809
Hegenbart, U., 1620
Hehlmann, R., 259, 375
Heidenreich, O., 1566, 3157
Heider, U., 2094

Heidorn, K., 3574
Heijmans-Antonissen, C., 1111
Heike, T., 2990
Heil, G., 3157
Heimfeld, S., 476
Heimpel, H., 1236
Heinecke, A., 64
Heinrich, M. C., 3597
Heiss-Neumann, M. S., 270
Heller, G., 1422
Hellewell, P. G., 921, 3249
Hellström-Lindberg, E., 1080, 4645
Hematti, P., 2199
Henderson, J. N., 415
Henderson, K. J., 4569
Hennig, E., 1941
Henrickson, S. E., 4944
Hensel, N., 1752
Hentze, M. W., 3690
Hentze, S., 3690
Henze, G., 3835
Herbault, N., 143
Herbert, K. E., 1654
Hercus, T. R., 1308
Herling, M., 5007
Herman, J. G., 2784
Hermann, J., 4070
Hermans, M. H. A., 1111, 2584
Hermanson, J. R., 3714
Hermine, O., 4576
Hernandez, H., 1543
Herne, K. L., 2132
Hérodin, F., 2609
Herouy, Y., 3985
Herremans, M. M. P. T., 3319
Herrmann, T., 3288
Hershko, C., 4172
Hertel, S., 1734
Hertzog, P., 1453
Herz, J., 3933
Herzig, R. H., 2015
Herzog, R., 3338
Herzog, R. W., 2963
Hesdorffer, C. S., 4643
Heslop, H. E., 1905
Hess, D. C., 2215
Hess, G., 2960
Hewes, D. K. M., 846
Hicks, A. E. R., 3249
Hicks, J. S., 4492
Hidalgo, A., 1705
Hiddemann, W., 64, 270, 1494, 2074
Hideshima, T., 703, 1530, 2377, 2762, 3606, 4055
Higgs, D., 2842
High, K. A., 2963, 3338
Hiki, Y., 4219
Hildebrandt, G., 2877
Hileman, E. O., 4098
Hilf, N., 2810
Hill, B. J., 2294, 2711
Hill, G. R., 2033, 2314
Hill, W. D., 2215
Hillery, C. A., 4625
Hilsenbeck, S., 4078
Himes, S. R., 1155
Hinds, E., 1118
Hines, P. C., 3281
Hines, R. N., 2896
Hino, M., 1164
Hipp, S., 278
Hirabayashi, H., 3386
Hirai, H., 886, 2675
Hirai, H., 1777
Hiraiwa, M., 3615
Hiraiwa, N., 3615
Hiraoka, A., 4219
Hirashima, M., 1367, 2261
Hirata, S., 3501
Hirose, I., 4733
Hirose, K., 3594
Hirota, S., 178
Hirschmann-Jax, C., 1718
Hiruma, T., 2870
Hisatsune, H., 1367
Hitzler, J. K., 4301
Ho, A. Y. L., 779
Ho, A. D., 289, 2191
Ho, M., 331, 2850
Hochberg, E. P., 363
Hochhaus, A., 259, 375
Hochrein, H., 1453
Hock, L. M., 2363
Hodzic, E., 3257
Hoelzer, D., 85
Hofbauer, L. C., 2094
Hofer, T., 348
Hofer-Warbinek, R., 3042
Hoffbrand, A. V., 3174
Hoffet, M., 4850
Hoffman, M., 3008
Hoffman, R., , 2999, 463
Hoffmann, T., 929
Hoffmann, T., 3198
Hoffmeister, K. M., 4789
Hoffmeyer, A., 4937
Hofling, A. A., 2054
Högerkorp, C.-M., 2307
Hogge, D. E., 3142, 4529
Hoke, E., 6
Holder, M. J., 3212
Hollander, G. A., 3550
Hollis, G. F., 58
Holte, H., 3840
Hölter, T., 2748
Holtz, M., 4701
Honczarenko, M., 3784
Honda, S., 3485
Hong, A. P., 3049
Hong, P., 1299
Hong, W., 3597
Hong-Geller, E., 236, 3240
Honigman, A., 463
Hood, A. F., 801
Hoover, R. R., 2070
Hoppe, C., 2865
Hoppe, R. T., 4285
Hocue, M., 1257
Horejsí, V., 1874
Horie, A., 4219
Horie, S., 4765
Horn, P. A., 4209
Horning, S. J., 4285
Horowitz, M. M., 2015, 2476
Horsman, D., 4539
Horwitz, M., 2898
Horwitz, S. M., 4285
Hosen, N., 1698
Hotta, T., 2905
Hou, M., 2721
Houdusse, A., 2736
Houldsworth, J., 2914
Houlgatte, R., 4998
Housman, D., 2570
Howes, J., 1919
Howlett, G. J., 1308
Howrey, R., 5061
Hoy, T., 624, 2454
Hoylaerts, M. F., 157, 1375, 3969
Hromas, R. A., , 801
Hsu, J. W., 781
Hsu, J., 3126
Hsu, S.-C., 970
Hu, L., 3126
Hu, P., 4853
Hua, T. A., 58
Huang, M.-L., 407
Huang, M., 4958
Huang, P., 4098
Huang, Z.-Y., 4479
Huber, C., 2960
Huber, S., 3872
Huber-Beckmann, R., 3042
Hübner, K., 4063
Hudson, S. A., 5014
Hudson, W., 3229
Hufnagl, P., 3042
Hugo, P., 292
Huhn, R. D., 71
Huizing, M., 4402
Huizinga, E. G., 345
Huls, M. H., 1905
Hume, D. A., 1155
Humphreys, T. L., 1677
Humphries, R. K., 4529
Hunter, S., 4479
Hurlet, A., 2401
Hutchinson, R. J., 3809
Hutchison, S., 2963
Hutter, J., 1970
Hüttmann, A., 2748
Hwang, P.-H., 4479

Iannitto, E., 2464
Ibbotson, R. E., 4944
Ibbotson, R., 1087
Idzko, M., 3985
Ignoffo, R., 466
Ihle, J. N., 4937
IJsseldijk, M., 4372
Ikebuchi, K., 532
Ikeda, H., 1094
Ikeda, H., 532
Ikeda, K., 3594
Ikeda, Y., 621
Ikegame, K., 1698
Ikehara, S., 2924
Ilaria Jr, R. L., 5010
Illigens, B. M. W., 4305
Imai, K., 4131
Imanishi, J., 886
Imbert, M., 1277
Inaba, N., 2870
Inaba, T., 3334
Inaba, T., 673
Inchauspe, G., 52
Indik, Z. K., 4479, 4615
Inghirami, G., 1919
Ingram, D. A., 1984
Ingram, D., 4725
Ingvarsson, S., 2307
Iniesta, J. A., 4224
Inman, S., 1718
Intergroupe Francophone du Myélome, 1570
Introna, M., 4589
Inukai, T., 3658
Invernizzi, R., 1996
Ionescu, I., 2137
Isaacson, P. G., 2547
Iseki, S., 2601
Iseki, T., 4711
Ishida, N., 178
Ishii, A., 2300
Ishii, E., 3622
Ishii, H., 4765
Ishii, K., 4711
Ishikawa, H., 4765
Isobe, H., 3029
Isoyama, K., 3622
Issa, J.-P., 4131
Issekutz, T. B., 4245
Italiano Jr, J. E., 4789
Ito, A., 2601
Ito, C. Y., 517
Ito, D., 1477
Ito, E., 3622
Ito, Y., 1801
Ito, Y., 2074
Ito, Y., 532
Itoh, H., 2675
Itoh, K., 3386
Iwai, T., 2870
Iwamoto, I., 3594
Iwamoto, S., 1185
Iwamoto, T., 1185
Iwasaki, H., 2870
Iwasaki, H., 383, 903
Izui, S., 594
Izumo, S., 3074

Jackson, C. W., 2646
Jackson, K. A., 492
Jackson, R. J., 3240
Jackson, S. P., 3477
Jackson, T. R., 3174
Jacob, M.-C., 949
Jacobi, P., 1384
Jacobsen, S.-E., 877
Jacobs-Helber, S. M., 524
Jacobson, J., 3849, 4982
Jacobson, R., 6
Jacquemin, M., 1351
Jaffe, E. S., 3181, 3407, 3590, 4653
Jaffredo, T., 4733
Jaffrézou, J.-P., 1543
Jagadeesh, G. J., 2563
Jagannath, S., 3849
Jakus, Z., 4155
Jalkanen, S., 4022
Jalla, S., 1645
James, C. M., 2727
James, S. J., 3302
Janda, J., 3574
Janin, A., 2073
Janka-Schaub, G. E., 1270, 2743
Jankovic, M., 3857
Jankowski, M., 157
Janowska-Wieczorek, A., 3784
Jansen, J. H., 5085
Jansen, M. J. H., 253
Janz, M., 3568
Jaroscak, J., 5061
Jarrousse, S., 4583
Jauch, A., 2191
Jean-Louis, F., 1203
Jeannin, P., 143
Jeddi-Tehrani, M., 1063
Jedlickova, K., 1591
Jeha, S., 97, 3794
Jelinek, D. F., 3778
Jelinek, J., 1591, 3294
Jelkmann, W., 4416
Jenkins, N. A., 1934
Jennings, M., 2999
Jensen, F. T., 91, 4632
Jensen, M. C., 1637
Jensen, P. D., 91, 4632
Jensen, T. L., 1551

Jeong, S., 5033
Jerkeman, M., 4047
Jesmok, G., 3002
Jezzard, S., 1359
Ji, C., 2721
Jiang, F., 124
Jiang, K., 236, 3240
Jiang, X., 3901
Jilani, I., 2507
Jin, J., 3908
Jin, Y., 4909
Jippo, T., 1344, 2601
Jirik, F. R., 3877
Jiroušková, M., 929
Johansen, L. M., 2074
Johansen, M., 338, 4836
Johansson, J.-E., 469
John, M., 3157
Johnsen, H. E., 4607
Johnson, A., 4047, 4952
Johnson, F. A., 2963
Johnson, H., 3093
Johnson, J. J., 3229
Johnson, K. W., 4305
Johnson, P. W. M., 1045
Johnson, R. M., 2898
Johnson, S. A., 1329
Johnston, H. M., 856
Johnston, K., 3809
Johnston, M., 1734
Johnstone, B., 1744
Jonas, M., 295
Jones, B. A., 4479
Jones, D., 5007
Jones, D. T., 3174
Jones, K. S., 3085
Jones, M., 3991
Jones, P. A., 1657, 4645
Jönsson, T., 2897
Joos, S., 3681
Jopling, C., 2996
Jordan, M. B., 594
Jose, A., 3082
Joseph, A., 4209
Joseph, M., 2377
Jouault, H., 1277
Joutsi-Korhonen, L., 4372
Julian, J., 4273
Juliusson, G., 4267, 4952
Jungermann, K., 907
Jungnickel, B., 1505
Junker, R., 2529
Jurecic, R., 3991
Jurisic, V., 2894
Jurlander, J., 4322

Kaberlein, J. J., 2355
Kadin, M. E., 1487
Kadoya, T., 178
Kaeda, J., 5084
Kafri, T., 104
Kagami, K., 3658
Kagami, S., 3594
Kageyama, R., 1777
Kahn, M. L., 1409
Kajigaya, S., 3118
Kakimoto, K., 3274
Kaku, M., 1188
Kalafatis, M., 20
Kaled, E. S., 4714
Kalhori, N., 2748
Kalhorn, T. F., 2043
Kalla, J., 699
Kaltwasser, J. P., 1236
Kamal, A. M., 4140
Kanakura, Y., 1094, 3164, 3668
Kanbach, K., 2001
Kanda, C., 4623
Kang, M.-A., 3534
Kang, S. W., 5033
Kang, S., 5046
Kannagi, R., 3615
Kansas, G. S., 4013
Kantarjian, H., 1692, 4714
Kantarjian, H. M., 97, 473, 2507, 3413, 3794, 4131
Kanz, L., 375
Kappel, B. J., 2440
Kappers-Klunne, M., 2426
Kappler, J., 594
Kapur, R., 1329, 4725
Karandikar, N. J., 2711
Karasawa, M., 3386
Karasuno, T., 4219
Kardon, T., 2381
Karlsson, Åsa, 2797
Karlsson, K., 4952
Karlsson, S., 1284
Karran, L., 4539
Karthaus, M., 3365
Kashiwagi, H., 3485
Kaspers, G. J. L., 3868
Kastner, P., 2219
Kataoka, Y., 3668
Kato, G., 4219
Kato, H., 3485
Kato, J., 532
Kato, S., 2905
Katsanis, E., 245, 4485
Katschinski, D. M., 4416
Katsikis, P. D., 1024
Katsoris, P., 3014
Katzenberger, T., 699
Kaufmann, S. H., 2534
Kaushansky, K., 3915
Kavalakis, Y. G., 3444
Kaveri, S. V., 758
Kavlick, M. F., 4653
Kawakami, M., 1698
Kawakami, T., 4155
Kawakami, Y., 621
Kawamoto, S., 178
Kawamoto, Y., 2924
Kawano, Y., 532
Kawasaki, A., 3668
Kawasaki, K., 2261
Kay, M. A., 2963
Kayagaki, N., 3658
Kayibanda, M., 4253
Kazatchkine, M. D., 758
Keating, A., 2015
Keating, M. J., 2507, 3413, 4098, 4903
Keats, J. J., 1520
Keefer, J. R., 3885
Kehrle, B., 3940
Keilholz, U., 4643
Kelly, C., 2314
Kelly, J. A., 992
Kelly, L. M., 1494, 3188
Kemball-Cook, G., 1359
Kenis, H., 4223
Kennedy, A. D., 1071
Kentouche, K., 1845
Kenyon, M., 779
Kern, W., 64
Kersey, J. H., 3229
Khaldoyanidi, S., 863
Khalil, D., 2314
Khanna, R., 3150
Khanna-Gupta, A., 3460
Khawli, L. A., 4853
Khetawat, R., 4333
Khoury, H., 5092
Khoury, H. J., 2067
Kielbik, M. C., 3953
Kiem, H.-P., 4209
Kienast, J., 2775
Kieras, C. J., 58
Kietzmann, T., 907
Killeen, N., 3741
Kilpatrick, J., 992
Kim, A. H. J., 1024
Kim, D.-K., 1094
Kim, E. H., 1698
Kim, F. J., 1913
Kim, H.-G., 4342
Kim, L., 4000
Kim, M., 2314
Kim, M.-K., 4479
Kim, R. S., 3606
Kim, S., 3875
Kim, S., 3908
Kim, S. H., 5033
Kim, S.-U., 5033
Kimball, J., 71
Kim-Han, T.-H., 4479
Kimura, A., 673
Kimura, S., 4219
Kimura, T., 2924
Kin, Y., 3386
Kincade, P. W., 178, 576
Kindler, T., 2960
Kinet, S., 1913
Kinoshita, C., 4623
Kirkham, F. J., 846
Kirkpatrick, C. J., 2960
Kironde, F., 2405
Kirschmeier, P., 2070
Kirstetter, P., 2219
Kiss, C., 2886
Kisseleva, E., 4878
Kitagawa, S., 1164
Kitamura, Y., 1094, 1344, 2601
Kitaura, J., 4155
Kitner, J. B., 4547
Kito, M., 1375
Kiyoi, T., 3485
Klapper, W., 3574
Klatzmann, D., 3416
Klausen, P., 4322
Kleemann, R., 545
Klein, C., 2159
Klein, J. R., 119
Klein, U., 1505, 4115
Kleinhans, M., 1487
Klein-Hitpass, L., 2748
Klemola, T., 1660
Klingebiel, T., 1630, 3835
Klion, A. D., 4660
Klisovic, M. I., 425
Klitz, W., 2865
Kluft, C., 1841
Klug, C. A., 4342
Kluijtmans, L. A. J., 2483
Kluin, P. M., 1149
Klump, H., 1759
Klüter, H., 2426
Knapp, W., 2184
Kneba, M., 2049
Knezetic, J. A., 1798
Knight, A., 2349
Knisely, A., 101
Knöbl, P., 946
Knop, J., 210, 4862
Knudsen, E., 4909
Kobayashi, T., 2675
Kobayashi, T., 2300
Kobune, M., 532
Koch, A. E., 3960
Kochanek, S., 1734
Koeffler, H. P., 1141, 3265
Koenderman, L., 134
Koening, M., 2184
Koerner, T. A. W., 711
Kogan, S. C., 1141, 3188
Kohashi, O., 3451
Kohler, H. P., 371
Köhler, T., 2152
Kohne, E., 1845
Koike, T., 3495
Koiso, H., 3386
Kole, R., 104
Kolev, K., 4380
Koller, C., 1692, 3413, 4714
Koma, Y., 2601
Komatsu, M., 3991
Komschlies, K., 2294
Komschlies, K. L., 1477
Komura, E., 2983
Kondo, N., 1367
Kondo, Y., 4131
Kong, M., 3002
Koniaris, L., 3977
Konijn, A. M., 4172
Koniski, A. D., 1669
Konrad, M., 3635
Kooistra, T., 545
Koolwijk, P., 1810
Koporc, Z., 2886
Kopper, L., 3590
Korsmeyer, S. J., 1270, 3093
Kortesmaa, J., 877
Korthof, E., 3373
Kosteas, T., 2591
Kosugi, S., 3485
Kotzé, H., 782
Koup, R. A., 2711
Kourlas, P. J., 425
Koury, M. J., 1790, 4164
Koutala, H., 2591
Kovacevic, M., 3014
Kovacic, B., 4937
Kovalszky, I., 4380
Koyama-Okazaki, T., 3658
Kozak, M., 1202
Krahl, R., 1941, 2152
Krämer, A., 289
Kramer, M. F., 348
Krampera, M., 3722
Krantz, S. B., 1324
Kra-Oz, Z., 463
Krause, K., 3574
Krause, V., 1149
Kraut, E. H., 425
Krauter, J., 3157
Krehmeier, U., 1882
Kreidberg, J. A., 2570
Kreil, S., 375
Krenacs, L., 3590
Krenacs, T., 3590
Krijanovski, Y., 4430
Krishnamurti, L., 1591
Kroemer, G., 541
Kroger, L. A., 3641
Kröger, M., 2775
Krohn, K., 1941
Kropff, M., 2775
Kruhoffer, M., 4598
Kruse, E., 2748
Kubagawa, H., 1030
Kubes, P., 331
Kubin, M., 1484

Kubo, H., 1367
Kubota, R., 3074
Kuçi, S., 869
Kudlacek, O., 4937
Kudo, T., 2870
Kudo, T., 2620
Kudoh, A., 1460
Kuehlcke, K., 2191
Kühl, J.-S., 3872
Kuhlman, T., 1484
Kühn, H., 722
Kühne, C. A., 2094
Kuijpers, M. J. E., 3969
Kuijpers, T. W., 1987, 5021
Kukis, D. L., 3641
Kukita, A., 3451
Kukita, T., 3451
Kumano, K., 1777
Kumar, P., 3960
Kumar, S., 1715
Kun, L. E., 3862
Kunapuli, S. P., 3908
Kunisato, A., 1777
Küppers, R., 1505
Kuprash, D. V., 1477
Kurachi, K., 1871
Kurachi, M., 3509
Kurachi, S., 1871
Kurata, M., 2789
Kurata, Y., 3485
Kurino, T., 2227
Kurnik, K., 1845
Kuroda, J., 4219
Kurtz, J., 2886
Kurtzberg, J., 2137, 5061
Kuruppu, J., 2711
Kurzrock, R., 1692
Kusy, S., 374
Kutler, D. I., 1249
Kutti, J., 783
Kuwahara, M., 1871
Kuwana, M., 621
Kuziel, W. A., 4253
Kuzushima, K., 1460
Kvaløy, S., 3840
Kvell, K., 1727
Kwok, S. H., 3265
Kwon, H. J., 5033
Kwon, K.-S., 5033
Kyle, R. A., 827, 1715, 2496, 3801, 4569
Kyriakides, T. R., 3915

La, M. K., 3809
La Rosée, P., 4611
la Sala, A., 3985
Labopin, M., 1611
Labrecque, N., 766
Lacerra, G., 104
Lacombe, C., 3436
Lacroix-Desmazes, S., 758
Lacy, M. Q., 827, 1715, 2496
Laffan, M. A., 1416
Laforet, M., 2426
Laftah, A. H., 3316
Lagadec, P., 4836
Lagarde, V., 2368
Laham, N., 2858
Lahaye, T., 259, 375
Lai, J. L., 1277
Lai, M.-Z., 970
Lallemand, J.-Y., 3014
Lamborn, K. R., 3641
Lambris, J. D., 3784
Lammers, J.-W., 134
Lamoureux, J., 1660
Lamprecht, A., 2335
Lam-Yuk-Tseung, S., 3699
Lan, Y., 124
Landgren, O., 4047
Landman-Parker, J., 2693
Lane, D. A., 1416, 4393
Lang, P., 1630
Langabeer, S. E., 2770
Lange, A., 2049
Lange, B. J., 3398
Lange, C., 226
Lange, T., 1620, 2152
Langer, F., 2886
Langeveld, A., 2842
Langsley, G., 1874
Lanham, S., 1087
Lansdorp, P. M., 375
Lanza, F., 3477
Lanzavecchia, A., 4260, 4500
Lap, P., 4223
Lapierre, L. A., 2115
Laporte, J., 52
Lappin, T. R. J., 1558
Larratt, L. M., 1520
Larregina, A. T., 611
Larsen, C., 374
Larson, D. R., 2496
Larson, M. K., 1409
Larson, P. J., 2963
Larson, R. A., 6
Larsson, M., 3520
Lassau, N., 2983
Lataillade, J.-J., 2609
Late Effect Working Party of the European Group for Blood and Marrow Transplantation, 3373
Laterveer, L., 1201
Lathrop, M., 163
Laudanna, C., 4775
Laufs, S., 2191
Lauletta, G., 3818
Launay, S., 3220
Laurent, G., 1543
Lavend'homme, R., 1351
Lavigne-Lissalde, G., 4850
Law, M. A., 4660
Lawrence, F., 3014
Laylor, R., 3722
Lazarus, A. H., 1658, 3708
Lazarus, H. M., 2476
Lazzarin, A., 4452
Le Beau, M. M., 3188
Le Couedic, J. P., 541
Le Couteur, D. G., 3338
Le Moine, A., 1469
Le Van Kim, C., 338
Leblond, V., 1891
LeBousse-Kerdilès, M.-C., 5087
Lechler, R., 2704
Lechler, R. I., 3560
Lecoeur, H., 3102
Lecompte, T., 1419
Lederlin, P., 4279
Lederman, M. M., 226
Ledru, E., 3102
Lee, C., 2542
Lee, C. A., 4783
Lee, C.-I., 2667
Lee, D., 466
Lee, G., 1790
Lee, J. M., 1928
Lee, J. Y., 351
Lee, K.-K., 5033
Lee, L. B., 3597
Lee, P.-L., 2667
Lee, S.-H., 1299
Lee, S. J., 226
Lee, S.-K., 4449
Lee, T.-H., 5033
Lee, Y.-J., 1141
Lees, C., 3741
Lefort, N., 4313
Legendre, P., 4363
LeGuern, C., 4305
Leiblein, S., 1941, 2152
Leigh, K. R., 492
Leiner, I., 4290
Leisenring, W., 407
Leitman, S. F., 71, 2563
Lemieux, R., 1660, 3065
Lemoine, F. M., 3416
Lenting, P. J., 3933
Lentzsch, S., 3568
Lenvik, T., 3527
Leo, R., 2775
Leonard, D. G. B., 2963
Lepage-Noll, A., 2973
Lepelletier, Y., 4576
Lepelley, P., 1277
Lépolard, C., 5025
Lerner, A., 4122
Leroux, D., 949
Leroy, K., 2756
Letterio, J. J., 498
Letvak, L., 97, 4714
Leuba, F., 1727
Leuzzi, R., 2381
Levan, G., 2797
Levi, M., 4823
Levi, S., 1996
Levin, B. C., 3118
Levine, J. E., 2476
Levi-Schaffer, F., 1898
Levitsky, H. I., 1645
Levy, A., 466
Levy, R. B., 3991
Levy, R., 433, 3109
Levy, V., 3373
Levy, Y., 4313
Levy-Toledano, S., 1400
Lew, V. L., 4189
Ley, K., 4916
Ley, T. J., 3093
Li, B., 1769
Li, C., 3606
Li, C.-Y., 2015, 2534, 3391
Li, C. Y. J., 517
Li, D., 4416
Li, G., 3606
Li, H. Y., 3628
Li, J. H., 2268
Li, L., 383
Li, S.-W., 1977
Li, W., 2721
Li, X., 1299, 2137
Li, Y., 4301
Li, Z., 4423
Li, Z., 1759, 2099
Liao, H.-I., 2388
Libermann, T. A., 2377
Licht, T., 1657
Lichtenstein, A., 2461, 3126
Lichter, P., 3681
Lieberman, J., 226
Liebminger, R., 4937
Liewehr, D. J., 3407
Likhacheva, A., 245
Liles, W. C., 295
Lillard Jr, J. W., 807
Lilleri, D., 5053
Lillicrap, D., 1734
Lillington, D. M., 1513
Lim, P., 2816
Lim, S. H., 955
Lin, B., 2762
Lin, H., 690
Lin, L., 2426
Lin, M., 2081
Lin, P.-M., 3205
Lin, S.-F., 3205
Lin, Y. S., 2896
Lin, Z.-P., 425
Linch, D., 783
Lindley, I., 3042
Lindorfer, M. A., 1071
Lindstedt, G., 783
Lindtner, S., 1934
Link, G., 4172
Lioure, B., 2426
Lipp, M., 815
Lisman, T., 1864
Little, M.-T., 1620
Little, R. F., 4653
Liu, B., 124
Liu, C., 2721
Liu, C., 2877
Liu, C.-H., 2159
Liu, C.-Y., 295
Liu, D., 2721
Liu, E., 1591, 3294
Liu, H., 955
Liu, H., 2547
Liu, H., 3885
Liu, J., 1919
Liu, J., 3240
Liu, J., 2646
Liu, J.-M., 3014
Liu, L., 2388
Liu, P., 1934
Liu, Q., 4078, 4105
Liu, T.-C., 3205
Liu, Y.-J., 3520
Livak, K. J., 2521
Livnat, T., 4783
Ljungman, P., 2426
Lo, A., 5039
Lo, L.-W., 2667
Loberiza Jr, F. R., 2476
Lobo, C.-A., 4628
Locasciulli, A., 3373
Locatelli, F., 1611, 2137, 3857, 5053
Loda, M., 2473
Lode, H. N., 649
Lodé, L., 1570
Lodie, T. A., 1141
Loewenthal, R., 4783
Löffler, H., 64
Löffler, J., 869
Löfvenberg, E., 4047
Logar, A. J., 611, 4457
Lohr, A., 699
Loken, M. R., 3398
Lokhorst, H. M., 1201, 2144
Lombardi, G., 3560
Lombardo, A., 2071
Long, Z., 2563
Looareesuwan, S., 331, 2850
Lopez, A. F., 1308
López, J. M., 3674
López-Berges, M. C., 4695
López-Guillermo, A., 78, 2489
Loring, J., 2570
Loriod, B., 4998
Los, M., 2895
Lossos, I. S., 433, 3109
Lotze, M. T., 2620

Louie, S. G., 3597
Love, P. E., 4520
Low, P. S., 4625
Low, S. Y., 3174
Lowell, C. A., 4155
Löwenberg, B., 837, 1336, 4290
Lowenstein, P., 3325
Lozano, M. L., 4224
Lu, H., 4209
Lübbert, M., 1657, 3753, 4645
Lubin, B. H., 351, 2137
Lucas, D., 425
Lucas, D. M., 4547
Lucas, J. B., 4285
Lucerna, M., 3042
Luciani, D., 1827
Lucio, P., 4695
Ludwiczek, S., 4148
Ludwig, H., 4137
Lui, G., 949
Luiten, R. M., 4512
Lundin, J., 4267
Lundquist, A., 4070
Luo, K.-L., 2434
Luo, R. T., 2355
Luong, Q. T., 3212
Lupu, F., 1810
Lurain, N. S., 463
Lusso, P., 4452
Lust, J. A., 827, 1715, 2496, 2557
Lustigman, S., 4628
Lutz, P., 2137
Luzi, L., 3514
Luznik, L., 1645
Lyakh, L. A., 498
Lymphoma Study Writing Committee of the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry, 2476
Lynch, J. C., 2363

Ma, H., 104
Ma, L., 3901
Ma, S., 1705
Ma, X., 4640
MacDonald, K. P. A., 2033
MacDonald, K., 831
MacGrogan, D., 2206
Machesky, L. M., 3220
Machovich, R., 4380
Macintyre, E., 1277, 2693
Mack, M., 4253
Mackall, C. L., 2294
Mackman, N., 3940
Macri, M. J., 216
Madan, R. A., 781
Madjic, O., 2184
Maekawa, T., 4219
Maes, B., 706
Maesako, Y., 2789
Maestre, N., 1543
Magaletti, D., 4464
Magdelénat, H., 4598
Magera, M. J., 3901
Maghazachi, A. A., 4909
Magistrelli, G., 143
Magnac, C., 4029
Magnani, Z., 1290
Magrangeas, F., 4998
Mahaira, L. G., 3444
Mahdi, F., 4430
Mahnke, K., 4862
Mahon, F.-X., 2368
Maianski, N. A., 1987, 5021
Maillere, B., 1351
Maillot, M.-C., 729
Maio, M., 4644
Majetschak, M., 1882
Majka, M., 3784
Maksimow, M., 4022
Malavasi, F., 2748
Malcovati, M., 173
Male, C., 4273
Malik, J., 1669
Malinoski, F., 831
Mallet, R., 2340
Malley, R., 831
Malnati, M., 4452
Maloney, D. G., 1620, 3319, 4209, 4225
Malphettes, M., 1891
Mammolenti, M., 3991
Manches, O., 949
Manegold, P. C., 1970
Manel, N., 1913
Mangin, P., 3477
Manici, S., 1038
Manie, E., 4313
Manithody, C., 4802
Mankelow, T. J., 1790
Manley, P. W., 664
Mann, K. G., 20, 372
Manning, W. C., 3597
Manno, C. S., 2963
Mannucci, P. M., 173
Mansat-De Mas, V., 1543
Manshouri, T., 2507
Mansour, A., 1205
Mant, M. J., 1520
Mantelli, B., 4452
Mantovani, A., 3495
Mao, N., 124
Mao, X., 1513
Mapara, M. Y., 3568
Marblie, S., 2426
Marchetti, M. C., 585
Marco, P., 4224
Marcolongo, P., 2381
Marcu, K. B., 3574
Marcucci, G., 425
Marder, V. J., 3002
Marelli-Berg, F., 3560
Marès, P., 4850
Mariani, G., 2826
Marín, F., 4224
Marin, M., 4539
Maris, M., 1620
Marks, P. A., 4055
Marktel, S., 1290
Marlton, P., 2314
Marodon, G., 3416
Marolleau, J.-P., 1891
Marquez, L., 3784
Marrack, P., 594
Marsh, J. C. W., 2833
Marti, G. E., 4944
Martín, C., 681
Martin, P. L., 5061
Martínez, A., 78
Martínez, C., 4224
Martínez, M. A., 681
Martínez, N., 4042
Martínez-A, C., 38, 3424
Martínez-Climent, J. A., 3109, 4042, 4539
Martínez-Sánchez, E., 163
Martin-Studdard, A., 2215
Martín-Subero, J. I., 706, 3681
Martyré, M.-C., 5087
Maruya, E., 3334
Maruyama, Y., 4623
Marx, A., 2960
Marx, P. F., 4844
Marynen, P., 4539
Masaki, R., 3274
Masci, A. M., 3106
Masdehors, P., 4598
Maserati, R., 2514
Masi, M., 2125
Mason, P. J., 1416
Massa, A., 2826
Massaccesi, L., 2071
Massop, M., 5085
Mastellos, D., 3784
Masuda, M., 3501
Masuda, S., 1777
Masuda, T., 1698
Masuya, M., 2215
Mateo, J., 163
Mateo, M., 4042
Mateo, V., 265, 292
Matherly, L. H., 1551
Mathes, R., 664
Matsuda, M., 915
Matsui, H., 915
Matsumoto, M., 915
Matsumura, I., 1094, 3164, 3668
Matsumura, K., 1367, 2261
Matsunaga, T., 532
Matsuoka, H., 2300
Matsushima, K., 3509
Matsushima, T., 3386
Matsuura, E., 4748
Matsuyama, T., 3581
Matsuyoshi, H., 3501
Matsuzawa, Y., 178, 3485
Matta, H., 1956
Mattes-Ritz, A., 363
Matthay, K., 4640
Matthes, T., 1727
Matthews, D. C., 2340
Mattsson, J., 469
Matutes, E., 4975
Mätz-Rensing, K., 1213
Maurel, P., 52
Maurer, M., 210
Maurillo, L., 2125
Maxwell, C. A., 1520
May, C., 2932
Mayaudon, V., 2426
Mayeux, P., 3436
Maynadie, M., 1277
Mayo, K., 4687
Mayol, J.-F., 2609
Mazda, O., 886
Mazorra, F., 681
Mazzanti, L., 2071
Mazzaro, C., 3827
Mazzone, C., 2125
McCann, S. R., 1200
McCarthy, H., 4903
McCarthy, J., 1329, 4725
McCarthy, K. F., 3431
McClelland, A., 2963
McClure, B. J., 1308
McCorkle, S. R., 2285
McCorquodale, S., 3924
McCoy, J., 3849
McDaniel, J. M., 552
McDermott, M., 466
McDonald, G. B., 2043
McElroy, E. A., 827
McEver, R. P., 552, 4775
McFarland, H. I., 4520
McGhee, J. R., 807
McGrath, K. E., 1669
McHale, C. M., 4640
McIntosh, J., 2833
McKie, V., 2401
McKinstry, R. C., 415
McLaughlin, J., 4088
McLaughlin, S. F., 363
McMaster, D., 2483
McMorrow, T., 2842
McMullan, C., 4055
McMullin, M. F., 1558
McNagny, K. M., 1103
McNamara, G., 4201
McNaughton-Smith, G. A., 2412
McNulty, H., 2483
McPartlin, J., 2483
McQueen, K. L., 3730
McSweeney, P. A., 1620
McVicar, D. W., 4520
Mechtersheimer, G., 3681
Medeiros, L. J., 5007
Medina, K. L., 576
Meerpohl, J., 5039
Mehdizadehkashi, Z., 454
Mehrotra, A., 3875
Mehta, A. B., 3174
Mei, Z., 1718
Meij, P., 4290
Meijerink, J. P. P., 1270, 2743
Meijers, J. C. M., 4844
Mekrache, M., 4363
Melenhorst, J. J., 1752
Mellado, M., 38
Mellstedt, H., 1063, 4607, 4930
Melnyk, S., 3302
Melo, J., 5084
Melo, J. V., 1007, 2368, 3560
Meloni, G., 1611
Menárguez, J., 681, 4042
Ménasché, G., 2736
Ménoret, S., 3325
Menz, C. K., 3681
Mercier, E., 4850
Merk, B., 2833
Merkulova-Rainon, T., 4816
Merle-Béral, H., 265, 4598
Meroni, P. L., 3495
Mertens, K., 3933
Merup, M., 4952
Mesa, R. A., 2534
Messina, C., 1611
Messina, J. L., 771
Messmer, K., 1970
Mesters, R. M., 2775
Mestre, M. J., 681
Metayer, C., 2015
Metcalfe, D. D., 4660
Metivier, D., 541
Metz, M., 210
Metzel, P., 2426
Metzger, M. E., 2199
Metzler, M., 3635
Meunier, M.-C., 766
Meyer, D., 2340
Meyer, J., 2099
Miah, M., 1359
Mian, A. M., 2321
Micheau, O., 194
Michel, L., 1203
Michelsen, B. K., 1430
Michelson, A. D., 2268
Michelutti, A., 3827
Middeldorp, J., 5053
Miedema, F., 4290
Mieli-Vergani, G., 101

Miers, L. A., 3641
Migliaccio, A. R., 5088
Migliazza, A., 2914
Migliorati, G., 585, 729
Migueles, S. A., 2711
Miki, H., 2159
Mikkola, H. K. A., 508
Miklos, D. B., 363
Milazzo, C., 977
Mille-Baker, B., 1416
Miller, C. B., 2015
Miller, J. L., 492
Miller, J. S., 3527
Miller, J. W., 3750
Milligan, D., 2454
Milon, G., 210
Minami, T., 4748
Minatchy, M.-N., 2575
Minden, M. D., 2074
Minetti, G., 3751
Miniero, R., 2137
Minvielle, S., 4998
Misra, N., 758
Mitchell, B. S., 4958
Mitchell, L., 4273
Mitchell, M., 4828
Mitchell, W. B., 2268
Mitchison, H., 3337
Mitina, O., 664
Mitsiades, C., 1530, 2762, 3606
Mitsiades, C. S., 2377, 4055
Mitsiades, N., 1530, 2377, 2762, 3606, 4055
Mitsui, T., 2990
Mitsuya, H., 4653
Mitsuyama, M., 2990
Miyaoka, K., 4623
Miyata, S., 915
Miyatake, H., 2905
Miyawaki, S., 3386
Mizoguchi, A., 2159
Mizokami, M., 4853
Mizuki, M., 1094, 3164
Mizuno, T., 915
Mizutani, A., 3029
Mizutani, S., 3029
Mizutani, S., 3622
Moarefi, I., 664
Mockridge, C. I., 3082
Mócsai, A., 4155
Mogass, M., 1744, 4333
Mohandas, N., 318, 325, 1790, 4164, 4180, 5039
Molens, J.-P., 949
Molina-Arcas, M., 2328
Mollejo, M., 681, 4042
Möller, P., 3681, 2756
Molrine, D. C., 831
Monaco, C., 983
Mone, A. P., 4547
Moniuszko, M., 2294
Mönkemeyer, S., 2001
Monroe, D. M., 3008
Monroe, J. G., 1950
Monson, T. P., 2542
Montalbán, C., 681
Montefusco, M. C., 173
Montefusco, V., 373
Montella, L., 3106
Montgomery, R. R., 1384
Montserrat, E., 78, 2328
Moog, S., 3477
Moon, E.-Y., 4122
Moon, H.-B., 5033
Mooney, N., 1874
Moore, M. A. S., 4982
Moore, S. B., 2156
Moreau-Gaudry, F., 2368
Morel, P., 4279
Morelli, A. E., 611, 4457
Morente, M., 681
Morgan, B. P., 1045
Morgan, G. J., 2770
Morgan, S. M., 1045
Moriggl, R., 4937
Morii, E., 1344, 2601
Morishima, Y., 1460
Morishita, S., 3509
Morison, I. M., 4222
Morita, I., 4748
Moriyama, K., 4402
Möröy, T., 2748
Morris, D. I., 4520
Morris, J., 4209
Morris, M. A., 3492
Morrison, V. A., 6
Morschhauser, F., 420
Morsilli, O., 1316, 2826
Mortazavi, Y., 2833
Mortensen, R. M., 1409
Moschatsis, S., 1864
Mosnier, L. O., 4844
Motta, T., 2489
Moulds, J. M., 2081
Mouly, E., 3416
Mounier, N., 4279
Mouro-Chanteloup, I., 338
Mouthon, L., 758
Mozziconacci, M. J., 1277
M'rini, C., 38
Muckenthaler, M., 3690
Muehlbacher, F., 2886
Mueller, B. U., 2074
Mueller, Y. M., 1024
Mueller-Wiefel, D., 1845
Muessig, A., 1284
Mufti, G. J., 779
Mugneret, F., 286, 1277
Muguruma, Y., 2905
Müller, C., 1941
Müller, J. G., 1213
Müller, M. C., 259
Müller, M. R., 977
Muller, O., 3436
Müller, W., 4887
Müller-Esterl, W., 4430
Müller-Hermelink, H. K., 699, 3590
Müller-Hermelink, K., 420
Müller-Tidow, C., 3164
Mulligan, R. C., 2159
Mulloy, J. C., 2206
Mundschau, G., 4298
Munoz, O., 1118
Munshi, N. C., 1530, 2377, 2762, 4055
Munshi, N., 3606, 3849
Münz, C., 3520
Murakami, H., 3386
Murakami, M., 1698
Murakami, T., 1477
Murciano, J.-C., 3977
Muriglan, S. J., 2440
Muro, S., 3977
Murphey-Corb, M. A., 1684
Murphy, B. J., 399
Murphy, G. F., 2440
Murphy, W. J., 5076
Murphy-Ullrich, J. E., 2253
Murray, A. G., 331
Murray, L. J., 3597
Murray, L., 2483
Musette, P., 1203
Musiol, S., 2152
Mitsuoki, S., 168
Muul, L. M., 2563
Muus, P., 5085
Muzykantov, V. R., 3977
Myerson, D., 407
Myhre, J., 3840

Nadaf, S., 4878
Nadler, L. M., 998
Nagahata, T., 3509
Nagai, R., 4748
Nagai, S., 3509
Nagamura, F., 4711
Nagasaki, J., 3386
Nagler, A., 441, 1898, 2137
Nagy, K. Z., 2191
Nagy, M., 1727
Naides, S. J., 711
Nakagami-Yamaguchi, E., 1777
Nakagawa, M., 3334
Nakagawa, T., 178
Nakahata, T., 2990
Nakajima, H., 1141
Nakajima, H., 3594
Nakajima, K., 3668
Nakajima, O., 1188
Nakamoto, B., 4739
Nakamura, K., 532
Nakamura, M., 2870
Nakamura, R., 71
Nakamura, T., 532
Nakamura, T., 3451
Nakamura, Y., 2905
Nakao, K., 2675
Nakauchi, H., 1777
Nakazawa, S., 3658
Nakhoda, K., 3875
Naparstek, E., 441
Napp, M., 3985
Naranjo, A., 1637
Narimatsu, H., 2870
Narla, G., 318
Narula, S., 5076
Narula, S. K., 2620
Nasr, R., 4576
Nasser, V., 4998
Natarajan, B., 492
Nath, M. D., 3085
Nath, S. K., 992
Nathan, D. G., 5089
Natkunam, Y., 4285
Natoli, T. A., 2570
Naundorf, S., 2191
Ndisang, J. F., 3893
Neben, K., 289
Nedospasov, S. A., 1477
Neelamegham, S., 2637
Neely, J. E., 4625
Neerman-Arbez, M., 1851, 3492
Negrin, R. S., 640, 3730
Neitzel, H., 3872
Nelson, M., 4000
Nelson, M. S., 2243
Nemeth, E., 2461
Nemoto, A., 3658
Nerlov, C., 1596
Néron, S., 3065
Nesmelova, I., 4687
Nestle, F. O., 1487
Neubauer, A., 259
Neuberg, D., 363
Neufeld, E., 1203
Nevill, T. J., 2015
Newman, P. J., 937
Ngai, T. J., 3597
Nguyen, C., 4998
Nguyen, D., 2159
Nguyen, J., 3953
Nguyen, K. N., 552
Nguyen, P., 1419
Nguyen, T. H., 1727
Niarchos, D. K., 3444
Nichols, K. E., 2473
Nichols, T. C., 3924
Nichols, W. G., 4195, 5091
Nickenig, C., 699
Nicolaou, F., 4033
Nicolas, V., 338
Niederwieser, D., 1620, 1941, 2152
Nielsen, F. C., 1596
Nielsen, J. L., 91, 4632
Niemeyer, C., 5039
Nienhuis, A. W., 2175
Nierwetberg, D., 1213
Niesters, H. G. M., 4290
Nieswandt, B., 3948
Niethammer, D., 869, 1630
Nieuwenhuis, H. K., 1864
Nieuwenhuis, H. K., 345
Niitsu, Y., 532
Nilsson, S. K., 856
Nimer, S. D., 2206
Nimmanapalli, R., 3236
Nishida, S., 1698
Nishikawa, M., 1777
Nishikawa, S., 1367, 2261, 2675
Nishikawa, S.-I., 886, 1367, 2261, 2675
Nishiki, S., 1164
Nishikori, M., 2789
Nishimura, Y., 3501
Nissen-Lie, G., 1204
Niu, C., 383
Niu, N., 4701
Nivsarkar, M., 1359
Nizet, S., 4894
Njoroge, J. M., 492
Nobili, B., 3857
Noble, J., 2865
Noel, P., 4660
Noetzel, M. J., 415
Noguchi, T., 3029
Nojima, H., 2601
Nojima, Y., 3386
Nolan, S. L., 3249
Nolta, J. A., 112, 4201
Nombela-Arrieta, C., 38
Noordhuis, P., 1270
Noordzij, J. G., 1446
Nooyen, P., 706
Nordheim, A., 3157
Nordic Lymphoma Group (NLG), 3840
Norgauer, J., 3985
Norman, K. E., 921, 3249
Novokhatny, V., 3002
Nowak-Göttl, U., 2529
Nückel, H., 2748
Nugent, D. J., 2137
Numasaki, M., 2620
Nuovo, G. J., 3052
Nurden, A. T., 1400
Nurden, P., 1400
Nusch, A., 2748
Nutku, E., 5014
Nutman, T. B., 4660
Nye, K. E., 399
Nyree, C. E., 937

Oba, T., 3778
Obata, A., 3509
Obata, T., 4131
Obertacke, U., 1882
Oboki, K., 1344
O'Brien, C. D., 2816
O'Brien, S., 97, 473, 1692, 3413, 3794
O'Brien, S. M., 2507
Obser, T., 1845
Occhiodoro, T., 856
Oceandy, D., 1155
Ochiai, N., 3334
O'Connell, N., 4783
Odeberg, J., 4870
O'Donnell, R. T., 3641
Ødum, N., 1430
Odyvanova, L., 259
Oehler, L., 2184
Oelsner, M., 278
O'Farrell, A. M., 3188
O'Farrell, A.-M., 3597
Offringa, R., 1439
Ogawa, H., 2318
Ogawa, H., 1698
Ogawa, H., 1801
Ogawa, M., 2215
Ogawa, M., 886, 1367, 2261, 2675, 4733
Ogihara, H., 1094
Oguchi, K., 3622
Ohm, J. E., 4878
Ohno, H., 2789
Ohno, N., 4711
Ohta, K., 1164
Oida, K., 4765
Oike, Y., 1801
Oji, Y., 1698
Oka, Y., 1698
Okada, Y., 4748
Okajima, K., 3029
Okamoto, Y., 1818
Okano, A., 3334
O'Keeffe, M., 1453
Oken, M. M., 4569
Okumura, K., 3658
Okuyama, H., 2227
Olivieri, N. F., 5089
Olivieri, N., 2401
Olofsson, T., 4047
Olsen, K., 3527
Olsson, K., 1284
Onai, N., 4500
Onda, H., 2601
O'Neill, C. M., 1558
Onley, C. M., 4372
Ono, M., 2620
Onoé, K., 4923
Ooi, J., 4711
Opare-Sem, O., 2419
Opdam, S. M., 358
Oppezzo, P., 4029
Or, R., 441, 5084
Orazi, A., 1299
Orchard, G., 1513
Orchard, J. A., 4944
Orchard, J., 3082, 4975
Orelio, C., 2246
Oren, A., 2388
Orfao, A., 4695
Oritani, K., 178
Orkin, S. H., 508
Orlandi, P., 3106
Orlofsky, A., 2679
Orme, L. M., 4982
Ormtoft, T. F., 4598
Orringer, E. P., 3281
Ortega, J., 1611
Ortolano, G. A., 370
Osame, M., 3074
Osato, M., 2074
Osawa, M., 1777
Ösby, E., 3840
Oscier, D., 1087, 4975
Oscier, D. G., 4944
O'Shaughnessy, M. J., 5076
Osieka, R., 2784
Ossenkoppele, G. J., 837
Österborg, A., 1063, 4267, 4607, 4930
Ostertag, W., 1759
Östreicher, I., 3635
Ostrowski, M. C., 1155
Ott, G., 699, 2335
Ott, M. M., 699
Ottinger, H., 446
Ottmann, O. G., 85
Ottoboni, L., 4775
Oura, H., 560
Oury, C., 3969
Ouwehand, W. H., 4372
Owens, B. M., 4966
Owusu-Ofori, S., 2419
Oyama, Y., 2064
Oyen, F., 1845
Oza, A., 2067
Ozaki, Y., 3469
Ozato, K., 305, 961
Ozelo, M., 2963

Pabby, N., 3407
Pabst, T., 2074
Packham, G., 1087
Padró, T., 2775
Pagel, J. M., 2340
Pagliuca, A., 779
Pahernik, S. A., 1970
Palis, J., 1669
Palmer, M. C., 1149
Palmér, M., 3749
Palmieri, G., 3106
Palmisano, G. L., 202
Palmqvist, L., 3174
Pamer, E., 4290
Pamphilon, D., 2426
Panetta, P., 2125
Panoskaltsis-Mortari, A., 3714, 3741, 5076
Panther, E., 3985
Panzer, S., 3635
Panzer-Grümayer, E. R., 3635
Panzeri, C., 4452
Paoletti, S., 815
Papac, N., 3042
Papadaki, H. A., 2591, 2898
Papadimitriou, E., 3014
Papamichail, M., 3444
Papayannopoulou, T., 3915, 4739
Papp, B., 3220
Papworth, G. D., 611
Pardanani, A., 827, 2534, 3391
Pardoll, D. M., 1645
Parenza, M., 568
Parfrey, P., 3037
Parham, P., 3730
Parise, L. V., 1409, 3281
Park, D. S., 5033
Park, D. J., 1141
Park, H., 894, 4033
Park, K., 6
PARKAA Investigators, 4273
Parks, W. T., 498
Parman, K. S., 4878
Parolini, I., 1316
Parra, M., 318
Parra, M. K., 4164
Parsons, S. F., 1790
Parwaresch, R., 3574
Parwaresch, R. M., 3681
Pasceri, P., 1603
Paschka, P., 375
Pascual-Ramirez, J. C., 2446
Pashov, A., 758
Pasqualucci, L., 2914
Passmore, J., 1713
Pastor-Anglada, M., 2328
Pastore, Y. D., 1591, 3294
Patel, B., 3188
Patel, D., 929
Patel, K., 2401
Patel, K., 4828
Patel, R. P., 4408
Patel, Y. M., 4828
Patterson, B. J., 2489
Patterson, S., 4000, 4505
Paulart, F., 1469
Pauwels, P., 706
Pavlakis, G. N., 1934
Pavli, P., 1155
Pawlinski, R., 3940
Payelle-Brogard, B., 4029
Pearce, L., 624
Pearn, L., 624
Pears, C. J., 1392
Pébusque, M.-J., 286
Peceny, R., 446
Pecora, A. L., 781, 2015
Pedersen, B., 3940
Pedicord, D. L., 58
Pedrinis, E., 2489
Pedron, B., 1277
Peerlinck, K., 1351
Peeters, T., 1201, 1653
Pegelow, C., 2401
Peham, M., 3635
Peired, A. J., 1705
Pekrun, A., 2001
Pelicci, P. G., 3514
Pelosi, E., 1316
Pene, F., 3436
Pène, J., 4512
Peng, J., 2721
Peng, K.-W., 2557
Pennington, D. J., 305
Peppelenbosch, M. P., 4446
Pepper, C., 2454
Perales, M., 78
Peretz, H., 4808
Pérez, J. J., 4695
Perez, S. A., 3444
Perna, F., 3106
Perrault, C., 3477
Perreault, C., 766
Perretti, M., 4140
Perrotta, P. L., 2285
Perrotta, S., 3857
Perrotti, D., 1141
Perruche, S., 194
Person, R. A., 2898
Persons, D. A., 2175
Persson, J., 877
Pertl, U., 649
Pertovaara, H., 3840
Peschel, C., 278
Peschle, C., 1316, 2826
Pesci, A., 1919
Pession, A., 1611
Pestina, T. I., 2646
Peters, C., 3835
Peters, E., 1810
Peters, G. J., 1270
Peters, L. L., 318, 338, 1790, 4180, 4402
Peters, T., 739
Petersdorf, E., 1620
Petershofen, E. K., 85
Peterson, B. L., 6
Peterson, J. A., 937
Petrovic, N., 1818
Petrow-Sadowski, C., 3085
Petrucci, E., 1316, 2826
Peuchmaur, M., 729
Peyvandi, F., 173
Pfeffer, K., 1477
Pfeifer, H., 85
Phan, V. T., 3188
Phelps, B., 2419
Philippoussis, F., 292
Philipsen, A., 3574
Philipsen, S., 2842
Phillips, S., 624
Piacentini, L., 2514
Piccio, L., 4775
Piccioli, M., 202
Piekorz, R., 4937
Pieniaszek, H. J., 58
Pierani, P., 3857
Pierce, S., 4131
Pierri, I., 202
Pieters, R., 1270, 2743
Piga, A., 5090
Piguet, V., 1727
Pikovski, I., 3477
Pilarski, L. M., 1520
Pileri, S., 202, 2489
Piliponsky, A. M., 1898
Pineault, N., 4529
Pinkel, D., 3109, 4539
Pinkus, G. S., 2473
Pinkus, J. L., 2473
Pinotti, G., 2489
Pinto, A., 4644
Pippard, M., 5089
Piris, M. A., 681, 1220, 4042
Pistillo, M. P., 202
Pitchford, S., 4687
Pitsilos, S., 3875
Pittaluga, S., 4653
Piva, R., 1919
Plachter, B., 4870
Platanias, L. C., 4667
Plo, I., 1543
Plow, E. F., 1582
Plumas, J., 949
Plumb, M., 2349
Plunkett, W., 4098
Pluskota, E., 1582
Podar, K., 1530, 2762, 3606
Podda, G., 2446
Podlosky, L., 454
Poggi, A., 186
Polak, P. E., 2355
Polito, L., 202
Pollard, J. W., 1155
Polverini, P. J., 3960
Polycarpou-Schwarz, M., 3690
Ponder, K. P., 3924
Pönisch, W., 1620
Ponka, P., 4172
Pontara, E., 151
Pontarotti, P., 286
Ponzoni, M., 2489
Poole, J., 752

Poole, L., 2897
Popek, E., 1718
Popovici, C., 286
Poppema, S., 1149
Popplewell, L., 1637
Porcu, P., 425
Porrata, L. F., 3391
Porter, J. B., 5089
Porter, L. A., 1928
Portier, A., 729
Portmann, B., 101
Portsmouth, S., 4000
Porwith, A., 4695
Porwit-MacDonald, A., 4047
Potier, P., 3014
Potocki de Montalk, G., 4598
Potter, K. N., 3082
Pötzsch, B., 2617
Poujol, C., 1400
Poulaki, V., 2377, 4055
Pousseau, N., 1400
Pownall, H. J., 3901
Poznansky, M. C., 45
Prandoni, P., 2955
Prchal, J. F., 3294
Prchal, J. T., 1591, 3294
Prentice, H. G., 3174
Press, O. W., 2340
Preudhomme, C., 1277
Price, T., 5091
Price, T. H., 4195
Price-Troska, T. L., 3801
Priestley, G. V., 4739
Prince, H. M., 1654
Princen, H. M. G., 545
Pritsch, O., 4029
Pro, B., 3413
Prohaska, R., 3751
Prostredna, M., 3948
Protti, M. P., 1038
Proulle, V., 4430
Provisor, A. J., 3809
Prystowsky, M. B., 2679
Pui, C.-H., 3862

Qi, H., 4551
Qian, Y., 4862
Quartier, P., 2693
Quax, P. H. A., 1810
Quéré, I., 4850
Quesenberry, P., 373
Quigley, M. M., 4708
Quillet-Mary, A., 1543
Quinn, M. F., 1558
Quintanilla-Martinez, L., 3181
Quintel, M., 1882

Rabbani, H., 4930
Rabbitts, T. H., 3229
Rabie, T., 3948
Racine, C., 3065
Racioppi, L., 3106
Racke, F. K., 1744, 4333
Rackoff, W., 1692
Raderer, M., 2335, 2547
Radford, I., 1277
Radsak, M. P., 2810
Raffeld, M., 3181, 3407, 3590, 4653, 4944
Rafii, S., 168
Ragni, M. V., 2963
Rahman, M. M., 3451
Rahman, S., 4828
Rai, K., 6
Raimondi, S., 3862
Raines, E. W., 485
Raja, T., 2137
Rajantie, J., 1660
Rajapaksa, R., 433
Rajewsky, K., 1505
Rajkumar, S. V., 827, 1715, 2496
Rake, J. P., 5021
Ramachandran, V., 552
Rambaldi, A., 4589
Ramenghi, U., 3857
Ramezani, A., 4717
Rammensee, H.-G., 2810
Ramon, R., 2955
Ramos, F., 4695
Ramsey, H., 801
Ramsey, W. J., 2563
Rance, J. B., 4393
Randell, E., 3037
Rangatia, J. S., 270
Rangel, R., 4903
Rankin, A., 4372
Ranson, T., 4887
Rao, K., 1713
Rao, S., 2521
Raschi, E., 3495
Raschke, W. C., 849
Raslova, H., 541
Rasmussen, T., 4607
Ratajczak, J., 3784
Ratajczak, M. Z., 3784
Ratnam, M., 4551
Ratta, M., 202
Ratzinger, G., 1422
Raubitschek, A., 1637
Rayburn, H., 2570
Raymer, R. A., 3924
Read, E. J., 71
Reagan, J. L., 1422
Reca, R., 3784
Reddy, P., 2877
Reed, W., 351, 2137
Reeder, T., 2534, 3391
Reeder, T. L., 1981
Regazzi Bonora, M., 3857
Regnault, V., 1419
Rehwald, U., 420
Reichardt, V. L., 977
Reid, M. E., 2081
Reid, M., 4628
Reid, S. D., 1007
Reidy, M. A., 3915
Reiffers, J., 2368
Reilly, C. M., 2215
Reiman, T., 1520
Reinhardt, D., 2001, 3868
Reinhart, T. A., 1684
Reis e Sousa, C., 305, 961
Reiser, M., 420
Reisfeld, R. A., 649
Reiter, R. A., 946
Reith, W., 3550
Reitsma, P., 4823
Relling, M. V., 3862
Remmerswaal, E. B. M., 2686
Ren, C., 2721
Ren, S., 2043
Rénia, L., 4253
Renner, A., 2184
Reny, J.-L., 1833
Renz, A., 2895
Repp, R., 3635
Repp, R., 4267
Resek, M. E., 2850
Resendes, K. K., 311
Resnick, I. B., 5084
Resnick, I., 441
Rettie, A. E., 2896
Rettig, M. P., 4625
Reutelingsperger, C. P. M., 4223
Revello, M. G., 5053
Rex, J. H., 2542
Reyes, F., 4279
Reynaud, D., 4313
Rezaie, A. R., 4802
Rezende, S. M., 1416
Rezvany, M.-R., 1063
Rhee, S. G., 5033
Ribeiro, M. L., 4180
Riccardi, C., 585, 729
Ricchetti, E. T., 2440
Richard, O., 4887
Richardson, J. A., 5010
Richardson, P., 703, 1530, 3606
Richardson, P. G., 2377, 4055
Richmond, A., 2115
Richon, V., 3236
Richon, V. M., 4055
Richter, A., 3690
Rick, M. E., 71
Rickinson, A. B., 4290
Riddell, S. R., 407, 476, 1290
Ridger, V. C., 3249
Ridley, A., 3560
Riedel, D., 3690
Riedel, H.-D., 3288
Riehle, H., 3157
Rieneck, K., 1430
Rigby, S. M., 2024
Rijksen, G., 345, 1596
Rill, D. R., 1718
Rimek, A., 1759
Ringdén, O., 469
Ringshausen, I., 278
Rios, M. B., 97, 473, 3794, 4714
Rissoan, M.-C., 1015
Rissotto, L., 202
Ritchey, C., 236, 3240
Ritgen, M., 2049
Ritz, J., 363
Rivas, C., 2446
Rivella, S., 2932
Rivera, A., 4347
Rivera, G. K., 3862
Rivera, J., 4224
Rives, S., 78
Rivière, I., 2932
Rizzo, J. D., 2015
Robb, D., 3037
Robbins, P. D., 2620
Robbins, S. M., 2850
Robert, E. S., 463
Robert-Hebmann, V., 399
Robert-Lézénès, Jacqueline, 2575
Roberts, A. B., 498
Roberts, H. R., 3008
Roberts, I., 2137
Rocha, V., 2137
Roche, J., 374
Roddam, P. L., 2770
Rodeghiero, F., 3749
Rodewald, H.-R., 3550
Rodrigues, N. P., 45
Rodríguez, A., 4042
Rodríguez, M. J., 4695
Rodriguez, M., 4628
Rodríguez-Frade, J. M., 38
Rodwell, R., 2314
Roederer, M., 2711
Roelofs, H., 358
Roerdinkholder-Stoelwinder, B., 747
Roh, K., 524
Rojnuckarin, P., 3915
Roland, J., 399
Rolandi, V., 1996
Roldan, V., 4224
Rollins, B. J., 2473
Rollinson, S., 2770
Roméo, P.-H., 2756
Ron, Y., 4347
Roncarolo, M. G., 5076
Rönndahl, G., 2001
Roodman, G. D., 3778
Rooney, C. M., 1905
Roos, D., 1987, 5021
Roos, G., 4047, 4952
Roosnek, E., 3198
Rosamond, W. D., 1243
Rose, A. L., 4225
Rosen, F. S., 2159
Rosen, H., 295
Rosenbaum, J. T., 815
Rosenberg, A. S., 4520
Rosenberg, J., 466
Rosenberg, N., 4808
Rosenberg, P. S., 822, 2072
Rosenblad, E., 4267
Rosendaal, F., 4387
Rosendaal, M., 2996
Rosenquist, R., 4047, 4952
Rosenwald, A., 4539, 4576, 4944
Rosito, P., 3857
Rosmarin, A. G., 311
Rosove, M. H., 4783
Ross, C. W., 2895
Rossi, B., 4775
Rossi Ferrini, P., 4615
Rossi, M. I. D., 576
Rossi, R. J., 58
Rossi, S., 3550
Rosten, P., 4529
Roth, E., 2886, 4990
Roth, U., 907
Rothammer, K., 4937
Rothenberg, M. E., 863
Rotolo, J. A., 2440
Roumier, C., 1277
Rouse, T., 2024
Rousseau, R. F., 1718
Rousselot, P., 4033
Rovelli, A., 3373
Rowe, J. M., 463
Rowe, V., 2033
Rowley, S. D., 781
Roy, A., 3065
Roy, L., 541
Roy-Proulx, G., 766
Rubenstein, J. L., 466
Rubin, C. M., 2137
Rubio, M., 265
Rubio-Moscardo, F., 3109
Rudert, W. A., 2804
Rüdiger, T., 420, 3590
Rudolph, R., 2748
Rue, M., 4569
Rüegg, R., 3755
Ruehlmann, J. M., 649
Rufer, N., 3198
Rugarli, C., 1038
Ruggeri, M., 3749
Ruíz-Ballesteros, E., 4042
Rumpel, M., 4641
Ruoff, G., 4853
Rupolo, M., 4644
Ruscetti, F. W., 498, 3085
Ruskone-Fourmestraux, A., 2547
Russell, S. J., 2557

Russell-Jones, R., 1513
Russo, K. M., 3687
Rutherford, T. R., 2833
Ryan, E. J., 4464
Ryan, J. J., 524
Ryan, T. M., 903
Rymo, L., 3749

Saas, P., 194
Saba, J. D., 351
Sabatier, L., 4598
Sabbion, P., 2955
Saccani, A., 4452
Sacco, S., 3827
Saci, A., 4363
Sackstein, R., 602, 771
Sadelain, M., 2932
Sadler, J. E., 2089
Sáez, A. I., 681
Saffer, H., 2507
Sahota, S., 4975
Sahota, S. S., 4137
Saint-Mezard, P., 1891
Saint-Remy, J.-M., 1351
Saito, T., 1777
Saito, Y., 3594
Sakamoto, C., 1164
Sakano, S., 2227
Sakura, T., 3386
Salati, E., 955
Sale, G. E., 4209
Saleh, N., 463
Sallah, S., 943
Sallan, S. E., 2473
Sallusto, F., 4260
Salmon, I., 1469
Salmon, P., 1284, 1727
Salomon, O., 4783
Salooja, N., 3373
Salven, P., 168
Salzer, U., 3751
Samii, K., 3198
Samoggia, P., 1316
Samoylenko, A., 907
Sampson, M., 2804
Samuel, S., 441
Samuelsson, J., 1080
Samuelsson, U., 3868
Sánchez, L., 681
Sánchez-Aguilera, A., 1220
Sánchez-Beato, M., 1220, 4042
Sanchez-Gonzalez, B., 2446
Sanchez-Izquierdo, D., 4539
Sander, B., 4047
Sandlund, J. T., 3862
Sandmaier, B. M., 1620, 5068
Sands, M. S., 2054, 3924
Sandset, P. M., 4387
Sane, D. C., 1857
Sang, H., 1572
Saniabadi, A., 4452
San-Miguel, J. F., 4695
Sansonno, D., 3818
Santagostino, E., 173
Santanen, M., 4022
Santer, M., 3477
Santer, R., 1845
Santiago, L., 4958
Santidrián, A. F., 3674
Santini, V., 4615
Santos, E. B., 5068
Santra, M., 2374
Sanz, E., 3424
Saresella, M., 2514
Sarfati, M., 265
Sargin, B., 3164
Sarkodie, F., 2419
Sartorello, F., 151
Sasaki, K., 532
Sasaki, T., 1188
Sasmono, R. T., 1155
Sassa, S., 1188, 4623
Satagopan, J., 1249
Sather, H. N., 3809
Satinger, J., 463
Sato, H., 3658
Sato, K., 3581
Sato, N., 4479
Sato, T., 2905
Sato, T., 4748
Sato, T., 2990
Sato, T., 3509
Sato, T., 532
Satoh, K., 3469
Sauer, U., 1213
Sauerland, M. C., 64
Saulle, E., 2826
Savasan, S., 4449
Savidge, G., 4828
Sawamura, M., 3386
Sawasdikosol, S., 3687
Sawyer, J., 3849
Sawyer, S. T., 524
Sawyers, C. L., 4701
Sayers, T. J., 3991
Scadden, D. T., 45
Scallan, C., 2963
Scappini, B., 4615
Scaradavou, A., 5046
Scarpini, E., 4775
Schaafsma, M. R., 2144
Schaefer, U. W., 446
Schaer, D. J., 3755
Schafer, A. I., 3901
Schäfer, F., 1213
Scharffetter-Kochanek, K., 739
Schechter, C., 2858
Schechter, G. P., 3754
Scheel-Walter, H., 1630
Scheffold, C., 2775
Scheibenbogen, C., 4643
Scheller, C., 1213
Scherer, S. W., 4301
Scherf, A., 5025
Scherr, M., 1566
Scheuring, U. J., 85
Schiedlmeier, B., 1759, 2191
Schiedner, G., 1734
Schiffer, C. A., 6
Schilbach, K., 869
Schild, H., 2810
Schiller, G., 2461
Schipul Jr, A. H., 576
Schlaeger, T. M., 508
Schlegel, P. G., 869, 1630
Schlossman, R., 703, 1530, 2377, 4055
Schmaier, A. H., 4430
Schmaltz, C., 2440
Schmid, J. A., 3042
Schmid, M., 2886
Schmidt, E., 1941
Schmidt, M., 1284
Schmidt, M., 259
Schmidt, V. A., 3021
Schneider, H., 1359
Schneider, T., 1213
Schneider, U., 2557
Schneller, F., 278
Schneppenheim, R., 1845
Schnittger, S., 1494
Schnitzer, B., 2895
Schobess, R., 2529
Schoch, C., 64, 270
Schoch, H. G., 2043
Schoedon, G., 3755
Schoof, J., 699
Schoormans, S., 4223
Schotte, R., 1015
Schouten, H. C., 2144
Schreiber, A. D., 4479, 4615
Schrezenmeier, H., 1236, 2833
Schröder, E., 2897
Schroeder, G., 827, 2156, 2534
Schroeder, V., 371
Schulte, V., 3948
Schultheis, B., 1007
Schulz, H., 420
Schulz, O., 305
Schuman, T. A., 1071
Schumann, C., 2529
Schümann, K., 3316
Schumm, M., 869, 1630
Schurman, S. H., 2563
Schuster, C., 655
Schuster, S. J., 3875
Schwab, R., 1494
Schwabe, D., 2529
Schwäble, J., 3164
Schwartz, E., 5090
Schwartzman, E., 4708
Schwarz, S., 699
Schwarzer, E., 722
Schweizer, S., 289
Schwering, I., 1505
Scielzo, C., 1262, 1962
Scofield, R. H., 992
Sconocchia, G., 1752
Scorrano, L., 3093
Scott, B., 1453
Scott, C., 2393
Scott, D., 3722
Scott, J. M., 2483
Scudder, L., 3021
Sebban, C., 4279
Segalini, G., 2071
Segeren, C. M., 2144
Segraves, R., 3109
Seiffert, D., 58
Seitz, G., 869
Seki, C., 2300
Selby, D. M., 2895
Seligsohn, U., 4783, 4808
Sellers, S. E., 2199
Selzer, E., 2886
Semple, J. W., 1658
Sempowski, G. D., 4878
Senfter, M., 4561
Senga, T., 1185
Senju, S., 3501
Sensel, M. R., 3809
Serafeim, A., 3212
Serody, J. S., 3714
Serrano, L. M., 1637
Serve, H., 3164
Sese, J., 3509
Setterblad, N., 1874
Sexl, V., 4937
Sezer, O., 2094
Sferruzza, A., 58
Shakhov, A. N., 1477
Shamri, R., 4437
Shan, J., 473, 3794
Shank, N. C., 2321
Shankar, P., 226
Shankaran, H., 2637
Shannon, K., 1984
Shannon, K. M., 2250
Shapira, M. Y., 441, 5084
Shapiro, L. H., 1818
Sharpe, A. H., 3741
Sharpe, R. W., 4708
Shatrov, V. A., 4847
Shaughnessy, J., 3849
Shaughnessy Jr, J., 1128, 2374, 4982
Shaunak, S., 4000
Shaw, P. J., 1205, 1611
She, J.-X., 1977
Shea, D. A., 3281
Shearer, G., 4653
Shearer, G. M., 2514
Shelhamer, J. H., 2652
Shelley, C. S., 894, 4033
Shen, A., 466
Shen, J., 2318
Shen, L., 4131
Shen, L., 2277
Shen, R. R., 5007
Shenoy, S., 2067
Shepherd, P., 1941
Sher, A., 305, 961
Sherritt, M., 3150
Shi, J., 2628
Shi, Y., 3126
Shibahara, S., 4623
Shibata, J., 4416
Shibayama, H., 1094
Shibuya, M., 2261
Shilling, H. G., 3730
Shimada, T., 4623
Shimano, S., 3386
Shimazaki, C., 3334
Shimohakamada, Y., 4711
Shin, H.-S., 5033
Shin, M. G., 3118
Shinonome, S., 3386
Shivdasani, R. A., 4789
Shizuno, K., 3509
Shizuru, J. A., 1620, 3730
Shobuike, T., 3451
Shortman, K., 1453
Shufesky, W. J., 611
Shuman, M. A., 466
Shyamala, V., 2419
Sica, A., 4452
Siddiqui, M. A. Q., 2253
Sieber, M., 420
Siebert, R., 3681, 706, 4539
Siegel, D., 3849
Siemens, H.-J., 4416
Sievers, E. L., 3398
Sigalotti, L., 4644
Sigouin, C. S., 3049
Sikora, L., 863
Sili, U., 1905
Silliman, C. C., 454
Simmonds, R. E., 1416, 4393
Simmons, P. J., 856
Simmons, W. J., 1919
Simon, N., 655, 664
Simon, S. I., 3257
Simone, F., 2355
Simpson, E., 3560, 3722
Simpson, R. J., 3316
Singh, B., 1249
Singh, F., 2268
Singh, S., 807
Singh, S. M., 270
Singh, S., 1053
Singh, U. P., 807
Singh-Jasuja, H., 2810
Sitbon, M., 1913

Skak, K., 1430
Skarsgard, E., 2963
Skibeli, V., 1204
Skikne, B. S., 3359
Skov, S., 1430
Slack, J. L., 2521
Slansky, J. E., 1645
Slater, R., 837, 2144, 2743
Slattery, J. T., 2043
Slavin, S., 441, 5084
Slovak, M. L., 4701
Slungaard, A., 4687
Smayra, T., 2983
Smethurst, P. A., 4372
Smit, E. M. E., 837
Smit, G. P. A., 5021
Smith, A., 5061
Smith, B. D., 4625
Smith, C., 983
Smith, E. L. P., 2253
Smith, F. O., 3398
Smith, J. R., 815
Smith, M., 3338
Smith, M. P., 4828
Smith, M. T., 2770, 4640
Smith, R., 351
Smith, R., 1128
Smith, S. C., 1718
Smolich, B. D., 3597
Smyth, M. J., 3590
Snapper, S. B., 2159
Snowden, R., 2349
Snyder, D. S., 4701
So, C. W., 633
Sobocinski, K. A., 2015
Sobolev, V., 4808
Socié, G., 1611, 2073, 3373
Söderberg, O., 4047, 4952
Söderberg-Nauclér, C., 4870
Soenen, S. L., 2563
Sohal, J., 3188
Soiffer, R. J., 363, 831
Soignier, Y., 3527
Sokolovsky-Eisenberg, M., 4437
Solanky, N., 3316
Solary, E., 194
Soldan, K., 2419
Soldera, C., 151
Solé, F., 4042
Soler, D., 1677
Solga, M. D., 1071
Soloviev, D. A., 1582
Soma, T., 1698
Song, S., 1658, 3708
Sonneveld, P., 837, 2144
Sonoda, Y., 2924
Sopper, S., 1213
Sorbara, L., 3181, 3407
Sorel, N., 374
Soria, J. M., 163
Soriano, S. F., 38
Sotiropoulou, P. A., 3444
Sotto, J.-J., 949
Souto, J. C., 163
Spanish Hodgkin Lymphoma Study Group, 681
Spiekermann, K., 1494
Spillmann, D., 2405
Spinola, S. M., 1677
Spits, H., 1015, 4512
Spooner, G., 4828
Sposi, N. M., 2826
Spring, F. A., 1790
Springett, G. M., 2570
Spruce, L. A., 3784
Srai, S. K. S., 3316
Srinouanprachan, S., 2896
Sriramarao, P., 863
Srivastava, P., 4000
Srour, E. F., 1299
St. Coeur, M., 311
Staak, J. O., 420
Staels, B., 545
Stafford, M. J., 1392
Stahl-Hennig, C., 1213
Stam, R. W., 1270
Stams, W. A. G., 2743
Stanford, W. L., 517
Stapley, J., 690
Staplin, W. R., 1798
Starr, M., 1329
Stasakova, J., 2184
Staudt, L., 4576
Staudt, L. M., 4539, 4944
Staunton, D. E., 4437
Stauss, H. J., 1007
Stebbing, J., 4000
Steckel, N., 446
Steenhard, B., 383
Steensma, D. P., 2156, 2534
Stefani, P. M., 2955
Steff, A.-M., 292
Steffen, B., 3164
Steijaert, M. M. C., 2144
Stein, J. V., 38
Stein, R. B., 58
Steinberg, D. M., 4783
Steinberg, S. M., 3407, 4653
Stella, S., 1262, 1962
Sterkers, Y., 5025
Stern, A. M., 58
Stetler-Stevenson, M., 4944
Steunou, V., 5087
Steur, C., 3164
Stevens-Ayers, T., 407
Stevenson, F., 1087
Stevenson, F. K., 3082, 4137
Steward, S. A., 2646
Stewart, D., 3002
Stewart, J. B., 921
Stigter, R. L., 2743
Stilgenbauer, S., 699, 2049
Stirpe, F., 202
Stitely, M., 492
Stobaugh, C., 3236
Stocker, J. W., 2412
Stockinger, B., 4472
Stoffregen, E. P., 4611
Stoiber, D., 4937
Stolte, M., 2335
Stone, W. H., 163
Storb, R. F., 1620
Storb, R., 5068
Storek, J., 3319, 4209
Storer, B., 1620, 3319
Storring, P. L., 1204
Strain, J. J., 2483
Strasser, A., 2393
Stratton, S. L., 2542
Stravos, P., 2314
Stremmel, W., 3288, 3690
Streubel, B., 2335
Stringer, S. E., 2243
Strobel, U., 2617
Strola, G., 1262
Strother, D., 1718
Stuhr, A., 2049
Sturlan, S., 4990
Styles, L., 2401, 2865
Suarez, G. A., 2496
Subbiah, K., 2340
Suda, T., 1801
Sueishi, K., 1871
Suen, T.-C., 4966
Suffredini, A. F., 2652
Sugahara, H., 1094
Sugimoto, M., 915
Sugita, K., 3658
Sugiyama, D., 4733
Sugiyama, H., 1698
Sumathipala, R., 4828
Sumbayev, V. V., 4847
Sumi, R., 2870
Summerbell, R. C., 2542
Sun, C.-W., 903
Sun, H., 3460
Sun, J., 2816
Sun, Q., 1956
Sun, Y., 124
Sun, Y.-H., 2277
Sundström, C., 4047, 4952
Sung, D., 5046
Suppo, G., 2125
Sutherland, W. M., 1071
Suto, A., 3594
Suwabe, N., 1188
Suzuki, K., 1164
Suzuki, K., 3594
Suzuki, N., 886
Suzuki, S., 4219
Suzuki, T., 1934, 3615
Suzuki, T., 3509
Suzuki, T., 3658
Svoboda, M., 1118
Sweeney, G., 5090
Sykes, M., 2886
Sykora, K.-W., 1845

Tadokoro, S., 3485
Tahara, H., 2620
Tai, G., 2896
Tai, S. J., 2963
Tai, Y.-T., 2377, 2762
Takada, K., 4765
Takafuta, T., 3469
Takagi, M., 3622
Takahashi, I., 178
Takahashi, K., 3658
Takahashi, S., 4711
Takahashi, S., 532
Takakura, N., 1801
Takasugi, K., 4711
Takemasa, A., 295
Takenawa, T., 2159
Taketani, S., 3274
Takigawa, E., 3668
Tallman, M. S., 2521
Talmant, P., 1277
Talpaz, M., 97, 473, 690, 1692, 3794
Talpur, R., 2132
Talwar, S., 2652
Tam, C., 2473
Tamaki, H., 1698
Tamasauskas, D., 5046
Tamburini, A., 2125
Tamura, T., 961
Tan, B. L., 4725
Tanaka, H., 673
Tanaka, Y., 3386
Tanaka, Y., 3615
Tanduo, C., 2955
Taner, T., 4457
Tang, D., 1977
Tang, F., 2797
Taniguchi, Y., 2990
Taniguchi, Y., 1698
Tanke, H. J., 358
Tanner, M. J. A., 4180
Tannoia, N., 2137
Tantravahi, R., 781
Tan-Un, K., 2842
Taras, E., 3714
Tardy, B., 1419
Tatarczuch, L., 1453
Tatsumi, N., 1164
Taub, D. D., 807
Taub, J. W., 1551
Taya, Y., 3622
Taylor, A. M., 1409
Taylor, B. J., 1520
Taylor, B. R., 2250
Taylor, K., 2314
Taylor, M., 3229
Taylor, N., 1913, 2167
Taylor, P. A., 3741
Taylor, R. P., 1071
Tazelaar, H. D., 3391
Tazzari, P. L., 202
Tchernia, G., 318, 5039
Tedder, T. F., 3641
Teerenhovi, L., 3840
Tefferi, A., 1981, 2156, 2534, 3391
Tehranchi, R., 1080
Teitell, M. A., 5007
Telen, M. J., 3281
Tellam, J., 3150
Ten Berge, I. J. M., 2686
Tenchini, M. L., 173
Tenekedjiev, K., 4380
Tenen, D. G., 270, 1141, 2074
Teo, I., 4000
Teodoridis, J. M., 4033
ter Meulen, V., 1213
Territo, M., 2461
Teshima, T., 2877
Testa, U., 1316, 2826
Testoni, C., 3495
Tettamanti, G., 2071
Tewari, R., 2842
Tezuka, T., 4765
Thatte, J., 4916
Themis, M., 1359
Theodore, L. J., 2340
Therneau, T. M., 2496
Theurl, I., 4148
Thibault, A., 1692
Thielemans, K., 1469
Thirman, M. J., 2355
Thomas, A., 2454
Thomas, D. A., 3413, 3794
Thomas, D., 97, 473, 1692, 2507, 4714
Thomas, D. W., 2646
Thomas, P. W., 4975
Thomas, R., 2033
Thomas-Tikhonenko, A., 1950
Thompson, A., 1558
Thompson, A., 2963
Thomson, A. W., 611, 4457
Thomson, S., 3150
Thorrez, L., 1734
Thorsélius, M., 4047
Thummel, K. E., 2896
Thunberg, U., 4047, 4952
Thys, C., 1375
Tian, C., 2235
Tian, E., 1128, 2374, 3849
Tibshirani, R., 433
Ticchioni, M., 4836
Ticheli, A., 3198
Tichelli, A., 3373

Tiffert, T., 4189
Tilbrook, P. A., 2727
Tilly, H., 4279
Tinguely, M., 1505
Tinhofer, I., 4561
Tissing, W. J. E., 3868
Tiwari, S., 4789
Tjønnfjord, G., 4267
Tobelem, G., 4816
Tobin, G., 4952
Togayachi, A., 2870
Tojo, A., 4711
Tomaszewski, J., 2294
Tomiyama, Y., 178, 3485
Tomonari, A., 4711
Tomra, S., 1430
Tong, W., 1155
Tonks, A., 624
Tonks, A. J., 624
Tönnies, H., 3872
Tönnissen, E., 5085
Tool, A. T. J., 5021
Toomey, N. L., 2321
Topp, M. S., 1637
Torbett, B. E., 3265
Torjesen, P., 1204
Toro, J. R., 3407
Torsellini, M., 5053
Tosato, G., 1535
Toth-Zsamboki, E., 3969
Touitou, I., 1205
Touw, I. P., 1111, 2584
Town, A., 3597
Townes, T., 903
Toyoda, N., 3509
Toyota, M., 4131
Trabattoni, D., 2514
Trachtenberg, E., 351
Tracy, R. P., 1243
Trainor, C. D., 1603
Tran, N., 3413
Traoré, B., 5025
Travaglino, E., 1996
Traver, D., 508
Travers, J. B., 801
Traversari, C., 1038, 1290
Travis, L. B., 2015
Traynor, A., 2064
Trenschel, R., 446
Treon, S. P., 2762
Tricot, G., 3849
Trigg, M. E., 3809
Tringali, C., 2071
Trinkaus, K., 2067
Trocciola, S., 831
Trono, D., 1284, 1727, 2167
Tropea, M., 2652
Truong, B.-T. ran., 1141
Tryggvason, K., 877
Tsai, H.-M., 4449
Tsang, J. Y. S., 2704
Tsuboi, A., 1698
Tsuchida, R., 3622
Tsuji, K., 2990, 4733
Tsuji, S., 915
Tsuji, T., 2924
Tsujimura, H., 305, 961
Tsujimura, K., 1460
Tsujimura, T., 1094
Tsukamoto, N., 3386
Tsuneto, M., 2227
Tsurumi, T., 1460
Tucci, F. A., 3818
Tucker, N., 1359
Tulliez, M., 2983
Tumanov, A. V., 1477
Tun-Kyi, A., 1487
Turecek, P. L., 946
Turhan, A. G., 4583
Turtle, C. J., 2314
Tuscano, J. M., 3641
Tuschong, L. M., 2563
Tutour, P. L., 2693
Twu, Y.-C., 2081

Uchiba, M., 3029
Uchida, R., 3334
Uchimaru, K., 4711
Uchiyama, T., 2789
Ueda, C., 2789
Ueda, S., 1094
Uemura, Y., 3501
Ueta, H., 3274
Uguccioni, M., 815
Ullmann, A. J., 3365
Underhill, G. H., 4013
Uno, K., 3658
Usami, S., 2667
Usuku, K., 3074
Uzan, G., 2973
Uzunel, M., 469

Väänänen, H., 929
Vacek, M. M., 104
Vainchenker, W., 541, 2983
Valdez, H., 226
Valdez, R., 2895
Valensi, F., 1277, 2693
Valente, E., 722
Valk, P. J. M., 837, 1111
Valkhof, M., 1111
Vallat, L., 4598
Vallejo, A. N., 3543
Valmori, D., 4643
Valore, E. V., 2461
van Baarle, D., 4290
Van Besien, K., 2476
Van Camp, B., 3136
van de Geijn, G.-J., 2584
van de Locht, L., 5085
van de Winkel, J. G. J., 253
van den Berg, A., 1149
van den Berg, E., 1149
van den Blink, B., 4446
van den Bos, A. G., 747
van den Brink, M. R. M., 2440
Van den Elsen, P. J., 3058
van der Bom, J. G., 1841
van der Bruggen, P., 1351
van der Burg, M., 1446
van der Holt, B., 2144
van der Kooij, S. W., 1439
van der Poel-van de Luytgaarde, S., 837
van der Poll, T., 4446, 4823
van der Reijden, B. A., 5085
van der Veen, A., 1149
van Deventer, S. J., 4446
van Dongen, J. J. M., 1446
van Esser, J. W. J., 4290
van Gent, D. C., 1446
van Heerde, W. L., 4223
van Hinsbergh, V. W. M., 1810
van Hoomissen, I., 2152
van Hylckama Vlieg, A., 4387
van Imhoff, G. W., 1149
van Kooten, C., 1439
van Leeuwen, D., 2584
van Lent, N., 1810
van Lier, R. A. W., 2686
Van Lint, C., 4894
Van Linthout, S. A., 2551
van Marwijk Kooy, M., 2144
Van Meirvenne, S., 1469
Van Ness, B., 3126, 4569
van Oers, M. H. J., 2144
van Ojik, H. H., 253
van Puijenbroek, A. A. F. L., 998
van Putten, W. L. J., 837
van Rhenen, D., 2426
Van Riet, I., 3136
van Rooijen, N., 594, 1734
van Schooten, C. J. M., 4222
van Solinge, W. W., 345, 1596
van Spriel, A. B., 253
van Veelen, L. R., 1446
ván Vlijmen, B. J. M., 3933
van Wering, E. R., 2743, 3868
Van Wier, S. A., 4569
van Wijk, R., 345, 1596
VandenDriessche, T., 1734
Vanderkerken, K., 3136
Vangala, R. K., 270
Vanhoorelbeke, K., 782
Vannucchi, A. M., 5088
Vantomme, V., 1351
Váradi, B., 4380
Varadi, K., 946
Vardiman, J. W., 6
Varnum-Finney, B., 1784
Vasconcelos, Y., 4029
Vazquez, L., 4695
Vecchi, A., 4452
Veenstra, D. L., 2896
Vegara-Aguilera, G., 2446
Velan, T., 4355
Velasco, P., 560
Velazquez, I., 2072
Vellenga, E., 1172, 2144
Veltkamp, C., 3288
Venditti, A., 2125
Venerando, B., 2071
Venkatraman, P., 2067
Ventress, N., 2842
Vercellotti, G. M., 3953
Verdonck, L. F., 837, 1201
Verfaillie, C. M., 4687
Vergilio, J.-A., 3875
Verhoef, G. E. G., 2144
Verhoef, G., 837
Verhoeyen, E., 2167
Verkaik, N. S., 1446
Verkleij, A. J., 747
Vermeij, H., 2426
Vermylen, C., 2137
Vermylen, J., 157, 1351, 1375, 3969
Verneris, M. R., 640
Verschuren, L., 545
Verstovsek, S., 3413
Vesole, D., 3849
Veys, P., 1713
Viale, A., 2206
Vicente, V., 4224
Vichinsky, E., 2865
Vichinsky, E. P., 5089
Vidriales, M.-B., 4695
Viganego, F., 3319
Vigil, L., 2865
Viguier, M., 4253
Vij, R., 2067, 5092
Villard, J., 3198
Villunger, A., 2393
Vilpo, J., 4952
Virts, E. L., 849
Visser, G., 5021
Vitiello, L., 3106
Voggenreiter, G., 1882
Vogler, C., 2054
Vogt, A. M., 2405
Vogt, T. M., 2008
von Kalle, C., 1284, 2099
von Stackelberg, A., 3835
von Stebut, E., 210
von Wasielewski, R., 4063
von Wasielewski, S., 4063
Vornlocher, H.-P., 3157
Vose, J., 2015
Vose, J. M., 2363, 2476
Vossen, J. M. J. J., 1446
Vosshenrich, C. A. J., 4887
Vourc'h, C., 541
Vozenin-Brotons, M.-C., 4583
Vremec, D., 1453
Vreys, I., 157, 3969
Vu, D., 3492
Vuckovic, S., 2314
Vuillier, F., 4029

Waclavicek, M., 2184
Waddell, T. K., 4245
Waddington, S. N., 1359
Wade, A., 846
Wagner, B. E., 921
Wagner, D. D., 2661, 4789
Wagner, F. F., 752
Wagner, J. E., 4233
Wagner, K. F., 4416
Wahl, A., 375
Wahlgren, M., 2405
Wai, A. W. K., 2842
Wainwright, B. J., 1155
Wajih, N., 1857
Wakayama, T., 2601
Waldburger, J.-M., 3550
Wallace, W. A. H., 921
Wallman, K., 4047
Walsh, S. H., 4047
Walsh, T. J., 2542
Walter, R. B., 3755
Walters, M. C., 351, 2137
Walzog, B., 739
Wan, J. Y., 943
Wandersee, N. J., 325
Wang, D., 2646
Wang, H.-C., 119
Wang, H., 3901
Wang, J., 2924
Wang, J., 4903
Wang, L., 2804
Wang, L., 4909
Wang, L., 1243
Wang, P.-X., 4966
Wang, Q., 3885
Wang, R., 3893
Wang, S., 3648
Wang, X.-H., 2870
Wang, X., 4201
Wang, X., 2507
Wang, Y., 4005
Wang, Y.-H., 1030
Wang, Z., 1759
Wang, Z., 2721
Wang, Z., 611, 3648
Wang, Z., 955
Wangensteen, O. D., 3714
Wanless, I. R., 5090
Ward, A. C., 2584
Warkentin, T. E., 3049
Warming, S., 1934
Warmuth, M., 655, 664
Warren, A., 3338

Warrington, K. J., 3543
Wassmann, B., 85
Watanabe, N., 1141
Watanabe, S., 2990
Waters-Pick, B., 5061
Watkins, N. A., 4372
Watkins, S. C., 611
Watson, S. P., 1392
Wdzieczak-Bakala, J., 3014
Weatherall, D. J., 5089
Webb, D., 1713
Webb, J., 4222
Weel, J. F., 2686
Weemaes, C. M. R., 1446
Wei, S., 236, 3240
Weibrecht, K. W., 45
Weijer, K., 1015
Weijer, S., 4446
Weill, B., 758
Weinmann, P., 739
Weis, J., 3373
Weisdorf, D. J., 2015
Weisenburger, D. D., 2363
Weiss, G., 4148
Weiss, L. A., 1705
Weissmann, D., 2285
Weisz, E., 4937
Wekerle, T., 2886
Weksler, B. B., 3754
Wellems, T. E., 3309
Wellik, L., 1715
Welply, J. K., 2033
Wendling, F., 2983
Wendon, J., 101
Wenger, R. H., 348, 4416
Wenning, D., 2775
Wenning, M. J., 1984
Wenz, B., 370
Werling, D., 1874
Werner-Favre, C., 1727
Werre, J. M., 747
Wessels, J. T., 869
Westerman, D. A., 1654
Westhoff, C. M., 1194
Wetzler, M., 2940
Weyand, C. M., 3543
White, C. R., 4408
White, D. A., 415
Whitehead, A. S., 2483
White-Scharf, M. E., 4305
Whittaker, S. J., 1513
Wickrema, A., 524
Wickremasinghe, R. G., 3174
Wiegant, W., 1446
Wiemels, J. L., 4640
Wierda, W., 3413, 3794, 4714
Wierda, W. G., 4903
Wiestner, A., 3754, 4944
Wietzerbin, J., 5087
Wigzell, H., 1063
Wijermans, P. W., 1657, 2144, 4645
Wiklund, T., 4267
Wilbur, D. S., 2340, 5068
Wildfire, A., 4000
Will, A. M., 2137
Will, E., 1759
Willekens, F. L. A., 747
Willems, F., 4894
Willemze, R., 358
Willerford, D. M., 4492
Williams, D. A., 2099, 4725
Williams, D. L., 2877
Williams, K., 2314
Williams, M. B., 4916
Williams, N., 2314
Williams, S. F., 2015
Williamson, D., 3477
Williamson, L. M., 370, 4372
Willig, T.-N., 318
Willis, L. M., 2440
Willman, C. L., 2521, 3628
Wilson, M., 831
Wilson, W. H., 4653, 4944
Winckler, J., 1400
Winkler, T., 1566
Winn, R. K., 295
Wiseman, G., 2534
Witek, J., 1024
Witherspoon, R. P., 3319
Witt, O., 2001
Witte, O. N., 4088
Wittebol, S., 2144
Wittevrongel, C., 157
Wittig, B., 259
Witzig, T. E., 827, 1715, 2496, 3391
Wlodarska, I., 706
Wodrich, H., 649
Wojda, U., 492
Wolber, E., 4416
Wolberg, A. S., 3008
Wolf, D. G., 463
Wolff, N. C., 5010
Wölfl, S., 259
Woltman, A. M., 1439
Won, J., 3534
Wong, L. M., 3597
Wong, S., 4088
Wong, W., 3606
Wood, C., 2321
Woodard, P., 2137
Woodcock, J. M., 1308
Woods, N.-B., 1284
Woods, W. G., 3398
Woolfrey, A., 1620
Worth, A., 1713
Worth, R. G., 4479
Wotherspoon, A., 2547
Wrba, F., 2886
Wright, C., 1637
Wright, G., 4944
Wright, S., 2314
Wu, C.-C., 970
Wu, J. Y., 690
Wu, K.-D., 4982
Wu, L., 3893
Wu, Y., 3469
Wu, Y., 124
Wulf, G. G., 2434
Wurthner, J. U., 498
Wynn, R., 58

Xia, L., 552
Xie, J., 4005
Xie, X., 1329
Xie, Y.-G., 3037
Xing, N., 2721
Xu, C., 2721
Xu, L., 3924
Xu, R., 1118
Xu, Z., 226

Yabuta, T., 3615
Yagita, H., 3658, 3741
Yahata, T., 2905
Yamada, M., 178
Yamada, T., 2227
Yamada, Y., 1801
Yamaguchi, M., 532
Yamaguchi, N., 3658
Yamaguchi, T., 1777
Yamaguchi, Y., 3265
Yamahara, K., 2675
Yamamoto, C., 4219
Yamamoto, H., 1375
Yamamoto, M., 886, 1188
Yamamura, K., 3501
Yamane, T., 2227
Yamashita, J., 2675
Yamashita, N., 3581
Yamazaki, H., 2227
Yanagawa, Y., 4923
Yang, F., 3901
Yang, F.-C., 1769
Yang, L., 1977
Yang, M.-Y., 3205
Yang, X., 124
Yang, X., 3901
Yang, X. O., 4492
Yang, Y., 1299
Yaniv, I., 1611, 2137
Yao, Q., 3229
Yarchoan, R., 4653
Yarovinsky, F. O., 1477
Yatomi, Y., 3469
Yatuv, R., 4808
Yazdanbakhsh, K., 5046
Yazicioglu, M. N., 4725
Ye, H., 2547, 4539
Ye, R. D., 1572
Yeap, B. Y., 2521
Yeboah, F., 2419
Yee, K. W. H., 3597
Yewdell, J. W., 2858
Yi, Q., 4005
Yin, D.-P., 2318
Yipp, B. G., 331, 2850
Yoder, M. C., 1329
Yokohama, A., 3386
Yokota, S., 2924
Yokota, T., 576
Yokota, T., 1185
Yokoyama, H., 1188
Yona, S., 4140
Yoritomi, K., 3615
Yoshida, M., 3615
Yoshida, S., 2300
Yoshida, T., 1185
Yoshikawa, H., 2784
Yoshikawa, T., 4219
Yoshino, M., 2227
Yoshioka, A., 915
Young, B. D., 1513
Young, D. C., 425
Young, I. S., 2483
Young, J. W., 1422
Young, N., 71
Young, N. S., 3118
Young, S. G., 2250
Yssel, H., 4512
Yu, D.-Y., 5033
Yu, D., 1950
Yu, L.-C., 2081
Yu, S.-L., 5033

Yuen, C-T., 1204
Yuen, H. A., 3597
Yule, D., 4797
Yun, S.-Y., 3534
Yun, T., 2983
Yurugi-Kobayashi, T., 2675
Yvon, E. S., 1718

Zager, R. A., 3628
Zagonel, V., 4644
Zahorchak, A. F., 611, 4457
Zaja, F., 3827
Zakaria, N., 101
Zalloua, P., 4576
Zangari, M., 3849
Zannini, L., 3622
Zappacosta, S., 3106
Zavodny, P. J., 2620
Zavrski, I., 2094
Zdzienicka, M. Z., 1446
Zecca, M., 3857, 5053
Zeldis, J. B., 2534
Zeller, W. J., 2191
Zen, Q., 3281
Zeng, H., 2215
Zeng, Y., 245, 4485
Zetterberg, H., 3749
Zettl, A., 3590
Zhan, F., 1128, 2374, 3849
Zhang, D. S., 711
Zhang, D., 226
Zhang, H., 2253, 4155
Zhang, J., 383
Zhang, L., 4640
Zhang, M., 2721
Zhang, S., 124
Zhang, Y., 955
Zhang, Z., 4342
Zhang, Z., 1030
Zhao, H., 4944
Zhao, J., 2253
Zhao, W., 3893
Zhelev, D. V., 1181
Zheng, H., 3037
Zhivotovsky, B., 1080
Zhong, B., 236, 3240
Zhou, J., 4847
Zhou, Q., 119
Zhou, Y., 4098
Zhu, Y.-X., 4966
Zhuang, H., 3875
Zibello, T., 3460
Zighetti, M. L., 2446
Zinzani, P. L., 2489
Zipursky, A., 4301
Zivelin, A., 4783, 4808
Zlokovic, B. V., 4797
Zocchi, M. R., 186
Zojer, N., 4137
Zubler, R. H., 1727
Zucca, E., 2489
Zuckerman, T., 463
Zwaan, C. M., 3868
Zwiebel, J. A., 425
Zwinderman, A. H., 358

Inside *Blood* segments are not included in this index but are included in on-line searches done at www.bloodjournal.org.

Subject index

January 1	pages	1-380	**March 1**	pages	1665-2076	**May 1**	pages	3341-3758
January 15	pages	381-786	**March 15**	pages	2077-2448	**May 15**	pages	3759-4226
February 1	pages	787-1202	**April 1**	pages	2449-2900	**June 1**	pages	4227-4646
February 15	pages	1203-1664	**April 15**	pages	2901-3340	**June 15**	pages	4647-5142

A1 is a growth-permissive T-cell survival factor, 2679-2685
ABC7, involvement in heme biosynthesis in erythroid cells, 3274-3280
Acadesine activates AMPK and induces apoptosis in B-CLL cells, 3674-3680
Acetyl-Ser-Asp-Lys-Pro (AcSDKP), angiogenesis induced by, 3014-3020
AcSDKP. *See* Acetyl-Ser-Asp-Lys-Pro
Activated protein C (APC)
  APC alters cytosolic calcium flux in brain endothelium, 4797-4801
  chromosome 18 locus influences APC resistance and thrombosis susceptibility, 163-167
  EFG2 in protein S and APC cofactor activity, 1416-1418
  exosite-dependent regulation of factor VIIIa by, 4802-4807
Activation-induced cytidine deaminase (AID)
  in B-cell non-Hodgkin lymphomas, 3574-3580
  expression in CLL B cells, 4029-4032
  expression in poor-prognosis CLL, 4903-4908
Acute lymphoblastic leukemia (ALL)
  Ara-C sensitivity in *MLL* gene-rearranged infant ALL, 1270-1276
  asparagine synthetase in t(12;21)$^+$ pediatric ALL, 2743-2747
  dexamethasone vs. prednisone and oral vs. intravenous mercaptopurine for, 3809-3817
  DNA methylation of p57KIP2 in, 4131-4136
  early MRD analysis during imatinib treatment of Ph$^+$ ALL, 85-90
  G-CSF and risk of secondary myeloid malignancy after etoposide, 3862-3867
  G3139 and chemotherapy for refractory or relapsed acute leukemia, 425-432
  late relapses evolve from slow-responding subclones in t(12;21)$^+$ ALL, 3635-3640
  LOH within *MLL* in childhood ALL (letter and response), 4222-4223
  MRD in adolescent and adult ALL, 4695-4700
  mutation of *ATM* gene in childhood ALL with *MLL* gene rearrangement, 3622-3627
  severe skin reaction to imatinib in Ph$^+$ ALL (letter), 2446
  TCR, pTα, and RAG-1 in T-ALL, 2693-2703
  thromboembolic events in children with ALL: prednisone vs. dexamethasone, 2529-2533
  unrelated donor SCT vs. chemotherapy for pediatric relapsed ALL, 3835-3839
Acute megakaryoblastic leukemia (AMKL)
  blood work, 2452
  GATA1 mutations in transient leukemia and AMKL in Down syndrome, 4301-4304
Acute myeloid leukemia (AML)
  AML1/MTG8 gene suppression supports myeloid differentiation of t(8;21)-positive leukemic cells, 3157-3163
  AML1 mutations in radiation- and therapy-related MDS/AML, 673-680
  C/EBPs repress leukemic phenotype of, 1141-1148
  CD163/HbSR as marker of monocytic lineage in (letter), 3755-3756
  centrosome aberrations in AML and cytogenetic risk profile, 289-291
  cholesterol reduction kills AML cells and sensitizes them to therapeutics, 3628-3634
  clinical and biologic features of minimally differentiated AML, 1277-1283
  *CYP1A1*2B (Val)* allele in AML patients with *NRAS* mutation, 2770-2774
  detection of quiescent leukemic progenitor cells in, 3142-3149
  differential response to AML cells to gemtuzumab ozogamicin, 4589-4597
  early blast clearance is prognostic factor in, 64-70
  G3139 and chemotherapy for refractory or relapsed acute leukemia, 425-432
  gemtuzumab ozogamicin for relapsed pediatric AML, 3868-3871
  heterozygous PU.1 mutations in (letter), 2074
  high *EVI1* expression predicts poor survival, 837-845
  immunophenotypic evidence of leukemia after induction therapy predicts relapse of, 3398-3406
  induction by *NUP98-HOXD13* in concert with *Meis1*, 4529-4538
  long-term complications after childhood SCT for, 1611-1619
  and MDS after autotransplantation for lymphoma, 2015-2023
  prenatal origin of translocations associated with pediatric AML (letter), 4640-4641
  PU.1 inactivation by AML1-ETO in t(8;21) myeloid leukemia, 270-277
  rapid identification of *CBFB-MYH11*–positive AML (letter), 5085-5086
  relative risk for radiation-induced AML in mice, 2349-2354
  retrovirus-mediated IL-7 expression in leukemic DCs generated from, 2184-2190
  role of AML1-ETO in leukemogenesis, 624-632
  SPAN-Xb in hematologic malignancies, 955-960
  spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in, 2125-2131
  SU5614 inhibits FLT3 and induces apoptosis in AML cell lines, 1494-1504
  suppression of myeloid transcription factors and STAT induction by AML-specific Flt3 mutations, 3164-3173
  sustained complete remission after imatinib in patient with refractory AML, 2960-2962
  transcriptional regulation of *CBS* in Down syndrome, 1551-1557
Acute promyelocytic leukemia (APL)
  APL model with FLT3 mutation is responsive to retinoic acid and SU11657, 3188-3197
  ATRA induces CD52 expression in, 1977-1980
  HOX gene expression in PML-RARα^{2b} APL, 1558-1565
  opposing effects of PML and PML-RARα on STAT3 activity, 3668-3673
  prognostic value of quantitative real-time RT-PCR analysis of PML-RARα mRNA in, 2521-2528
ADA. *See* Adenosine deaminase
ADAMTS-13. *See* von Willebrand factor–cleaving protease
Adeno-associated virus (AAV)–mediated factor IX gene transfer to muscle in hemophilia B, 2963-2972
Adenosine, activity on human DCs, 3985-3990
Adenosine deaminase (ADA) gene therapy trial, long-term results, 2563-2569
Adenosine diphosphate (ADP), in collagen-induced platelet aggregation, 2646-2651
Adenosine monophosphate-activated protein kinase (AMPK), acadesine activates AMPK and induces apoptosis in B-CLL cells, 3674-3680
Adenoviral vectors
  gene therapy and humoral immune response in mice, 2551-2556
  gene therapy for hemophilia A using, 1734-1743
Adhesion. *See also* specific adhesion molecules
  activation of BCAM/Lu-dependent sickle (SS) RBC adhesion, 3281-3287
  CD47 and platelet adhesion on inflamed endothelium under flow, 4836-4843
  GPIIb/IIIa-mediated platelet-platelet interaction, 929-936
  increased adhesiveness of CD8$^+$ T cells in multiple sclerosis, 4775-4782
  L-selectin stimulation up-regulates CXCR4 in lymphocytes, 4245-4252
  laminin isoform–specific adhesion and migration of hematopoietic progenitors, 877-885
  leukocyte antiadhesive actions of annexin 1, 4140-4147
  novel mutation in GDP-fucose transporter gene in LADII, 1705-1712
  novel secreted isoform of ICAM-4, 1790-1797
  PECAM-1–dependent neutrophil transmigration, 2816-2825
  rFVIIa enhances $\alpha_{IIb}\beta_3$-deficient platelet adhesion, 1864-1870
  role of intracellular domains of GPIb in controlling adhesive properties of GPIb/V/IX complex, 3477-3484

SgIGSF: new MITF-dependent mast-cell adhesion molecule, 2601-2608
shear stress inhibits adhesion molecule expression in endothelial cells, 2667-2674
Src-family kinase signaling modulates *Plasmodium falciparum* adhesion, 2850-2857
Tyr143Hisα_{IIb} mutation abolishes $\alpha_{IIb}\beta_3$ function for soluble ligands, 3485-3491
urokinase-type plasminogen activator/$\alpha_M\beta_2$ interactions, 1582-1590
ADP. *See* Adenosine diphosphate
Afibrinogenemia, congenital
order of splicing and outcome of *FGA* donor splice site mutations in, 1851-1856
prenatal diagnosis of *FGB* gene mutation causing, 3492-3494
Agranulocytosis, unresponsive to growth factors after rituximab (letter), 4225-4226
AID. *See* Activation-induced cytidine deaminase
Akt signaling
in CD40-induced MM cell migration, 2762-2769
reduced PKB/Akt and ERK phosphorylation in MDS, 1172-1180
Syk and Rac regulation of Akt-dependent cell survival, 236-244
ALAS. *See* Aminolevulinate synthase
Albumin, protection of B-CLL cells from chlorambucil- and radiation-induced apoptosis by, 3174-3180
ALCL. *See* Anaplastic large cell lymphoma
Alemtuzumab
differential CD52 expression by myeloid DC subsets, 1422-1429
in mycosis fungoides/Sézary syndrome, 4267-4272
plus rituximab in relapsed and refractory lymphoid malignancies, 3413-3415
pure red-cell aplasia due to parvovirus B19 after therapy with (letter), 1654
reduced-intensity SCT with (letter), 779-780
ALK. *See* Anaplastic lymphoma kinase
ALL. *See* Acute lymphoblastic leukemia
All-*trans* retinoic acid (ATRA)
enhancement of ATRA-induced cell differentiation by inhibition of calcium accumulation into ER, 3220-3228
induction of CD52 expression in APL, 1977-1980
Aminolevulinate synthase (ALAS)
hypoxic up-regulation of erythroid ALAS2, 348-350
iron accumulation in ALAS2-deficient erythroblasts, 1188-1193
AMKL. *See* Acute megakaryoblastic leukemia
AML. *See* Acute myeloid leukemia
AML1-ETO
inactivation of PU.1 by, in t(8;21) myeloid leukemia, 270-277
role in leukemogenesis, 624-632
AML1 mutations
in minimally differentiated AML, 1277-1283
in radiation- and therapy-related MDS/AML, 673-680
AMPK. *See* Adenosine monophosphate-activated protein kinase
Amyloidosis
circulating plasma cells as prognostic indicator in, 827-830
light chain–associated, VL genes affect presentation and outcome in, 3801-3808
Anaplasma phagocytophila infection, role of neutrophil β2 integrins in mice, 3257-3264
Anaplastic large cell lymphoma (ALCL), *BCL3* expression differentiates Hodgkin disease from, 2789-2796
Anaplastic lymphoma kinase (ALK), T-cell lymphomas and plasma cell tumors in NPM-ALK transgenic mice, 1919-1927
Anemia
aplastic
11-year follow-up of ATG/cyclosporin A in, 1236-1242
PIG-A gene mutations in aplastic anemia/PNH, 2833-2841
ATG efficacy and toxicity in anemic patients with MDS, 2156-2158
Fanconi
cancer in (letter), 2072-2073
cancer incidence in, 822-826 (erratum, 2136)
gains of 3q26q29 in bone marrow cells in, 3872-3874
retroviral-mediated Fancc expression enhances repopulating ability of *Fancc*$^{-/-}$ stem cells, 1299-1307
sensitivity of *Fancc*$^{-/-}$ bone marrow cells to nitric oxide, 3877-3884
20-year perspective on International Fanconi Anemia Registry, 1249-1256
hemoglobin H disease, 791-800
hemolytic
autoimmune, liposomal clodronate for mouse model of, 594-601
autoimmune, rituximab for children with, 3857-3861
HK Utrecht: mutation associated with hexokinase deficiency and, 345-347
spur-cell, in severe alcoholic cirrhosis (blood work), 3
hepatocellular injury and transfusional iron overload during desferrioxamine therapy in patients with, 91-96
of inflammation, hepcidin is putative mediator of, 2461-2463
late-onset X-linked sideroblastic, after hemodialysis, 4623-4624
mitochondrial ferritin in sideroblastic anemias, 1996-2000
nucleolar localization of RPS19 protein in Diamond-Blackfan anemia, 5039-5045
peripheral smear in pernicious anemia (blood work), 1668
sickle cell (*See* Sickle cell disease)
Angiogenesis
CD13/APN is an endothelial target of Ras, 1818-1826
HGF receptor expression in, 4816-4822
IL-17 promotes angiogenesis and tumor growth by, 2620-2627
induced by AcSDKP, 3014-3020
membrane-type MMP-mediated angiogenesis in fibrin-collagen matrix, 1810-1817
platelet-endothelial interaction in tumor angiogenesis, 1970-1976
prognostic value in solitary bone plasmacytoma, 1715-1717
role of placental growth factor in inflammation, 560-567
Src and PI3K mediate soluble E-selectin–induced angiogenesis, 3960-3968
stage of embryonic stem cell differentiation and adult neovascularization, 2675-2678
Angiostatin, inhibition of HGF in endothelial and smooth muscle cells, 1857-1863
Annexin 1, leukocyte antiadhesive actions of, 4140-4147
Annexin A5, plasma levels and -1C>T mutation in gene for (letter and response), 4223-4225
Antibodies. *See also* Monoclonal antibodies
antibody testing reduces incidence of roxifiban-associated thrombocytopenia, 58-63
antihirudin antibodies after desirudin for thrombosis prophylaxis for hip-replacement surgery, 2617-2619
anti–protein Z antibodies in women with pathologic pregnancies, 4850-4852
donor immunization with pneumococcal vaccine and protective responses after SCT, 831-836
factors affecting antibody levels after allogeneic SCT, 3319-3324
MyD88 pathway in endothelial activation by antiphospholipid antibodies, 3495-3500
platelets activation induced by antibodies to IL-8, 1419-1421
target for antibodies associated with quinine-induced immune thrombocytopenia, 937-942
thrombogenicity of β_2-GPI–dependent antiphospholipid antibodies, 157-162
Anticoagulation
combined anticoagulant and antiselectin treatments prevent DIC, 921-928
CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians (letter), 2896-2897
Gla domain–mutated hyperactive protein C, 2277-2284
HIT in patients treated with subcutaneous unfractionated heparin, 2955-2959
Antifungal prophylaxis in patients with hematologic malignancies, 3365-3372
Antigens. *See also* Human leukocyte antigens
human blood group I antigen expression, 2870-2876
human CMV US2 affects antigen presentation and iron homeostasis, 2858-2864
I locus, adult i phenotype, and congenital cataracts, 2081-2088
proliferation potential of CD8$^+$ T-cell subsets in response to cytokines or, 4260-4266
Antiphospholipid antibodies
lupus anticoagulants and risk of thrombosis in antiphospholipid syndrome, 1827-1832
MyD88 pathway in endothelial activation by, 3495-3500
Antithrombin, reduction of ischemia/reperfusion-induced renal injury in rats by, 3029-3036
Antithymocyte globulin (ATG)
efficacy and toxicity in anemic patients with MDS, 2156-2158
11-year follow-up of ATG/cyclosporin A in aplastic anemia, 1236-1242
Aorta-gonad-mesonephros region, novel mouse genes in, 2246-2249
APC. *See* Activated protein C
Apicidin, induction of fetal hemoglobin by, 2001-2007
APL. *See* Acute promyelocytic leukemia
Aplastic anemia
11-year follow-up of ATG/cyclosporin A in, 1236-1242

PIG-A gene mutations in aplastic anemia/PNH, 2833-2841
Apolipoprotein E (ApoE)
gene therapy of ApoE-deficient mice using macrophage-specific retroviral vector, 485-491
hyperhomocysteinemia accelerates atherosclerosis in CBS and ApoE knock-out mice, 3901-3907
Apoptosis
A1 is a growth-permissive antiapoptotic T-cell survival factor, 2679-2685
acadesine activates AMPK and induces apoptosis in B-CLL cells, 3674-3680
albumin protects B-CLL cells from chlorambucil- and radiation-induced apoptosis, 3174-3180
antiapoptotic cytokines reduce radiation lethality, 2609-2616
antisense Bcl-2 potentiates apoptosis in drug-resistant myeloma cells, 4105-4114
apoptotic synergism between STI571 and SCH66336 on imatinib-sensitive cell line (letter and response), 2070-2071
caspase inhibition augments cell death in TNF-α–stimulated neutrophils, 295-304
CD57 expression defines replicative senescence and apoptosis of $CD8^+$ T cells, 2711-2720
cell-cycle and apoptosis deregulation in Hodgkin and Reed-Sternberg cells, 681-689
circulating apoptotic neutrophils in glycogen storage disease type 1b, 5021-5024
CTLA-4 in normal and leukemic hematopoietic cells, 202-209
cyclin B1 regulates DNA damage–induced apoptosis, 1928-1933
dexamethasone-induced apoptosis of thymocytes, 585-593
DHA enhances arsenic trioxide–mediated apoptosis in arsenic trioxide–resistant leukemia, 4990-4997
EB1089 induces apoptosis in B-CLL cells in vitro, 2454-2460
exogenous stress proteins enhance immunogenicity of apoptotic tumor cells, 245-252
expression of IAP in neutrophils, 1164-1171
HHV8–encoded viral FLICE inhibitory protein protects against apoptosis via NF-κB activation, 1956-1961
hTERT extends life span of $CD4^+$ T cells and confers resistance to, 4512-4519
IL-4 variant associated with, 3102-3105
induced by arsenic trioxide in myeloma cells, 4078-4087
induced by curcumin down-regulation of NF-κB and IκBα kinase in MM cells, 1053-1062
induced by inhibition of STAT3 signaling in PEL, 1535-1542
induced by monoglycerides in leukemic cells, 292-294
induction in IL-3–dependent hematopoietic cell lines, 4958-4965
inhibition of G6P transport in neutrophils results in, 2381-2387
inhibition of p53-dependent apoptosis by distinct signaling pathways (*see Blood* 100:3990-4000, December 1, 2002) (erratum), 2114
internalization of apoptotic cells by splenic marginal zone DCs, 611-620
LF 15-0195 enhances activation-induced T-cell death, 194-201
ligation of Siglec-8 and induction of eosinophil apoptosis, 5014-5020
PDE4 inhibitors activate mitochondrial apoptotic pathway in CLL, 4122-4130
PECAM-1–driven antiapoptotic signal in $CD34^+$ cells, 186-193
rapamycin induced $p27^{KIP1}$-mediated apoptosis in DCs, 1439-1445
resistance of B-CLL cells to DNA damage–induced apoptosis, 4598-4606
role in control of neutrophil homeostasis in circulation, 739-746
SCF inhibits IFNγ-induced apoptosis by up-regulation of FLIP, 1324-1328
sildenafil and vardenafil induce apoptosis of B-CLL cells, 265-269
spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in AML, 2125-2131
SSRIs signal apoptosis in Burkitt lymphoma cells, 3212-3219
SU5614 inhibits FLT3 and induces apoptosis in AML cell lines, 1494-1504
Syk and Rac regulation of Akt-dependent cell survival, 236-244
tetrocarcin-A–induced ER stress mediates apoptosis in B-CLL cells, 4561-4568
TNF-α induces caspase-independent cell death in neutrophils, 1987-1995
TRAIL induces apoptosis in Ph^+ leukemia cells, 3658-3667
Ara-C. *See* Cytosine arabinoside
Arsenic trioxide
apoptosis induced in myeloma cells by, 4078-4087
arsenic/IFN reverses two-gene networks in HTLV-1 cells, 4576-4582
DHA enhances arsenic trioxide–mediated apoptosis in arsenic trioxide–resistant leukemia, 4990-4997
Artemis mutations in radiosensitive SCID patients, 1446-1452
Asian patients
CYP2C9 exon 4 mutations and warfarin dose phenotype in (letter), 2896-2897
no exon 4 polymorphism of CYP2C9 in Taiwanese (letter), 5086-5087
Asparagine synthetase, in $t(12;21)^+$ pediatric ALL, 2743-2747
Aspergillus, pathogenic molds in hospital water distribution systems, 2542-2546
ATG. *See* Antithymocyte globulin
Atherosclerosis
hyperhomocysteinemia accelerates atherosclerosis in CBS and ApoE knock-out mice, 3901-3907
platelet P-selectin facilitates development of, 2661-2666
ATM gene mutation, in childhood ALL with *MLL* gene rearrangement, 3622-3627
ATRA. *See* All-*trans* retinoic acid
Autoimmunity
CD40/CD154 blockade in ITP, 621-623
CLL preceded by cold agglutinin disease (*see Blood* 100:3419-3422, November 1, 2002) (erratum), 1676
cyclophosphamide with lymphocyte-depleted peripheral blood stem cell support for refractory autoimmune thrombocytopenia, 71-77
effects of B7-blocking agent and/or CsA on induction of T-cell anergy in chronic ITP, 2721-2726
endothelial induction of CCL21 in T-cell autoimmune diseases, 801-806
ITP and *Helicobacter pylori* in children (letter), 1660
IVIG induces dose-dependent amelioration of ITP in rodents (letter and response), 1658-1659
liposomal clodronate for murine autoimmune hemolytic anemia, 594-601
monoclonal IgG can ameliorate immune thrombocytopenia in murine ITP, 3708-3713
rituximab for children with autoimmune hemolytic anemia, 3857-3861
AZT. *See* Zidovudine

B-cell neoplasia
acadesine activates AMPK and induces apoptosis in B-CLL cells, 3674-3680
AID in B-cell non-Hodgkin lymphomas, 3574-3580
albumin protects B-CLL cells from chlorambucil- and radiation-induced apoptosis, 3174-3180
anti-CD20 vs. anti-CD45 antibodies for radioimmunotherapy of B-cell lymphomas, 2340-2348
cell cycle deregulation in B-cell lymphomas, 1220-1235
EB1089 induces apoptosis in B-CLL cells in vitro, 2454-2460
expression of ribosomal and translation-associated genes in CLL, 2748-2755
fludarabine uptake mechanisms in B-CLL, 2328-2334
fludarabine with concurrent vs. sequential rituximab in B-CLL, 6-14
genetic analysis of $CD5^+$ DLBCL, 699-702
HGAL predicts survival in DLBCL, 433-440
immunophenotyping in patients with DLBCL, 78-84
Jak1 deficiency and *Abelson*-induced B-cell tumor formation, 4937-4943
KRN5500 mediates cytotoxicity in B-CLL cells, 4547-4550
MALT1 deregulation in B-cell non-Hodgkin lymphoma, 4539-4546
molecular sequelae of histone deacetylase inhibition in malignant B cells, 4055-4062
rapamycin-induced G_1 arrest in cycling B-CLL cells, 278-285
resistance of B-CLL cells to DNA damage–induced apoptosis, 4598-4606
sildenafil and vardenafil induce apoptosis of B-CLL cells, 265-269
splenic marginal zone lymphoma, 2464
TCR-BV use in B-CLL, 1063-1070
tetrocarcin-A–induced ER stress mediates apoptosis in B-CLL cells, 4561-4568
B cells
age-related changes in B lymphopoiesis, 576-584
AID expression in CLL B cells, 4029-4032
B and T cell clonal involvement in MMM, 1981-1983
B-cell transformation, Csk, and glycolipid-enriched microdomains, 1874-1881
CD100/Plexin-B1 interactions in $CD5^+$ B cells, 1962-1969
gene expression profiling of plasma cells, 4013-4021
human cord blood $CD34^+Pax\text{-}5^+$ B-cell progenitors, 3424-3430

idiotype vaccination in MM reduces clonal tumor B cells, 4607-4610
IVIGs induce B-cell differentiation and IgG secretion, 3065-3073
macrophage- and DC-dependent regulation of B-cell proliferation requires BAFF, 4464-4471
oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors, 1950-1955
Pax5 determines B- vs. T-cell fate, 4342-4346
profiling of CD44-stimulated human B cells, 2307-2313
Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development, 1015-1023
survival pathway induced by integrin in, 1118-1127
T-cell expansion in thymoma with B lymphopenia, 3106-3108
Toll-like receptor function in human naive and memory B cells, 4500-4504
transduction with lentiviral vectors, 1727-1733
V(D)J diversification during intraclonal B-cell differentiation, 1030-1037

B7
B7-H1 up-regulation in HIV infection is marker of disease progression, 2514-2520
effects of B7-blocking agent and/or CsA on induction of T-cell anergy in chronic ITP, 2721-2726

Basal cell adhesion molecule (BCAM), activation of BCAM/Lu-dependent sickle (SS) RBC adhesion, 3281-3287

Basophils, MDS with bone marrow eosinophilia or basophilia, 3386-3390

Bax
Bcl-2 family's regulation of granulocyte survival, 2393-2400
levels of *BAX, MRP-1,* and platelets predict response to imatinib in CML, 2152-2155
spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in AML, 2125-2131

BCAM. *See* Basal cell adhesion molecule

Bcl-2
antisense Bcl-2 potentiates apoptosis in drug-resistant myeloma cells, 4105-4114
Bcl-2 family's regulation of granulocyte survival, 2393-2400
G3139 and chemotherapy for refractory or relapsed acute leukemia, 425-432
impact of rituximab plus CHOP on bcl-2–associated drug resistance in geriatric DLBCL, 4279-4284
spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in AML, 2125-2131

Bcl-x
Bcl-X_L required for heme synthesis during erythroid differentiation, 2575-2583
function of *bcl-x* promoter in erythroid progenitors, 2235-2242

BCL3, expression differentiates ALCL from Hodgkin disease, 2789-2796

BCL6
mutations disrupt its negative autoregulation in DLBCL, 2914-2923
rearrangements in Hodgkin lymphoma, 706-710

Bcr-Abl
cell context–specific effects of *BCR-ABL* in hematopoietic progenitors, 4088-4097
CNS is sanctuary for leukemic cells in imatinib-treated mice, 5010-5013
down-regulation of BRCA1 in BCR-ABL–expressing cells, 4583-4588
early MRD analysis during imatinib treatment of Ph^+/$Bcr\text{-}Abl^+$ ALL, 85-90
imatinib reverses effects of Bcr-Abl on neutrophilic differentiation, 655-663
inhibition of *bcr-abl* gene expression by small interfering RNA, 1566-1569
and LYN kinase in CML cells resistant to STI571, 690-698
monitoring CML after nonmyeloablative transplantations (letter and response), 5084-5085
NK function and acquisition of KIRs altered by, 3527-3533
persistence of $Bcr\text{-}Abl^+$ progenitors in CML in remission after, 4701-4707
PP1 and CGP76030 inhibit cells expressing imatinib-resistant Bcr-Abl kinases, 664-672
sensitivity of Bcr-Abl mutants to imatinib, 4611-4614

Bim, Bcl-2 family's regulation of granulocyte survival, 2393-2400

Bioluminescence to monitor lymphoma growth and treatment efficacy, 640-648

Biomagnetic susceptometry, noninvasive measurement of iron, 15-19

Blood, a changing of the guard, 5

Blood groups
association of CD47 with Rh and erythrocyte cytoskeleton, 1194-1199
human blood group I antigen expression, 2870-2876
I locus, adult i phenotype, and congenital cataracts, 2081-2088
Scianna antigens expressed by ERMAP, 752-757
tolerance induction to mammalian blood group–like carbohydrate antigen, 2318-2320

Blood pressure, hemin treatment in aortic tissues from hypertensive rats, 3893-3900

Blood work
acute megakaryoblastic leukemia, 2452
human granulocytotropic ehrlichiosis, 4232
mast cell leukemia, 789
myelodysplastic syndrome with isolated del(5q) chromosome abnormality, 3346
peripheral smear in pernicious anemia, 1668
spur-cell hemolytic anemia in severe alcoholic cirrhosis, 3

Bone
nonmalignant late effects after allogeneic SCT, 3373-3385
regulation of osteoclastogenesis by Notch signaling, 2227-2234
trichostatin A and sodium butyrate suppress osteoclastogenesis, 3451-3459

Bone marrow
gains of 3q26q29 in Fanconi anemia bone marrow cells, 3872-3874
hematopoietic origin of glomerular mesangial cells, 2215-2218
imatinib normalizes bone marrow vascularity in CML (letter), 4641-4643
intra–bone marrow injection in SCID-repopulating cell assay, 2905-2913
intrinsic thyrotropin-mediated pathway of TNF-α production in, 119-123
marrow frequency of rat long-term repopulating cells and species body weight, 3431-3435
marrow vs. cord blood for unrelated donor transplantation, 4233-4244
MDS with bone marrow eosinophilia or basophilia, 3386-3390
RANKL and osteoprotegerin in myeloma bone disease, 2094-2098
retroviral vector integration in preferred genomic targets of bone marrow–repopulating cells, 2191-2198
SCID-repopulating activity of $CD34^-$ cells by intra–bone marrow injection, 2924-2931
sensitivity of $Fancc^{-/-}$ bone marrow cells to nitric oxide, 3877-3884
targeting p38 MAPK inhibits MM cell growth in bone marrow milieu, 703-705
transcription factors during neutrophil differentiation in marrow, 4322-4332

Bone marrow transplantation (BMT)
allogeneic vs. autologous BMT for lymphoblastic lymphoma, 2476-2482
allograft resistance in cytotoxic-deficient hosts, 3991-3999
donor pretreatment with IL-18 attenuates acute GVHD and preserves graft-versus-leukemia effects, 2877-2885
donor T cell–derived TNF required for GVHD and graft-versus-tumor activity after, 2440-2445
for familial Mediterranean fever (letter and response), 1205-1206
heterologous cell cooperation in stem cell migration, homing, and engraftment, 45-51
idiopathic pneumonia syndrome in absence of donor MIP-1α after allogeneic BMT, 3714-3721
immunosuppressive drugs, BMT, and costimulation blockade, 2886-2893
in vivo tracking of stem cells transplanted into irradiated or nonirradiated recipients (*see Blood* 100:3545-3552, November 15, 2002) (erratum), 390
nephrotic syndrome after allogeneic BMT for NK cell leukemia/lymphoma, 4219-4221
nonmyeloablative conditioning with bismuth-213–labeled anti-TCRαβ, 5068-5075
OX40 ligation regulates GVHD and graft rejection after, 3741-3748
reconstitution of NK cell receptor repertoire after *HLA*-matched BMT, 3730-3740
T cell inhibition by mesenchymal stem cells, 3722-3729
tolerance induction after EGFP BMT, 4305-4312
tumor cell vaccines for metastatic cancer after, 1645-1652

Brain. *See also* Central nervous system
APC alters cytosolic calcium flux in brain endothelium, 4797-4801
CCR5 deficiency decreases susceptibility to cerebral malaria, 4253-4259
increased adhesiveness of $CD8^+$ T cells in brain venules in multiple sclerosis, 4775-4782
posterior leukoencephalopathy syndrome and cerebral infarcts associated with acute chest syndrome in childhood SCD, 415-419

BRCA1, down-regulation in BCR-ABL–expressing cells, 4583-4588

Burkitt lymphoma, SSRIs signal apoptosis in, 3212-3219

C/EBP. *See* CCAAT/enhancer binding protein
C-reactive protein (CRP), mechanism of fibrate down-regulation of IL-1–stimulated CRP expression in hepatocytes, 545-551
Calcineurin, role in differential chemokine expression in peripheral blood T cells, 216-225
Calcium
  APC alters cytosolic calcium flux in brain endothelium, 4797-4801
  enhancement of ATRA-induced cell differentiation by inhibition of calcium accumulation into ER, 3220-3228
cAMP. *See* Cyclic adenosine monophosphate
Cannabinoid receptors, Cb2 induces reversible block in neutrophilic differentiation, 1336-1343
Cappucino is a component of BLOC-1, 4402-4407
Cardiac catheterization, for pulmonary hypertension in SCD, 1257-1261
Cardiac lymphoma mimicking myxoma presenting with embolic stroke, 4708-4710
Cardiopulmonary bypass (CPB), estimating rate of thrombin and fibrin generation during, 4355-4362
Caspase
  inhibition augments cell death in TNF-α–stimulated neutrophils, 295-304
  role in dexamethasone-induced apoptosis of thymocytes, 585-593
CBS. *See* Cystathionine β-synthase
CCAAT/enhancer binding protein (C/EBP)
  C/EBPα affects gene expression and differentiation of CD34$^+$ cells, 2206-2214
  C/EBPε and PU.1 regulation of neutrophil and eosinophil gene expression, 3265-3273
  chromatin immunoprecipitation studies of C/EBPα and C/EBPε and CDP/cut in lactoferrin gene expression, 3460-3468
  effects of C/EBPα and PKCδ on JunB expression and monocytic differentiation, 3885-3892
  repression of leukemic phenotype of AML by, 1141-1148
CCL21, endothelial induction of, in T-cell autoimmune diseases, 801-806
CCR3, functional expression in CD30$^+$ CTCL, 1487-1493
CCR4, vs. CCR10 in T_H lymphocyte trafficking, 1677-1683
CCR5, deficiency decreases susceptibility to cerebral malaria, 4253-4259
CCR6, expression in LCH, 2473-2475
CCR7
  CCR7 ligands induce endocytosis in mature DCs, 4923-4929
  expression in LCH, 2473-2475
  G-CSF increases CD123^{hi} blood DCs with altered CD62L and CCR7 expression, 2314-2317
  tyrosine kinase activation and lymphocyte homing mediated by, 38-44
CCR10, vs. CCR4 in T_H lymphocyte trafficking, 1677-1683
CD3$^+$ lymphogranular leukemia, T-cell population phenotypically indistinguishable from (letter), 4643-4644
CD4$^+$ cells
  activation of influenza virus–specific T cells by plasmacytoid DCs, 3520-3526
  CD4-cell–specific lentiviral vectors, 3416-3423
  CD4 on human peripheral blood neutrophils, 4452-4456
  factor VIII-specific T-cell clones in hemophilia A, 1351-1358
  hTERT extends life span of, 4512-4519
  IL-7 improves CD4 T-cell reconstitution after CD34 cell transplantation in monkeys, 4209-4218
  IL-10 and TGF-β induce CD4$^+$CD25$^-$ T cells to acquire regulatory function, 5076-5083
  IL-12 reversal of CD28 loss in senescent CD4$^+$ T cells, 3543-3549
  immunodominant MAGE-3 CD4 epitopes, 1038-1044
  in vivo induction of CD4$^+$/CD25$^+$ regulatory T cells, 4862-4869
  mutual inactivation of CD4 T cells and tumor cells, 4472-4478
  promoter IV of class II transactivator gene essential for positive selection of, 3550-3559
  role of IFN-γ–producing CD4$^+$ T cells in protection against CMV disease, 2686-2692
  T-cell turnover in SIV-infected rhesus monkeys, 1213-1219
  TCL1 in plasmacytoid DCs and CD4$^+$CD56$^+$ blastic tumors of skin, 5007-5009
  total lymphoid irradiation preconditioning enriches for IL-4–producing CD4$^+$ cells, 2024-2032
CD5
  CD100/Plexin-B1 interactions in CD5$^+$ B cells, 1962-1969
  genetic analysis of CD5$^+$ DLBCL, 699-702
CD8$^+$ cells
  activation of influenza virus–specific T cells by plasmacytoid DCs, 3520-3526
  allograft resistance in cytotoxic-deficient hosts, 3991-3999
  antiviral CD8 T cell function in chronic viral infection, 226-235
  CD57 expression defines replicative senescence and apoptosis of, 2711-2720
  heterologous cell cooperation in stem cell migration, homing, and engraftment, 45-51
  HLA A*2402–restricted EBV-specific CD8$^+$ T cells, 1460-1468
  IL-15 effects on HIV-specific CD8$^+$ T cells, 1024-1029
  increased adhesiveness of CD8$^+$ T cells in multiple sclerosis, 4775-4782
  LFA-1 required for retention of effector CD8 T cells in mouse lungs, 4916-4922
  proliferation potential of CD8$^+$ T-cell subsets in response to antigen or cytokines, 4260-4266
  role for ICSBP in development of murine CD8α$^+$ DCs, 305-310
CD11b, ZBP-89 is a repressor of, 894-902
CD11c, *ras* and *junB* activation drive *CD11c* expression in HCL, 4033-4041
CD13/APN is an endothelial target of Ras, 1818-1826
CD18, GABP, Sp1, and RAR activate CD18 transcription in myeloid cells, 311-317
CD19, engineering CD19-specific human cytotoxic T lymphocytes, 1637-1644
CD20
  anti-C3b(i) mAb enhances complement activation and rituximab killing of CD20$^+$ cells, 1071-1079
  circulating CD20 in CLL is of prognostic significance, 2507-2513
  complement-mediated lysis by anti-CD20 mAb, 1045-1052
  rituximab for relapsed CD20$^+$ Hodgkin lymphoma, 420-424
CD25
  IL-10 and TGF-β induce CD4$^+$CD25$^-$ T cells to acquire regulatory function, 5076-5083
  in vivo induction of CD4$^+$/CD25$^+$ regulatory T cells, 4862-4869
CD26/DPPIV mediates G-CSF mobilization in mouse progenitor cells, 4680-4686
CD28, IL-12 reversal of CD28 loss in senescent CD4$^+$ T cells, 3543-3549
CD30, functional expression of CCR3 in CD30$^+$ CTCL, 1487-1493
CD34$^+$ cells
  C/EBPα affects gene expression and differentiation of, 2206-2214
  GATA1 expression in CD34$^+$ progenitors in idiopathic myelofibrosis (letter and response), 5087-5089
  HOXB4 effect on CD34$^+$ cell growth and lymphomyeloid differentiation, 1759-1768
  human cord blood CD34$^+$Pax-5$^+$ B-cell progenitors, 3424-3430
  outcome of CD34$^+$ peripheral blood SCT in first chronic phase CML, 446-453
  PECAM-1–driven antiapoptotic signal in, 186-193
  retroviral transduction efficiency of G-CSF+SCF–mobilized peripheral blood CD34$^+$ cells, 2199-2205
  reversibility of CD34 expression on human stem cells, 112-118
  STAT5a required for eosinophil differentiation of cord blood–derived CD34$^+$ cells, 134-142
  transplantation of unrelated-donor CD34$^+$ cells in pediatric leukemia, 1630-1636
  VEGFR-3 and CD133 identify CD34$^+$ lymphatic/vascular endothelial precursor cells, 168-172
CD38
  expression in CLL patients at risk of disease progression, 1262-1269
  oncolytic measles viruses display antibody against, 2557-2562
  V_H gene mutational status and CD38 expression in CLL, 1087-1093
CD40
  CD40/CD154 blockade in ITP, 621-623
  induction of MM cell migration by, 2762-2769
CD41, hematopoiesis in mouse embryo and expression of, 508-516
CD44, profiling of CD44-stimulated human B cells, 2307-2313
CD45
  anti-CD45–mediated cytoreduction for, 2434-2439
  antileukemic activity of allorestricted cytotoxic T cells specific for, 1007-1014
  CD45 minigene corrects CD45 deficiency in mice, 849-855
CD47
  association with Rh and erythrocyte cytoskeleton, 1194-1199
  and platelet adhesion on inflamed endothelium under flow, 4836-4843
  red cell skeleton protein 4.2 interacts with, 338-344

CD52
ATRA induces CD52 expression in APL, 1977-1980
differential expression by myeloid DC subsets, 1422-1429
CD56
CD56^{bright} NK cells link adaptive and innate immunity, 3052-3057
TCL1 in plasmacytoid DCs and CD4$^+$CD56$^+$ blastic tumors of skin, 5007-5009
CD57, in replicative senescence and apoptosis of CD8$^+$ T cells, 2711-2720
CD62L, G-CSF increases CD123^{hi} blood DCs with altered CD62L and CCR7 expression, 2314-2317
CD91, HSP receptor CD91 in HIV-1–infected nonprogressors, 4000-4004
CD100/Plexin-B1 interactions in CD5$^+$ B cells, 1962-1969
CD123, G-CSF increases CD123^{hi} blood DCs with altered CD62L and CCR7 expression, 2314-2317
CD133, and VEGFR-3 identify CD34$^+$ lymphatic/vascular endothelial precursor cells, 168-172
CD154, CD40/CD154 blockade in ITP, 621-623
CD158, CD158k/p140/KIR3DL2 polymorphisms in Sézary patients (letter), 1203
CD163/HbSR. *See* Hemoglobin scavenger receptor
2-CDA. *See* 2-Chlorodeoxyadenosine
Cell cycle
cAMP inhibits Ras and Rap1 activation in T cells, 998-1006
cell-cycle and apoptosis deregulation in Hodgkin and Reed-Sternberg cells, 681-689
cell cycle deregulation in B-cell lymphomas, 1220-1235
CUL-4A interferes with granulocytic differentiation and exit from cell cycle, 1769-1776
rapamycin-induced G_1 arrest in cycling B-CLL cells, 278-285
Cell death. *See also* Apoptosis
caspase inhibition augments cell death in TNF-α–stimulated neutrophils, 295-304
induced by granzyme C, 3093-3101
LF 15-0195 enhances activation-induced T-cell death, 194-201
TNF-α induces caspase-independent cell death in neutrophils, 1987-1995
Cell differentiation
Bcl-X_L required for heme synthesis during erythroid differentiation, 2575-2583
C/EBPα affects gene expression and differentiation of CD34$^+$ cells, 2206-2214
Cb2 induces reversible block in neutrophilic differentiation, 1336-1343
combined effects of *Notch* signaling and cytokines on stem cell differentiation, 1784-1789
CUL-4A interferes with granulocytic differentiation and exit from cell cycle, 1769-1776
E26 leukemia virus converts primitive erythroid cells into multilineage progenitors, 1103-1110
effects of C/EBPα and PKCδ on JunB expression and monocytic differentiation, 3885-3892
enhancement of ATRA-induced cell differentiation by inhibition of calcium accumulation into ER, 3220-3228
gene expression profiling of plasma cell differentiation and MM, 1128-1140
HOXB4 effect on CD34$^+$ cell growth and lymphomyeloid differentiation, 1759-1768
human pro-B cells that give rise to macrophages, NK cells and T cells, 4313-4321
IFN-γ switches monocyte differentiation from DCs to macrophages, 143-150
Ikaros regulates neutrophil differentiation, 2219-2226
imatinib reverses effects of Bcr-Abl on neutrophilic differentiation, 655-663
IVIGs induce B-cell differentiation and IgG secretion, 3065-3073
novel class of CD34$^-$ cells that give rise to SCID-repopulating cells, 869-876
Pax5 determines B- vs. T-cell fate, 4342-4346
proliferation potential of CD8$^+$ T-cell subsets in response to antigen or cytokines, 4260-4266
ribosomal protein S19 expression during erythroid differentiation, 318-324
role of phospho-Smad2/3 in HL-60 cell differentiation, 498-507
RUNX1 and GATA-1 cooperation in megakaryocytic differentiation, 4333-4341
stage of embryonic stem cell differentiation and adult neovascularization, 2675-2678
STAT5a required for eosinophil differentiation of cord blood–derived CD34$^+$ cells, 134-142
stromal inhibition of megakaryocytic Rap1 signaling, 1744-1751
transcription factors during neutrophil differentiation in bone marrow, 4322-4332
transcriptional accessibility in hematopoietic stem cells, 383-390
V(D)J diversification during intraclonal B-cell differentiation, 1030-1037
YY1 is a myeloid transforming gene interfering with neutrophilic differentiation, 1111-1117
Central nervous system (CNS). *See also* Brain
cobalamin deficiency with and without neurologic abnormalities, 3302-3308
expression of BCA-1 in CNS lymphoma, 815-821
late CMV central nervous system disease after SCT, 463-465
as sanctuary for leukemic cells in imatinib-treated mice, 5010-5013
Central venous catheter–related thrombosis in children, 4273-4278
upper-extremity DVT and HIT, 3049-3051
cGMP. *See* Cyclic guanosine monophosphate
CGP76030 and PP1 inhibit cells expressing imatinib-resistant Bcr-Abl kinases, 664-672
Chaperone-rich cell lysate activates DCs and elicits antitumor immunity, 4485-4491
Chelation therapy
deferiprone and hepatic fibrosis (letter and response), 5089-5091
effects of combined pyridoxal isonicotinoyl hydrazone analog and deferoxamine, 4172-4179
hepatocellular injury and transfusional iron overload during desferrioxamine therapy, 91-96
lack of hepatic fibrosis with deferiprone in beta-thalassemia (*see Blood* 100:1566-1569, September 1, 2002) (erratum), 2460
MRI evaluation of myocardial iron during iron chelation therapy, 4632-4639
Chemokines
AML-1A and AML-1B regulation of MIP-1α expression in MM, 3778-3783
C3a and C3a receptor in hematopoiesis, 3784-3793
CCR4 vs. CCR10 in T_H lymphocyte trafficking, 1677-1683
CCR5 deficiency decreases susceptibility to cerebral malaria, 4253-4259
CCR7 ligands induce endocytosis in mature DCs, 4923-4929
CCR7-mediated lymphocyte homing and tyrosine kinase activation, 38-44
CD26/DPPIV mediates G-CSF mobilization in mouse progenitor cells, 4680-4686
chemokine–cytokine allogeneic antitumor vaccine for neuroblastoma, 1718-1726
differential chemokine expression in peripheral blood T cells, 216-225
differential regulation of CXCR2 trafficking by Rab GTPases, 2115-2124
disruption of homeostatic chemokines and DCs by SIV, 1684-1691
endothelial induction of CCL21 in T-cell autoimmune diseases, 801-806
expression of BCA-1 in primary CNS lymphoma, 815-821
expression of CCR6 and CCR7 in LCH, 2473-2475
functional expression of CCR3 in CD30$^+$ CTCL, 1487-1493
G-CSF increases CD123^{hi} blood DCs with altered CD62L and CCR7 expression, 2314-2317
heterologous cell cooperation in stem cell migration, homing, and engraftment, 45-51
intracellular domains of CXCR4 in SDF-1–mediated signaling, 399-406
L-selectin stimulation up-regulates CXCR4 in lymphocytes, 4245-4252
MIP-1α and MIP-1β mediate immunity, 807-814
PF4 inhibition of hematopoiesis, 4687-4694
proliferation potential of CD8$^+$ T-cell subsets in response to antigen or cytokines, 4260-4266
Chemotherapy. *See also* specific drugs
albumin protects B-CLL cells from chlorambucil- and radiation-induced apoptosis, 3174-3180
Ara-C sensitivity in *MLL* gene-rearranged infant ALL, 1270-1276
CHOP vs. CNOP in elderly patients with lymphoma, 3840-3848
cyclophosphamide metabolism, liver toxicity, and mortality after SCT, 2043-2048
cyclophosphamide with lymphocyte-depleted peripheral blood stem cell support for refractory autoimmune thrombocytopenia, 71-77
decitabine treatment of hematopoietic malignancies (letter and response), 4644-4646
dexamethasone vs. prednisone and oral vs. intravenous mercaptopurine for ALL, 3809-3817
EPOCH for AIDS-related lymphoma, 4653-4659

fludarabine with concurrent vs. sequential rituximab in B-CLL, 6-14
G-CSF and risk of secondary myeloid malignancy after etoposide, 3862-3867
and G3139 for refractory or relapsed acute leukemia, 425-432
impact of rituximab plus CHOP on bcl-2–associated drug resistance in geriatric DLBCL, 4279-4284
PKCζ mediated Raf-1/ERK activation by daunorubicin, 1543-1550
PS-341 potentiates sensitivity of MM cells to, 2377-2380
survival not improved after high-dose therapy in MM, 2144-2151
unrelated donor SCT vs. chemotherapy for pediatric relapsed ALL, 3835-3839
unrelated SCT with reduced conditioning can induce complete chimerism and sustained remissions, 1620-1629
Chimerism
kinetics of MRD and chimerism after SCT for CML, 469-472
non-T-cell–depleted HLA haploidentical SCT based on feto-maternal microchimerism, 3334-3336
SNP-based quantitation of hematopoietic chimerism after allogeneic SCT, 363-369
unrelated SCT with reduced conditioning can induce complete chimerism and sustained remissions, 1620-1629
2-Chlorodeoxyadenosine (2-CDA), efficacy in refractory factor VIII inhibitors in persons without hemophilia, 943-945
Cholesterol reduction kills AML cells and sensitizes them to therapeutics, 3628-3634
Chromosome abnormalities
AML1/MTG8 gene suppression supports myeloid differentiation of t(8;21)-positive leukemic cells, 3157-3163
asparagine synthetase in t(12;21)$^+$ pediatric ALL, 2743-2747
centrosome aberrations in AML and cytogenetic risk profile, 289-291
chromosome 18 locus influences APC resistance and thrombosis susceptibility, 163-167
endogenous retroviral sequence fused to FGFR1 kinase in 8p12 MPD, 286-288
gains of 3q26q29 in Fanconi anemia bone marrow cells, 3872-3874
graft versus myeloma and chromosome 13 deletion in MM (letter), 1201-1202
IgV$_H$ genes in t(11;14) lymphoma with mantle cell features, 4975-4981
MDS with isolated del(5q) chromosome abnormality (blood work), 3346
metaphase cytogenetic abnormalities and survival in MM, 3849-3856
MM with t(4;14)(p16;q32) translocation maintains *IGH/MMSET* fusion transcript, 2374-2376
prenatal origin of translocations associated with pediatric AML (letter), 4640-4641
recurrent genomic aberrations in MM, 4569-4575
t(4;14)(p16;q32) is adverse prognostic factor in MM, 1520-1529
t(11;14)(q13;q32) in IgM, IgE, and nonsecretory MM variants, 1570-1571
t(11;18)(q21;q21) in *Helicobacter pylori*–negative gastric MALT lymphoma, 2547-2550
t(14;18)(q32;q21) involving *IGH* and *MALT1* in MALT lymphoma, 2335-2339
three cytogenetic subgroups in follicular lymphoma grade 3B, 1149-1154
Chronic lymphocytic leukemia (CLL)
acadesine activates AMPK and induces apoptosis in B-CLL cells, 3674-3680
AID expression in CLL B cells, 4029-4032
albumin protects B-CLL cells from chlorambucil- and radiation-induced apoptosis, 3174-3180
alemtuzumab plus rituximab in relapsed and refractory lymphoid malignancies, 3413-3415
CD38 expression in patients at risk of disease progression, 1262-1269
circulating CD20 in CLL is of prognostic significance, 2507-2513
combined V_H3-21 and V_L2-14 gene use in, 4952-4957
EB1089 induces apoptosis in B-CLL cells in vitro, 2454-2460
expression of ribosomal and translation-associated genes in, 2748-2755
fludarabine uptake mechanisms in B-CLL, 2328-2334
fludarabine with concurrent vs. sequential rituximab in B-CLL, 6-14
free radical stress and drug sensitivity in, 4098-4104
high AID expression in poor-prognosis CLL, 4903-4908
KRN5500 mediates cytotoxicity in B-CLL cells, 4547-4550
overexpressed *V1-69* genes in unmutated CLL not related to aging process, 3082-3084
PDE4 inhibitors activate mitochondrial apoptotic pathway in, 4122-4130
preceded by cold agglutinin disease (*see Blood* 100:3419-3422, November 1, 2002) (erratum), 1676
prognostic impact of unmutated V_H gene status after SCT for, 2049-2053
rapamycin-induced G_1 arrest in cycling* B-CLL cells, 278-285
resistance of B-CLL cells to DNA damage–induced apoptosis, 4598-4606
sildenafil and vardenafil induce apoptosis of B-CLL cells, 265-269
SPAN-Xb in hematologic malignancies, 955-960
TCR-BV use in B-CLL, 1063-1070
tetrocarcin-A–induced ER stress mediates apoptosis in B-CLL cells, 4561-4568
V_H gene mutational status and CD38 expression in, 1087-1093
ZAP-70 expression identifies CLL subtype, 4944-4951
Chronic myeloid leukemia (CML)
abnormalities in Ph$^-$ cells of CML patients on imatinib, 1941-1949
apoptotic synergism between STI571 and SCH66336 on imatinib-sensitive cell line (letter and response), 2070-2071
Bcr-Abl and LYN kinase in CML cells resistant to STI571, 690-698
CNS is sanctuary for leukemic cells in imatinib-treated mice, 5010-5013
cytoskeletal and functional defects in DCs from patients with, 3560-3567
dose escalation of imatinib can overcome resistance in, 473-475
down-regulation of BCR-ABL–expressing cells, 4583-4588
IFN-α induces myeloblastin expression and specific T-cell response in, 259-264
imatinib in newly diagnosed patients with Ph$^+$ CML, 97-100
imatinib normalizes bone marrow vascularity in (letter), 4641-4643
imatinib reverses effects of Bcr-Abl on neutrophilic differentiation, 655-663
inhibition of *bcr-abl* gene expression by small interfering RNA, 1566-1569
kinetics of MRD and chimerism after SCT for, 469-472
levels of *BAX, MRP-1,* and platelets predict response to imatinib in, 2152-2155
MDR1 gene overexpression confers imatinib resistance in leukemia cell lines, 2368-2373
methylated *JunB* in, 3205-3211
molecular response to imatinib following relapse after SCT for (letter), 1200-1201 (erratum, 1683)
monitoring CML after nonmyeloablative transplantations (letter and response), 5084-5085
myelodysplastic subclones and imatinib therapy for (letter), 781
nonmyeloablative SCT for CML in first chronic phase, 441-445
outcome of CD34$^+$ peripheral blood SCT in first chronic phase CML, 446-453
p14$^{ARF, p15INK4b}$ and *p16^{INK4a}* methylation status in (letter), 374-375
persistence of Bcr-Abl$^+$ progenitors during remission after imatinib, 4701-4707
PP1 and CGP76030 inhibit cells expressing imatinib-resistant Bcr-Abl kinases, 664-672
R115777 in hematologic malignancies, 1692-1697
SAHA enhances imatinib-induced apoptosis of Bcr-Abl–positive leukemia cells, 3236-3239
sensitivity of Bcr-Abl mutants to imatinib, 4611-4614
significance of cytogenetic clonal evolution in imatinib-treated CML, 3794-3800
SPAN-Xb in hematologic malignancies, 955-960
telomere length in peripheral blood granulocytes after imatinib treatment (letter), 375-376
Circulation, stepwise onset in mammalian embryo, 1669-1676
CLA. *See* Cutaneous lymphocyte–associated antigen
CLL. *See* Chronic lymphocytic leukemia
Clodronate, liposomal, for murine autoimmune hemolytic anemia, 594-601
CML. *See* Chronic myeloid leukemia
CMV. *See* Cytomegalovirus
CNS. *See* Central nervous system
Cobalamin deficiency, with and without neurologic abnormalities, 3302-3308
Cold hemagglutinin disease, CLL preceded by (*see Blood* 100:3419-3422, November 1, 2002) (erratum), 1676
Collagen
collagen-induced platelet aggregation, 2646-2651
targeting of collagen-binding site on GPVI and in vivo depletion of receptor, 3948-3952
Complement
anti-C3b(i) mAb enhances complement activation and rituximab killing of CD20$^+$ cells, 1071-1079

C3a and C3a receptor in hematopoiesis, 3784-3793
complement-mediated lysis by anti-CD20 mAb, 1045-1052
complement receptor 1 inhibitors in transfusion therapy, 5046-5052
Connexin43 wild-type and knock-out fetal liver cells, hematopoietic capacity of, 2996-2998
Corticosteroids
combination low-dose thalidomide and prednisone for MMM, 2534-2541
dexamethasone-induced apoptosis of thymocytes, 585-593
dexamethasone vs. prednisone and oral vs. intravenous mercaptopurine for ALL, 3809-3817
thromboembolic events in children with ALL: prednisone vs. dexamethasone, 2529-2533
CPB. *See* Cardiopulmonary bypass
Crohn disease, refractory, autologous SCT in, 2064-2066
CRP. *See* C-reactive protein
Cryoglobulinemia, mixed
treatment with rituximab, 3818-3826
type II, efficacy and safety of rituximab in, 3827-3834
CsA. *See* Cyclosporin A
Csk, B-cell transformation, Csk, and glycolipid-enriched microdomains, 1874-1881
CTCL. *See* Cutaneous T-cell lymphoma
CTLA-4. *See* Cytotoxic T-lymphocyte antigen–4
CUL-4A, interference with granulocytic differentiation and exit from cell cycle, 1769-1776
Curcumin, down-regulation of NF-κB and IκBα kinase in MM cells by, 1053-1062
Cutaneous lymphocyte–associated antigen (CLA)
CCR4 vs. CCR10 in human cutaneous T_H lymphocyte trafficking, 1677-1683
glycosylation-dependent inhibition of, 602-610
Cutaneous T-cell lymphoma (CTCL)
alemtuzumab in mycosis fungoides/Sézary syndrome, 4267-4272
CD158k/p140/KIR3DL2 polymorphisms in Sézary patients (letter), 1203
CMV seropositivity associated with mycosis fungoides and Sézary syndrome, 2132-2136
functional expression of CCR3 in $CD30^+$ CTCL, 1487-1493
γδ T-cell phenotype and survival in, 3407-3412
JUNB overexpression in, 1513-1519
CXCR2, differential regulation of trafficking by Rab GTPases, 2115-2124
CXCR4
intracellular domains of CXCR4 in SDF-1–mediated signaling, 399-406
L-selectin stimulation up-regulates in lymphocytes, 4245-4252
Cyclic adenosine monophosphate (cAMP)
cAMP-dependent protein kinase mediates cGMP-induced VASP phosphorylation, 4423-4429
Ras and Rap1 activation in T cells inhibited by, 998-1006
Cyclic guanosine monophosphate (cGMP), cAMP-dependent protein kinase mediates cGMP-induced VASP phosphorylation, 4423-4429
Cyclin B1 regulates DNA damage–induced apoptosis, 1928-1933
Cyclin K, Kaposi sarcoma–associated, repression of STAT3 activity by, 4070-4077
Cyclophosphamide
with lymphocyte-depleted peripheral blood stem cell support for refractory autoimmune thrombocytopenia, 71-77
metabolism, liver toxicity, and mortality after SCT, 2043-2048
Cyclosporin A (CsA)
effects of B7-blocking agent and/or CsA on induction of T-cell anergy in chronic ITP, 2721-2726
11-year follow-up of ATG/cyclosporin A in aplastic anemia, 1236-1242
Cystathionine β-synthase (CBS)
hyperhomocysteinemia accelerates atherosclerosis in CBS and ApoE knock-out mice, 3901-3907
transcriptional regulation in Down syndrome, 1551-1557
Cytochrome *c*, G-CSF–inhibited release in MDS, 1080-1086
Cytochrome P450 enzymes
*CYP1A1*2B (Val)* allele in AML patients with *NRAS* mutation, 2770-2774
CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians (letter), 2896-2897
no exon 4 polymorphism of CYP2C9 in Taiwanese (letter), 5086-5087
Cytokines. *See also* Chemokines; specific cytokines
antiapoptotic cytokines reduce radiation lethality, 2609-2616
chemokine–cytokine allogeneic antitumor vaccine for neuroblastoma, 1718-1726
combined effects of *Notch* signaling and cytokines on stem cell differentiation, 1784-1789
contributions of TNF and LT cytokines to DC development, 1477-1483
cytokine-mediated regulation of iron transport in monocytes, 4148-4154
endotoxin-induced DIC and cytokine activation in protein C–deficient mice, 4823-4827
proliferation potential of $CD8^+$ T-cell subsets in response to antigen or, 4260-4266
SOCS-1 hypermethylation in MM, 2784-2788
T cells produce interferonlike cytokine limitin, 178-185
Cytomegalovirus (CMV)
CMV seropositivity associated with mycosis fungoides and Sézary syndrome, 2132-2136
donor CMV status and CMV viremia after SCT, 2067-2069
down-regulation of HLA-DR by human CMV protein pp65, 4870-4877
granulocyte transfusions and (letter and response), 5091-5092
human CMV immediate-early mRNAemia vs. pp65 antigenemia in SCT recipients, 5053-5060
human CMV US2 affects antigen presentation and iron homeostasis, 2858-2864
increased CMV infection after nonmyeloablative SCT (letter), 2071-2072
infection after receipt of leukoreduced blood products, 4195-4200
late CMV central nervous system disease after SCT, 463-465
late CMV disease and mortality after allogeneic SCT, 407-414
role of IFN-γ–producing $CD4^+$ T cells in protection against CMV disease, 2686-2692
Cytosine arabinoside (Ara-C) sensitivity in *MLL* gene-rearranged infant ALL, 1270-1276
Cytotoxic T-lymphocyte antigen–4 (CTLA-4), in normal and leukemic hematopoietic cells, 202-209
Cytotoxicity
antileukemic activity of allorestricted cytotoxic T cells, 1007-1014
antiviral CD8 T cell function in chronic viral infection, 226-235
engineering CD19-specific human cytotoxic T lymphocytes, 1637-1644
IFN-α induces myeloblastin expression and specific T-cell response in CML, 259-264
KRN5500 mediates cytotoxicity in B-CLL cells, 4547-4550
LMP1-specific cytotoxic T cells for adoptive immunotherapy of EBV-associated malignancies, 1905-1912
mechanisms of action of rituximab in non-Hodgkin's lymphomas, 949-954
RNA-transfected DCs induce myeloma-specific cytotoxic T cells, 977-982

D-dimer, and risk of future venous thrombosis, 1243-1248
Daunorubicin, PKCζ mediated Raf-1/ERK activation by, 1543-1550
Decitabine treatment of hematopoietic malignancies (letter and response), 4644-4646
Deep vein thrombosis (DVT). *See* Thrombosis
Deferiprone
and hepatic fibrosis (letter and response), 5089-5091
lack of hepatic fibrosis with, in beta-thalassemia (*see Blood* 100:1566-1569, September 1, 2002) (erratum), 2460
Deferrioxamine, MRI evaluation of myocardial iron during iron chelation therapy, 4632-4639
Dendritic cells (DCs)
activation of influenza virus–specific T cells by plasmacytoid DCs, 3520-3526
activity of adenosine on human DCs, 3985-3990
alloantigen-specific suppression of mixed leukocyte reactions by, 3325-3333
CCR7 ligands induce endocytosis in mature DCs, 4923-4929
chaperone-rich cell lysate activates DCs and elicits antitumor immunity, 4485-4491
contributions of TNF and LT cytokines to DC development, 1477-1483
cytoskeletal and functional defects in DCs from CML patients, 3560-3567
DC precursor populations of mouse blood, 1453-1459 (erratum, 3364)
DCs overexpressing CD95L elicit allospecific T-cell responses, 1469-1576
differential CD52 expression by myeloid DC subsets, 1422-1429
disruption of homeostatic chemokines and DCs by SIV, 1684-1691
dysfunction and infection in HIV, 4505-4511

G-CSF increases CD123^{hi} blood DCs with altered CD62L and CCR7 expression, 2314-2317
generation of DCs from mouse embryonic stem cells, 3501-3508
hepatitis C virus quasispecies in liver cells and, 52-57
ICSBP retrovirus transduction rescues DC development, 961-969
IFN-γ switches monocyte differentiation from DCs to macrophages, 143-150
induction of CD4$^+$/CD25$^+$ regulatory T cells by targeting antigens to immature DCs, 4862-4869
internalization of apoptotic cells by splenic marginal zone DCs, 611-620
IVIG inhibits maturation and function of, 758-765
macrophage- and DC-dependent regulation of B-cell proliferation requires BAFF, 4464-4471
β_2-microglobulin inhibits generation of, 4005-4012
modified myeloid DCs induce anergic and regulatory T cells, 3581-3589
rapamycin induced p27^{KIP1}-mediated apoptosis in, 1439-1445
rapamycin inhibits mobilization and function of, 4457-4463
retrovirus-mediated IL-7 expression in leukemic DCs generated from AML, 2184-2190
RNA-transfected DCs induce myeloma-specific cytotoxic T cells, 977-982
role for ICSBP in development of murine CD8α$^+$ DCs, 305-310
role of IKK2 and NIK in DC antigen presentation, 983-991
Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development, 1015-1023
TCL1 in plasmacytoid DCs and CD4$^+$CD56$^+$ blastic tumors of skin, 5007-5009
Desirudin, antihirudin antibodies after desirudin for thrombosis prophylaxis for hip-replacement surgery, 2617-2619
Desmopressin, ADAMTS-13 activity after infusion of, 946-948
Dexamethasone
apoptosis of thymocytes induced by, 585-593
in fetal hemoglobin reactivation in adult life, 2826-2832
vs. prednisone and oral vs. intravenous mercaptopurine for ALL, 3809-3817
thromboembolic events in children with ALL: prednisone vs. dexamethasone, 2529-2533
DHA. *See* Docosahexaenoic acid
Diabetes, acidic and neutral sialidase in erythrocytes of patients with (letter), 2071
Diamond-Blackfan anemia, nucleolar localization of RPS19 protein in, 5039-5045
DIC. *See* Disseminated intravascular coagulation
Dietary factors, genetic and nutritional factors in hyperhomocysteinemia in young adults, 2483-2488
Diffuse large B-cell lymphoma (DLBCL)
BCL6 mutations disrupt its negative autoregulation in, 2914-2923
genetic analysis of CD5$^+$ lymphoma, 699-702
HGAL predicts survival in, 433-440
immunophenotyping in patients with, 78-84
impact of rituximab plus CHOP on bcl-2–associated drug resistance in geriatric patients, 4279-4284
transformation of follicular lymphoma to, 3109-3117
Disseminated intravascular coagulation (DIC)
endotoxin-induced DIC and cytokine activation in protein C–deficient mice, 4823-4827
prevention by combined anticoagulant and antiselectin treatments, 921-928
DLBCL. *See* Diffuse large B-cell lymphoma
DLI. *See* Donor lymphocyte infusions
DNA
cyclin B1 regulates DNA damage–induced apoptosis, 1928-1933
DNA methylation inhibitors and reversal of transcriptional silencing (letter and response), 1656-1658
DNA methylation of p57KIP2 in ALL, 4131-4136
homeodomain-DNA interactions required for HOX11-mediated transformation, 4966-4974
mitochondrial DNA mutations in MDS, 3118-3125
resistance of B-CLL cells to DNA damage–induced apoptosis, 4598-4606
Docosahexaenoic acid (DHA), enhancement of arsenic trioxide–mediated apoptosis in arsenic trioxide–resistant leukemia by, 4990-4997
Donor lymphocyte infusions (DLI)
for JMML relapsing after SCT, 1713-1714
as primary therapy for neoplasms (letter and response), 373-374
reactivity of T cells expressing a suicide gene after T-cell–depleted SCT, 1290-1298
Down syndrome
GATA1 mutatgenesis and leukemogenesis in, 4298-4300
GATA1 mutations in transient leukemia and AMKL in Down syndrome, 4301-4304
transcriptional regulation of *CBS* in, 1551-1557
Drug resistance
antisense Bcl-2 potentiates apoptosis in drug-resistant myeloma cells, 4105-4114
Bcr-Abl and LYN kinase in CML cells resistant to STI571, 690-698
dose escalation of imatinib can overcome resistance in CML, 473-475
impact of rituximab plus CHOP on bcl-2–associated drug resistance in geriatric DLBCL, 4279-4284
MDR1 gene overexpression confers imatinib resistance in leukemia cell lines, 2368-2373
PP1 and CGP76030 inhibit cells expressing imatinib-resistant Bcr-Abl kinases, 664-672
sensitivity of Bcr-Abl mutants to imatinib, 4611-4614
DVT (deep vein thrombosis). *See* Thrombosis

E-selectin, Src and PI3K mediate soluble E-selectin–induced angiogenesis, 3960-3968
E26 leukemia virus converts primitive erythroid cells into multilineage progenitors, 1103-1110
EAF-2. *See* ELL-associated factor 2
EB1089 induces apoptosis in B-CLL cells in vitro, 2454-2460
EBV. *See* Epstein-Barr virus
ECFP. *See* Enhanced cyan fluorescent protein
Editorials
a (blood) smear campaign, 2453
a changing of the guard, 5
EGF2. *See* Epidermal growth factor 2
EGFP. *See* Enhanced green fluorescent protein
Egr-1, regulation of TF and inflammatory mediators in mouse endotoxemia model by, 3940-3947
Ehrlichiosis, human granulocytotropic (blood work), 4232
Elastase
in vitro regulation of granulopoiesis by neutrophil elastase, 1752-1758
serum elastase levels and ELA-2 elastase mutations in chronic idiopathic neutropenia (letter), 2898-2899
ELL-associated factor 2 (EAF-2), functional homolog of EAF-1, 2355-2362
Embryology
characterization of fetal liver stroma, 2973-2982
fetal diagnosis of congenital afibrinogenemia caused *FGB* gene mutation, 3492-3494
hematopoietic capacity of connexin43 wild-type and knock-out fetal liver cells, 2996-2998
immune tolerance after prenatal gene transfer of human factor IX to fetal mice, 1359-1366
stepwise onset of circulation in mammalian embryo, 1669-1676
Endocrine function, nonmalignant late effects after allogeneic SCT, 3373-3385
Endoplasmic reticulum (ER)
enhancement of ATRA-induced cell differentiation by inhibition of calcium accumulation into ER, 3220-3228
tetrocarcin-A–induced ER stress mediates apoptosis in B-CLL cells, 4561-4568
Endothelium
angiostatin inhibits HGF in smooth muscle cells and, 1857-1863
APC alters cytosolic calcium flux in brain endothelium, 4797-4801
CD13/APN is an endothelial target of Ras, 1818-1826
CD47 and platelet adhesion on inflamed endothelium under flow, 4836-4843
endothelial induction of CCL21 in T-cell autoimmune diseases, 801-806
erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis, 4625-4627
erythropoiesis from acetyl LDL incorporating endothelial cells at preliver stage, 4733-4738
Flk-1 activity in hemogenic and nonhemogenic endothelium, 886-893
heparan sulfate on endothelial cells mediates binding of malaria-infected erythrocytes, 2405-2411
inflammatory effects of HMGB1 on, 2652-2660
modulation of VEFGR-2–mediated endothelial-cell activity by VEGF-C/VEGRF-3, 1367-1374
MyD88 pathway in endothelial activation by antiphospholipid antibodies, 3495-3500
novel genetic LAD results in impaired leukocyte arrest on vascular endothelium, 4437-4445

oxidized phospholipids in oxidized LDL down-regulate thrombomodulin in, 4765-4774
platelet-endothelial interaction in tumor angiogenesis, 1970-1976
regulation of human endothelial cell protein C receptor gene promoter, 4393-4401
role in severe sepsis and multiple organ dysfunction syndrome, 3765-3777
RSP-2 in adhesion of malaria-infected erythrocytes to endothelial cells and placenta, 5025-5032
shear stress inhibits adhesion molecule expression in, 2667-2674
threshold for VEGF in developing endothelial cells, 2261-2267
VEGFR-3 and CD133 identify CD34+ lymphatic/vascular endothelial precursor cells, 168-172

Endotoxin
Egr-1 regulation of TF and inflammatory mediators in mouse endotoxemia model, 3940-3947
endotoxin-induced DIC and cytokine activation in protein C–deficient mice, 4823-4827
p38 MAPK mediates procoagulant response during endotoxemia, 4446-4448
ubiquitin inhibits TNF-α response to, 1882-1890

Enhanced cyan fluorescent protein (ECFP), live erythroid and myeloid cells in β-globin ECFP x lysozyme EGFP mice, 903-906

Enhanced green fluorescent protein (EGFP)
live erythroid and myeloid cells in β-globin ECFP x lysozyme EGFP mice, 903-906
tolerance induction after EGFP BMT, 4305-4312
transgenic mice with a CSF-1R reporter gene, 1155-1163

Eosinophils
C/EBPε and PU.1 regulation of neutrophil and eosinophil gene expression, 3265-3273
efficacy of imatinib in idiopathic hypereosinophilic syndrome, 4714-4716
imatinib for eosinophilic disorders, 3391-3397
ligation of Siglec-8 and induction of eosinophil apoptosis, 5014-5020
mast cell activation induced by eosinophil major basic protein, 1898-1904
MDS with bone marrow eosinophilia or basophilia, 3386-3390
myeloproliferative variant of idiopathic hypereosinophilic syndrome, 4660-4666
and severe GVHD (letter), 2073-2074
STAT5a required for eosinophil differentiation of cord blood–derived CD34+ cells, 134-142

Epidemiology
cancer incidence in Fanconi anemia, 822-826 (erratum, 2136)
and etiology of transfusion-related acute lung injury, 454-462
incidence of HIT in patients treated with subcutaneous unfractionated heparin, 2955-2959
quantitative assessment of body iron, 3359-3364

Epidermal growth factor 2 (EGF2) in protein S and APC cofactor activity, 1416-1418

EPO. *See* Erythropoietin

Epstein-Barr virus (EBV)
HLA A*2402–restricted EBV-specific CD8+ T cells, 1460-1468
LMP1-specific cytotoxic T cells for adoptive immunotherapy of malignancies associated with, 1905-1912
prognostic significance of impaired recovery of EBV-specific T cells after SCT, 4290-4297
therapeutic LMP1 vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma, 3150-3156

ER. *See* Endoplasmic reticulum

ERK. *See* Extracellular signal-regulated kinase

ERMAP. *See* Erythrocyte membrane-associated protein

Errata
cancer incidence in Fanconi anemia (*see Blood* 101:822-826, February 1, 2003), 2136
CLL preceded by cold agglutinin disease (*see Blood* 100:3419-3422, November 1, 2002), 1676
DC precursor populations of mouse blood (*see Blood* 101:1453-1459, February 15, 2003), 3364
inhibition of p53-dependent apoptosis by distinct signaling pathways (*see Blood* 100:3990-4000, December 1, 2002), 2114
in vivo tracking of stem cells transplanted into irradiated or nonirradiated recipients (*see Blood* 100:3545-3552, November 15, 2002), 390
lack of hepatic fibrosis with deferiprone in beta-thalassemia (*see Blood* 100:1566-1569, September 1, 2002), 2460
molecular response to imatinib following relapse after SCT for CML (letter) (*see Blood* 101:1200, February 1, 2003), 1683
SAM-1 erythroid cell line derived from K-562 cells (letter) (*see Blood* 100:3435, November 1, 2002), 2088
tumor rejection by single-chain Fv-CD28/TCR-ζ engineered T cytotoxic T cells (*see Blood* 100:3155-3163, November 1, 2002), 3808

Erythrocyte membrane-associated protein (ERMAP), Scianna antigens expressed by, 752-757

Erythrocytosis, hemostasis and coagulation in, 4416-4422

Erythroid cells
Bcl-X_L required for heme synthesis during erythroid differentiation, 2575-2583
E26 leukemia virus converts primitive erythroid cells into multilineage progenitors, 1103-1110
fetal hemoglobin modulation during erythropoiesis, 492-497
function of *bcl-x* promoter in erythroid progenitors, 2235-2242
involvement of ABC7 in heme biosynthesis in, 3274-3280
live erythroid and myeloid cells in β-globin ECFP x lysozyme EGFP mice, 903-906
modulation of erythroid cells by TNF-α, 524-531
PI3K in control of EPO-induced erythroid progenitor proliferation, 3436-3443
ribosomal protein S19 expression during erythroid differentiation, 318-324
SAM-1 erythroid cell line derived from K-562 cells (letter) (*see Blood* 100:3435, November 1, 2002) (erratum), 2088
SCF inhibits apoptosis in erythroid progenitors by up-regulation of FLIP, 1324-1328

Erythroleukemia
acute, diagnostic criteria for (letter), 2895-2896
STAT activation by type I IFN differential therapy for, 2727-2735

Erythropoietin (EPO)
differences between *N*-glycans of human serum EPO and recombinant human EPO (letter and response), 1204-1205
inhibition of p53-dependent apoptosis by distinct signaling pathways (*see Blood* 100:3990-4000, December 1, 2002) (erratum), 2114
PI3K in control of EPO-induced erythroid progenitor proliferation, 3436-3443
risk factors for thromboembolic complications in essential thrombocythemia (letter), 783-784

Etoposide, G-CSF and risk of secondary myeloid malignancy after, 3862-3867

EVI1, high expression predicts poor survival in AML, 837-845

Evi3 encodes an EBFAZ-related Krüppel-like zinc finger protein, 1934-1940

Extracellular signal-regulated kinase (ERK)
PKCζ mediated Raf-1/ERK activation by daunorubicin, 1543-1550
reduced PKB/Akt and ERK phosphorylation in MDS, 1172-1180

F-actin, two distinct pathways signal polymerization of, 1181-1184

Factor V
Arg2074Cys mutation of factor V causing moderately severe factor V deficiency, 173-177
combination of Dr Jekyll and Mr Hyde, 20-30

Factor VIII
efficacy of 2-CDA in refractory factor VIII inhibitors in persons without hemophilia, 943-945
elevated plasma factor VIII in murine model of LRP, 3933-3939
exosite-dependent regulation of factor VIIIa by APC, 4802-4807
factor VIII-specific T-cell clones in hemophilia A, 1351-1358
rFVIIa enhances $\alpha_{IIb}\beta_3$-deficient platelet adhesion, 1864-1870
rituximab for acquired factor VIII inhibitors (letter and response), 3753-3755

Factor IX
AAV-mediated factor IX gene transfer to muscle in hemophilia B, 2963-2972
immune tolerance after prenatal gene transfer of human factor IX to fetal mice, 1359-1366
myocardial fibrosis in mice with overexpression of, 1871-1873
retroviral vector gene therapy for hemophilia B, 3924-3932

Factor XI, factor XI inhibitors in patients with inherited factor XI deficiency, 4783-4788

Factor XIII
activation by thrombin depends on FXIIIVal34Leu genotype (letter and response), 371-372
risk of combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles for myocardial infarction, 3037-3041

FADD-like interleukin 1β–converting enzyme–inhibitory protein (FLIP), SCF inhibits IFN-γ-induced apoptosis by up-regulation of, 1324-1328

Familial Mediterranean fever, BMT for (letter and response), 1205-1206
Fanconi anemia
cancer in (letter), 2072-2073
cancer incidence in, 822-826 (erratum, 2136)
gains of 3q26q29 in bone marrow cells in, 3872-3874
retroviral-mediated Fancc expression enhances repopulating ability of *Fancc*$^{-/-}$ stem cells, 1299-1307
sensitivity of *Fancc*$^{-/-}$ bone marrow cells to nitric oxide, 3877-3884
20-year perspective on International Fanconi Anemia Registry, 1249-1256
Farnesyl transferase inhibitors
apoptotic synergism between STI571 and SCH66336 on imatinib-sensitive cell line (letter and response), 2070-2071
R115777 in hematologic malignancies, 1692-1697
Fas, sensitivity of naive T cells to Fas engagement, 4022-4028
Fas ligand, DCs overexpressing CD95L elicit allospecific T-cell responses, 1469-1576
Fatty acids, malaria-parasitized erythrocytes and hemozoin generate hydroxy fatty acids, 722-728
Fc receptors (FcR)
Fcγ receptor transmembrane domains, 4479-4484
Mac-1 in FcR–mediated immunity to melanoma, 253-258
FcR. *See* Fc receptors
Felic localizes to phagocytic cup, 2804-2809
Ferritin, mitochondrial, in sideroblastic anemias, 1996-2000
Fetal diagnosis of congenital afibrinogenemia caused *FGB* gene mutation, 3492-3494
Fetal hemoglobin
induction by apicidin, 2001-2007
modulation during erythropoiesis, 492-497
reactivation in adult life, 2826-2832
Fetal therapy, immune tolerance after prenatal gene transfer of human factor IX to fetal mice, 1359-1366
FGB gene, prenatal diagnosis of congenital afibrinogenemia caused by mutation of, 3492-3494
FGF. *See* Fibroblast growth factor
FGFR. *See* Fibroblast growth factor receptor
Fibrates, mechanism of down-regulation of IL-1–stimulated CRP expression in hepatocytes by, 545-551
Fibrin
estimating rate of thrombin and fibrin generation during CPB, 4355-4362
myosin as stabilizer of fibrin during clot dissolution, 4380-4386
Fibrinogen
order of splicing and outcome of *FGA* donor splice site mutations in congenital afibrinogenemia, 1851-1856
prenatal diagnosis of congenital afibrinogenemia caused by *FGB* gene mutation, 3492-3494
Fibroblast growth factor (FGF), paracrine interactions of basic FGF and IL-6 in MM, 2775-2783
Fibroblast growth factor receptor (FGFR), endogenous retroviral sequence fused to FGFR1 kinase in 8p12 MPD, 286-288
FIG1 gene, activation in primary mediastinal large B-cell lymphoma, 2756-2761
Filgrastim. *See* Granulocyte colony-stimulating factor
Fitzgerald trait, molecular defects of, 4430-4436
FLIP. *See* FADD-like interleukin 1β–converting enzyme–inhibitory protein
Flk-1 activity in hemogenic and nonhemogenic endothelium, 886-893
Flt1 receptor, VEGF potentiates megakaryocyte maturation through, 1316-1323
FLT3
APL model with FLT3 mutation is responsive to retinoic acid and SU11657, 3188-3197
SU5614 inhibits FLT3 and induces apoptosis in AML cell lines, 1494-1504
SU11248 is a novel inhibitor of, 3597-3605
suppression of myeloid transcription factors and STAT induction by AML-specific Flt3 mutations, 3164-3173
Fludarabine
with concurrent vs. sequential rituximab in B-CLL, 6-14
uptake mechanisms in B-CLL, 2328-2334
Folate receptor β gene, modulation by retinoic acid receptors, 4551-4560
Follicular lymphoma
grade 3, predictor of inferior survival in, 2363-2367
three cytogenetic subgroups in grade 3B of, 1149-1154
transformation to DLBCL, 3109-3117
Folts model to evaluate new antithrombotics (letter and response), 782-783
Forkhead family proteins, oncogenic activation of MLL by, 633-639
fos, HPK1 negatively regulates PGE_2-induced *fos* gene transcription, 3687-3689
Fucosyltransferase VII gene, transactivation by HTLV-1 Tax, 3615-3621
Fungal infection, primary antifungal prophylaxis in patients with hematologic malignancies, 3365-3372

G-CSF. *See* Granulocyte colony-stimulating factor
G-protein–coupled receptor (GPCR), LSSIG is novel murine leukocyte-specific GPCR, 1185-1187
G proteins
G-protein–coupled receptor signaling in Syk-deficient neutrophils and mast cells, 4155-4163
role for $G\alpha_{i1}$ in mediating platelet aggregation, 4828-4835
signaling in stem cell mobilization, 4739-4747
G6P. *See* Glucose-6-phosphate
G3139, and chemotherapy for refractory or relapsed acute leukemia, 425-432
GA-binding protein (GABP), GABP, Sp1, and RAR activate CD18 transcription in myeloid cells, 311-317
GABP. *See* GA-binding protein
GATA1
expression in $CD34^+$ progenitors in idiopathic myelofibrosis (letter and response), 5087-5089
mutagenesis and Down syndrome leukemogenesis, 4298-4300
mutations in transient leukemia and AMKL in Down syndrome, 4301-4304
RUNX1 and GATA-1 cooperation in megakaryocytic differentiation, 4333-4341
Gemtuzumab ozogamicin
differential response to AML cells to, 4589-4597
for relapsed pediatric AML, 3868-3871
Gene mutations
ADAMTS13 mutation in congenital TTP, 4449-4451
αIIb calcium-binding domain mutations and αIIbβ3 biogenesis, 2268-2276
AML1 mutations in minimally differentiated AML, 1277-1283
AML1 mutations in radiation- and therapy-related MDS/AML, 673-680
APL model with FLT3 mutation is responsive to retinoic acid and SU11657, 3188-3197
Arg760Cys mutation of VWF propeptide cleavage site responsible for new VWD variant, 151-156
Arg2074Cys mutation of factor V causing moderately severe factor V deficiency, 173-177
Artemis mutations in radiosensitive SCID patients, 1446-1452
BCL6 mutations disrupt its negative autoregulation in DLBCL, 2914-2923
*CYP1A1*2B (Val)* allele in AML patients with *NRAS* mutation, 2770-2774
CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians (letter), 2896-2897
effect of mouse strain and *MITF* mutation on decrease of skin mast cells, 1344-1350
GATA1 mutatgenesis and Down syndrome leukemogenesis, 4298-4300
GATA1 mutations in transient leukemia and AMKL in Down syndrome, 4301-4304
Gla domain–mutated hyperactive protein C, 2277-2284
heterozygous PU.1 mutations in AML (letter), 2074
HFE Cys282Tyr mutation as necessary but not sufficient cause of hereditary hemochromatosis, 3347-3350
HK Utrecht: mutation associated with hexokinase deficiency and hemolytic anemia, 345-347
leukemic potential of doubly mutant *Nf1* and *W*^{v} hematopoietic cells, 1984-1986
mitochondrial DNA mutations in MDS, 3118-3125
in murine erythroid α-spectrin gene, 325-330
mutation of *ATM* gene in childhood ALL with *MLL* gene rearrangement, 3622-3627
mutations in calf-1 and calf-2 domains of GPIIb in Glanzmann thrombasthenia, 4808-4815
novel mutation in GDP-fucose transporter gene in LADII, 1705-1712
order of splicing and outcome of *FGA* donor splice site mutations in congenital afibrinogenemia, 1851-1856
PIG-A gene mutations in aplastic anemia/PNH, 2833-2841
plasma levels and -1C>T mutation in annexin 5A gene (letter and response), 4223-4225
prenatal diagnosis of congenital afibrinogenemia caused by *FGB* gene mutation, 3492-3494
Rab27a mutations in Griscelli syndrome, 2736-2742
serum elastase levels and ELA-2 elastase mutations in chronic idiopathic neutropenia (letter), 2898-2899

signaling of Asp814Val c-*kit* activating mutant, 1094-1102
suppression of myeloid transcription factors and STAT induction by AML-specific Flt3 mutations, 3164-3173
Tyr143Hisα_{IIb} mutation abolishes $\alpha_{IIb}\beta_3$ function for soluble ligands, 3485-3491
V_H gene mutational status and CD38 expression in CLL, 1087-1093
V_H gene mutations define transformation from MGUS to MM, 4137-4139
VHL gene mutations in congenital polycythemia, 1591-1595
VWF-cleaving protease and *ADAMTS13* mutations in childhood TTP, 1845-1850
Gene polymorphisms
CD158k/p140/KIR3DL2 polymorphisms in Sézary patients (letter), 1203
circadian oscillation of PAI-1 and *4G5G* polymorphism, 1841-1844
designation of transcobalamin codon 259 polymorphism (letter and response), 3749-3751
genetic and nutritional factors in hyperhomocysteinemia in young adults, 2483-2488
GPVI polymorphism and platelet response, 4372-4379
no exon 4 polymorphism of CYP2C9 in Taiwanese (letter), 5086-5087
PAR-1 polymorphism associated with platelet receptor density and response to SFLLRN, 1833-1840
polymorphisms close to AUG codon and initiation of translation (letter and response), 1202-1203
Gene therapy
AAV-mediated factor IX gene transfer to muscle in hemophilia B, 2963-2972
of ApoE-deficient mice using macrophage-specific retroviral vector, 485-491
CD4-cell–specific lentiviral vectors, 3416-3423
CD45 minigene corrects CD45 deficiency in mice, 849-855
chemokine–cytokine allogeneic antitumor vaccine for neuroblastoma, 1718-1726
for hemophilia A using high-capacity adenoviral vectors, 1734-1743
and humoral immune response in mice, 2551-2556
IFN-β scaffold attachment region and chicken β-globin insulator in lentiviral vectors, 4717-4724
immune tolerance after prenatal gene transfer of human factor IX to fetal mice, 1359-1366
immunomagnetic selection of low-affinity nerve growth factor-positive T cells for, 476-484
lentiviral transduction of thalassemic cells, 104-111
lentiviral vector multiple copy integration in NON/SCID repopulating cells, 1284-1289
liver sieve and (letter and response), 3338-3339
long-term results of the first ADA gene therapy trial, 2563-2569
oncolytic measles viruses display antibody against CD38, 2557-2562
phenotypic correction of β-thalassemia after lentiviral-mediated transfer of γ-globin gene, 2175-2183
reactivity of T cells expressing a suicide gene after T-cell–depleted SCT, 1290-1298
rescue from murine model of Cooley anemia by, 2932-2939
retroviral-mediated Fancc expression enhances repopulating ability of *Fancc*$^{-/-}$ stem cells, 1299-1307
retroviral transduction efficiency of G-CSF+SCF–mobilized peripheral blood CD34$^+$ cells, 2199-2205
retroviral vector gene therapy for hemophilia B, 3924-3932
retroviral vector integration in preferred genomic targets of bone marrow–repopulating cells, 2191-2198
retrovirus-mediated IL-7 expression in leukemic DCs generated from AML, 2184-2190
side effects of retroviral gene transfer into hematopoietic stem cells, 2099-2114
T-cell transduction by IL-7–displacing lentiviral vectors, 2167-2174
tolerance induction after EGFP BMT, 4305-4312
transduction of B cells with lentiviral vectors, 1727-1733
tumor rejection by single-chain Fv-CD28/TCR-ζ engineered T cytotoxic T cells (*see Blood* 100:3155-3163, November 1, 2002) (erratum), 3808
VL30 promoter directs sustained activity in erythroid progenitors, 1798-1800
for Wiskott-Aldrich syndrome, 2159-2166
Genetic linkage studies, of thrombocytopenic SLE, 992-997
GILZ. *See* Glucocorticoid-induced leucine zipper
Glanzmann thrombasthenia
mutations in calf-1 and calf-2 domains of GPIIb in, 4808-4815
Tyr143Hisα_{IIb} mutation abolishes $\alpha_{IIb}\beta_3$ function for soluble ligands, 3485-3491
Globins. *See also* Hemoglobin
globin loci in pufferfish and humans, 2842-2849
live erythroid and myeloid cells in β-globin ECFP x lysozyme EGFP mice, 903-906
locus control region dependency on β-globin intron-2, 1603-1610
phenotypic correction of β-thalassemia after lentiviral-mediated transfer of γ-globin gene, 2175-2183
Glomerular mesangial cells, hematopoietic origin of, 2215-2218
Glucocorticoid-induced leucine zipper (GILZ), synthesis by macrophages, 729-738
Glucose-6-phosphate (G6P) transport, inhibition in neutrophils results in apoptosis, 2381-2387
Glycogen storage disease type 1b
circulating apoptotic neutrophils in, 5021-5024
inhibition of G6P transport in neutrophils results in apoptosis, 2381-2387
Glycophorin C is receptor for PfEBP-2, 4628-4631
Glycoprotein IIb/IIIa antagonists
antibody testing reduces incidence of roxifiban-associated thrombocytopenia, 58-63
thrombocytopenia after treatment with (letter and response), 1655
Glycoproteins (GPs)
αIIb calcium-binding domain mutations and αIIbβ3 biogenesis, 2268-2276
GPIIb/IIIa-mediated platelet-platelet interaction, 929-936
GPIIIa domains as target for quinine-induced immune thrombocytopenia antibodies, 937-942
GPVI polymorphism and platelet response, 4372-4379
interaction between VWF and GPIb activates Src kinase in platelets, 3469-3476
mutations in calf-1 and calf-2 domains of GPIIb in Glanzmann thrombasthenia, 4808-4815
$P2Y_{12}$ in GPVI-mediated Rap1 activation in platelets, 1409-1415
role of intracellular domains of GPIb in controlling adhesive properties of GPIb/V/IX complex, 3477-3484
shielding front-strand β3 of VWF A1 domain inhibits its binding to GPIbα, 1375-1383
targeting of collagen-binding site on GPVI and in vivo depletion of receptor, 3948-3952
thrombogenicity of β_2-GPI–dependent antiphospholipid antibodies, 157-162
Glycosphingolipids, in acute nonlymphocytic leukemia, 711-721
GM-CSF. *See* Granulocyte-macrophage colony-stimulating factor
GPCR. *See* G-protein–coupled receptor
Graft-versus-host disease (GVHD)
donor pretreatment with IL-18 attenuates acute GVHD and preserves graft-versus-leukemia effects, 2877-2885
donor pretreatment with progenipoietin-1 for prevention of, 2033-2042
donor T cell–derived TNF required for GVHD and graft-versus-tumor activity after BMT, 2440-2445
eosinophils and severe GVHD (letter), 2073-2074
lymphocyte adherence to dermal endothelium in, 771-778
nonmalignant late effects after allogeneic SCT, 3373-3385
OX40 ligation regulates GVHD and graft rejection after BMT, 3741-3748
Graft-versus-leukemia effect
antileukemic activity of allorestricted cytotoxic T cells, 1007-1014
donor pretreatment with IL-18 attenuates acute GVHD and preserves graft-versus-leukemia effects, 2877-2885
donor T cell–derived TNF required for GVHD and graft-versus-tumor activity after BMT, 2440-2445
engineering CD19-specific human cytotoxic T lymphocytes, 1637-1644
Granulocyte colony-stimulating factor (G-CSF)
CD26/DPPIV mediates G-CSF mobilization in mouse progenitor cells, 4680-4686
CHOP vs. CNOP in elderly patients with lymphoma and, 3840-3848
expansion of myeloid progenitor cells induced by, 2584-2590
G-CSF and risk of secondary myeloid malignancy after etoposide, 3862-3867
G-CSF increases CD123^{hi} blood DCs with altered CD62L and CCR7 expression, 2314-2317
impaired neutrophil maturation in truncated G-CSF receptor–transgenic mice, 2990-2995
inhibition of cytochrome *c* release in MDS by, 1080-1086
in vitro regulation of granulopoiesis by neutrophil elastase, 1752-1758

phagocytic signal transduced by carboxy-terminal region of G-CSF receptor, 4615-4622
retroviral transduction efficiency of G-CSF+SCF–mobilized peripheral blood CD34+ cells, 2199-2205
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
molecular assembly of GM-CSF receptor complex, 1308-1315
rapamycin induced $p27^{KIP1}$-mediated apoptosis in DCs by interference with, 1439-1445
Granulocyte transfusions and CMV infection (letter and response), 5091-5092
Granulomas, cutaneous, mast cell–derived TNFα induces macrophage recruitment in, 210-215
Granulopoiesis
CUL-4A interferes with granulocytic differentiation and exit from cell cycle, 1769-1776
impaired granulocytopoiesis in chronic idiopathic neutropenia, 2591-2600
in vitro regulation by neutrophil elastase, 1752-1758
Granzyme C, cell death induced by, 3093-3101
Granzyme M, expression in NK-cell, γδ-T cell, and intestinal T-cell lymphomas, 3590-3593
Griscelli syndrome, Rab27a mutations in, 2736-2742
Growth factors. *See* specific growth factors
GTPase. *See* Guanine triphosphatase
Guanine triphosphatase (GTPase), differential regulation of CXCR2 trafficking by Rab GTPases, 2115-2124
GVHD. *See* Graft-versus-host disease

Hairy cell leukemia (HCL), *ras* and *junB* activation drive *CD11c* expression in, 4033-4041
HB22.7 has lymphomacidal properties and augments efficacy of radioimmunotherapy, 3641-3647
HCL. *See* Hairy cell leukemia
Heat shock proteins (HSPs)
exogenous stress proteins enhance immunogenicity of apoptotic tumor cells, 245-252
Gp96 binds to neutrophils and monocytes and stimulates effector functions, 2810-2815
HSP receptor CD91 in HIV-1–infected nonprogressors, 4000-4004
Helicobacter pylori, and ITP in children (letter), 1660
Hematopoiesis
antiapoptotic cytokines reduce radiation lethality, 2609-2616
Bcl-X_L required for heme synthesis during erythroid differentiation, 2575-2583
C/EBPα affects gene expression and differentiation of CD34+ cells, 2206-2214
c-Kit and integrin-directed migration in mast cells, 4725-4732
C3a and C3a receptor in, 3784-3793
Cb2 induces reversible block in neutrophilic differentiation, 1336-1343
CD41 expression and hematopoiesis in mouse embryo, 508-516
characterization of fetal liver stroma, 2973-2982
chromatin immunoprecipitation studies of C/EBPα and C/EBPε and CDP/cut in lactoferrin gene expression, 3460-3468
combined effects of *Notch* signaling and cytokines on stem cell differentiation, 1784-1789
constitutive IL-5 overexpression induces extramedullary hematopoiesis in spleen, 863-868
CTLA-4 in normal and leukemic hematopoietic cells, 202-209
CUL-4A interferes with granulocytic differentiation and exit from cell cycle, 1769-1776
distribution of mesenchymal stem cells after systemic infusion in primates, 2999-3001
effect of mouse strain and *MITF* mutation on decrease of skin mast cells, 1344-1350
effects of C/EBPα and PKCδ on JunB expression and monocytic differentiation, 3885-3892
erythropoiesis from acetyl LDL incorporating endothelial cells at preliver stage, 4733-4738
expansion of umbilical cord progenitor cells by human telomerase catalytic subunit–transfected stromal cells, 532-540
fetal hemoglobin modulation during erythropoiesis, 492-497
Flk-1 activity in hemogenic and nonhemogenic endothelium, 886-893
function of *bcl-x* promoter in erythroid progenitors, 2235-2242
G-CSF–induced expansion of myeloid progenitor cells, 2584-2590
G-protein signaling in stem cell mobilization, 4739-4747
hematologic effects of inactivating *Rce1,* 2250-2252
hematopoietic capacity of connexin43 wild-type and knock-out fetal liver cells, 2996-2998
hematopoietic origin of glomerular mesangial cells, 2215-2218
host stem cells selectively reconstitute missing lymphoid lineages, 4347-4354
HOXB4 effect on CD34+ cell growth and lymphomyeloid differentiation, 1759-1768
human cord blood CD34+Pax-5+ B-cell progenitors, 3424-3430
human pro-B cells that give rise to macrophages, NK cells and T cells, 4313-4321
hyaluronan and stem cell biology, 856-862
IFN-γ switches monocyte differentiation from DCs to macrophages, 143-150
Ikaros regulates neutrophil differentiation, 2219-2226
impaired granulocytopoiesis in chronic idiopathic neutropenia, 2591-2600
impaired neutrophil maturation in truncated G-CSF receptor–transgenic mice, 2990-2995
inhibition of p53-dependent apoptosis by distinct signaling pathways (*see Blood* 100:3990-4000, December 1, 2002) (erratum), 2114
in vitro regulation of granulopoiesis by neutrophil elastase, 1752-1758
in vivo tracking of stem cells transplanted into irradiated or nonirradiated recipients (*see Blood* 100:3545-3552, November 15, 2002) (erratum), 390
intra–bone marrow injection in SCID-repopulating cell assay, 2905-2913
intrinsic thyrotropin-mediated pathway of TNF-α production in bone marrow, 119-123
laminin isoform–specific adhesion and migration of hematopoietic progenitors, 877-885
live erythroid and myeloid cells in β-globin ECFP x lysozyme EGFP mice, 903-906
marrow frequency of rat long-term repopulating cells and species body weight, 3431-3435
megakaryocyte polyploidization associated with functional gene amplification, 541-544
MEIS1 and PBXs regulate transcription of PF4 gene, 4748-4756
MIP-1α–binding heparan sulfate oligosaccharide supports long-term culture-initiating cells, 2243-2245
modulation of erythroid cells by TNF-α, 524-531
molecular assembly of GM-CSF receptor complex, 1308-1315
novel class of CD34− cells that give rise to SCID-repopulating cells, 869-876
novel mouse genes in aorta-gonad-mesonephros region, 2246-2249
novel myeloid-like NK cell progenitor in human UCB, 3444-3450
novel secreted isoform of ICAM-4, 1790-1797
OPG and osteosclerosis in mice overexpressing TPO, 2983-2989
PAR domain transcription factor regulates human *LMO2* gene expression, 4757-4764
Pax5 determines B- vs. T-cell fate, 4342-4346
PF4 inhibition of, 4687-4694
preservation and accumulation of hematopoietic stem cells by HES-1, 1777-1783
regulation of osteoclastogenesis by Notch signaling, 2227-2234
reversibility of CD34 expression on human stem cells, 112-118
role of phospho-Smad2/3 in HL-60 cell differentiation, 498-507
RUNX1 and GATA-1 cooperation in megakaryocytic differentiation, 4333-4341
SCF inhibits IFNγ-induced apoptosis by up-regulation of FLIP, 1324-1328
SCID-repopulating activity of CD34− cells by intra–bone marrow injection, 2924-2931
SgIGSF: new MITF-dependent mast-cell adhesion molecule, 2601-2608
Smad5 gene disruption and high-proliferative potential precursors during embryonic hematopoiesis, 124-133
SNP-based quantitation of hematopoietic chimerism after allogeneic SCT, 363-369
STAT5a required for eosinophil differentiation of cord blood–derived CD34+ cells, 134-142
stem cell and progenitor defects in Sca-1/Ly-6A–null mice, 517-523
stromal inhibition of megakaryocytic Rap1 signaling, 1744-1751
TPO effects in early murine yolk sac hematopoiesis, 1329-1335

transcription factors during neutrophil differentiation in bone marrow, 4322-4332
transcriptional accessibility in hematopoietic stem cells, 383-390
trichostatin A and sodium butyrate suppress osteoclastogenesis, 3451-3459
VEGF potentiates megakaryocyte maturation, 1316-1323
WT1 in murine hematopoiesis, 2570-2574
ZBP-89 is a repressor of *CD11b* gene, 894-902
Hematopoietic progenitor kinase 1 (HPK1), negative regulation of PGE_2-induced *fos* gene transcription by, 3687-3689
Hemin, treatment in aortic tissues from hypertensive rats, 3893-3900
Hemodialysis, late-onset X-linked sideroblastic anemia after, 4623-4624
Hemoglobin
aberrant development of *Plasmodium falciparum* in hemoglobin CC red cells, 3309-3315
fetal
induction by apicidin, 2001-2007
modulation during erythropoiesis, 492-497
reactivation in adult life, 2826-2832
hemoglobin A expression after lentiviral transduction of thalassemic cells, 104-111
hemoglobin digestion and osmotic stability of malaria-infected RBCs, 4189-4194
hemoglobin H disease, 791-800
spleen-facilitated vesiculation and hemoglobin loss from erythrocytes, 747-751
vasoactivity of S-nitrosohemoglobin, 4408-4415
Hemoglobin scavenger receptor (CD163/HbSR), as marker of monocytic lineage in AML (letter), 3755-3756
Hemolytic anemia
autoimmune
liposomal clodronate for mouse model of, 594-601
rituximab for refractory anemia in children, 3857-3861
HK Utrecht: mutation associated with hexokinase deficiency and, 345-347
spur-cell, in severe alcoholic cirrhosis (blood work), 3
Hemophilia
AAV-mediated factor IX gene transfer to muscle in hemophilia B, 2963-2972
factor VIII-specific T-cell clones in hemophilia A, 1351-1358
gene therapy or hemophilia A using high-capacity adenoviral vectors, 1734-1743
immune tolerance after prenatal gene transfer of human factor IX to fetal mice, 1359-1366
retroviral vector gene therapy for hemophilia B, 3924-3932
Hemostasis
Arg2074Cys mutation of factor V causing moderately severe factor V deficiency, 173-177
and coagulation in erythrocytosis, 4416-4422
collagen-induced platelet aggregation, 2646-2651
desmopressin-induced changes in ADAMTS-13 activity, 946-948
dose-dependent effects of plasmin and tPA on coagulation and hemorrhage, 3002-3007
efficacy of 2-CDA in refractory factor VIII inhibitors in persons without hemophilia, 943-945
factor V: combination of Dr Jekyll and Mr Hyde, 20-30
Gla domain–mutated hyperactive protein C, 2277-2284
GPIIb/IIIa-mediated platelet-platelet interaction, 929-936
GPVI polymorphism and platelet response, 4372-4379
lactadherin inhibits blood coagulation, 2628-2636
mechanisms and implications of platelet discoid shape, 4789-4796
megakaryocytes require TSP2 for normal platelet formation and function, 3915-3923
myosin as stabilizer of fibrin during clot dissolution, 4380-4386
role for $G\alpha_{i1}$ in mediating platelet aggregation, 4828-4835
role of extracellular cysteines in $P2Y_{12}$ receptor inactivation, 3908-3914
shear-induced platelet activation and self-association of VWF in suspension, 2637-2645
shear stress inhibits adhesion molecule expression in endothelial cells, 2667-2674
VWF and shear-dependent p125FAK phosphorylation, 4363-4371
Hemozoin, malaria-parasitized erythrocytes and hemozoin generate hydroxy fatty acids, 722-728
Heparan sulfate
on endothelial cells mediates binding of malaria-infected erythrocytes, 2405-2411
MIP-1α–binding heparan sulfate oligosaccharide supports long-term culture-initiating cells, 2243-2245
Heparin, combined anticoagulant and antiselectin treatments prevent DIC, 921-928
Heparin-induced thrombocytopenia (HIT)
central venous catheters, upper-extremity DVT, and HIT, 3049-3051
how I treat HIT and thrombosis, 31-37
in patients treated with subcutaneous unfractionated heparin, 2955-2959
Hepatitis B, risk of infection by transfusion in Kumasi, Ghana, 2419-2425
Hepatitis C, hepatitis C virus quasispecies in DCs and liver cells, 52-57
Hepatocyte growth factor (HGF)
HGF receptor expression in angiogenesis, 4816-4822
inhibition by angiostatin in endothelial and smooth muscle cells, 1857-1863
Hepcidin, as mediator of anemia of inflammation, 2461-2463
Hereditary hemochromatosis. *See also* Iron
clinical consequences of iron overload in hemochromatosis homozygotes, 3351-3358
duodenal iron in *Hfe* knock-out mice, 3316-3318
HFE Cys282Tyr mutation as necessary but not sufficient cause of, 3347-3350
UbcH5A up-regulation in, 3288-3293
Hereditary hydrocytosis, erythrocyte endothelial adherence and membrane phospholipid asymmetry in, 4625-4627
Hermansky-Pudlak syndrome, cappucino is a component of BLOC-1, 4402-4407
HES-1, preservation and accumulation of hematopoietic stem cells by, 1777-1783
Hexokinase deficiency, HK Utrecht: mutation associated with hemolytic anemia and, 345-347
HFE gene
clinical consequences of iron overload in hemochromatosis homozygotes, 3351-3358
duodenal iron in *Hfe* knock-out mice, 3316-3318
HFE Cys282Tyr mutation as necessary but not sufficient cause of hereditary hemochromatosis, 3347-3350
HGAL predicts survival in large B-cell lymphoma, 433-440
HGF. *See* Hepatocyte growth factor
HHV-8. *See* Human herpesvirus 8
HIF-1. *See* Hypoxia-inducible factor-1
High-mobility group protein-1 (HMGB1), inflammatory effects on endothelial cells, 2652-2660
Histone deacetylase
inhibitors of, 1430-1438
molecular sequelae of inhibition in malignant B cells, 4055-4062
HIT. *See* Heparin-induced thrombocytopenia
HIV-1. *See* Human immunodeficiency virus type 1
HLA. *See* Human leukocyte antigens
HMGB1. *See* High-mobility group protein-1
Hodgkin disease
BCL3 expression differentiates ALCL from, 2789-2796
BCL6 rearrangements in, 706-710
c-Rel protein accumulation in, 3681-3686
cell-cycle and apoptosis deregulation in Hodgkin and Reed-Sternberg cells, 681-689
IL-3 and SCF in (letter), 376-377
lost B-cell identity of Hodgkin and Reed-Sternberg cells of, 1505-1512
nodular sclerosing, prognostic grading of, 4063-4069
rituximab for relapsed $CD20^+$ lymphoma, 420-424
rituximab in lymphocyte-predominant Hodgkin disease, 4285-4289
therapeutic LMP1 vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma, 3150-3156
Homeobox (HOX) genes
homeodomain-DNA interactions required for HOX11-mediated transformation, 4966-4974
HOX gene expression in PML-$RAR\alpha^{2b}$ APL, 1558-1565
HOXB4 effect on $CD34^+$ cell growth and lymphomyeloid differentiation, 1759-1768
induction of AML by *NUP98-HOXD13* in concert with *Meis1*, 4529-4538
Homocysteine
cobalamin deficiency with and without neurologic abnormalities, 3302-3308
fasting plasma total homocysteine and protein C activity in vitro (letter), 2446-2447
genetic and nutritional factors in hyperhomocysteinemia in young adults, 2483-2488
hyperhomocysteinemia accelerates atherosclerosis in CBS and ApoE knock-out mice, 3901-3907
Hospital water distribution systems, pathogenic molds in, 2542-2546

How I treat, HIT and thrombosis, 31-37
HOX. *See* Homeobox genes
HPK1. *See* Hematopoietic progenitor kinase 1
HSPs. *See* Heat shock proteins
hTERT. *See* Telomerase reverse transcriptase
HTLV. *See* Human T-cell leukemia virus
Human granulocytotropic ehrlichiosis (blood work), 4232
Human herpesvirus 8 (HHV-8)
  HHV8–encoded viral FLICE inhibitory protein protects against apoptosis via NF-κB activation, 1956-1961
  remission of PEL by AZT-mediated inhibition of NF-κB, 2321-2327
  repression of STAT3 activity by Kaposi sarcoma–associated viral cyclin K, 4070-4077
Human immunodeficiency virus type 1 (HIV-1)
  B7-H1 up-regulation is marker of disease progression, 2514-2520
  DC dysfunction and infection in, 4505-4511
  EPOCH for AIDS-related lymphoma, 4653-4659
  gene expression profiling of AIDS-related PEL, 4115-4121
  HSP receptor CD91 in HIV-1–infected nonprogressors, 4000-4004
  IL-4 variant associated with apoptosis, 3102-3105
  IL-15 effects on HIV-specific $CD8^+$ T cells, 1024-1029
Human leukocyte antigens (HLA)
  distinct HLA associations by stroke subtype in children with SCD, 2865-2869
  down-regulation of HLA-DR by human CMV protein pp65, 4870-4877
  HLA A*2402–restricted EBV-specific $CD8^+$ T cells, 1460-1468
  non-T-cell–depleted HLA haploidentical SCT based on feto-maternal microchimerism, 3334-3336
Human T-cell leukemia virus (HTLV)
  arsenic/IFN reverses two gene networks in HTLV-1 cells, 4576-4582
  degenerate specificity of HTLV-1–specific T cells, 3074-3081
  HTLV receptor is early T-cell activation marker, 1913-1918
  leukocyte reduction and HTLV-I in transfusion recipients (letter and response), 370-371
  regulation of HTLV-I binding protein in T cells during immune activation, 3085-3092
  transactivation of fucosyltransferase VII gene by HTLV-1 Tax, 3615-3621
Hyaluronan and stem cell biology, 856-862
Hydroxyurea, long-term use in young patients with essential thrombocythemia (letter), 3749
Hypereosinophilic syndrome
  efficacy of imatinib in, 4714-4716
  imatinib for, 3391-3397
  serum tryptase in myeloproliferative variant of, 4660-4666
Hypertension, hemin treatment in aortic tissues from rats with, 3893-3900
Hypoxemia, nocturnal, and painful sickle cell crises in children, 846-848
Hypoxia
  hypoxic up-regulation of erythroid ALAS2, 348-350
  Smad proteins in cellular response to, 2253-2260
Hypoxia-inducible factor-1 (HIF-1)
  in insulin induction of PAI-1 expression in rat hepatocytes, 907-914
  oxidized LDL triggers accumulation of HIF-1α, 4847-4849

I blood group
  antigen expression, 2870-2876
  I locus, adult i phenotype, and congenital cataracts, 2081-2088
IAP. *See* Inhibitor of apoptosis
ICA-17043, prevention of sickled red blood cell dehydration by, 2412-2418
ICAM. *See* Intercellular adhesion molecule
ICSBP. *See* Interferon consensus sequence-binding protein
IFN. *See* Interferon
Ikaros, regulation of neutrophil differentiation, 2219-2226
IκB kinase (IKK)
  curcumin down-regulates NF-κB and IκBα kinase in MM cells, 1053-1062
  role of IKK2 and NIK in DC antigen presentation, 983-991
IKK. *See* IκB kinase
Imaging
  MRI evaluation of myocardial iron during iron chelation therapy, 4632-4639
  noninvasive measurement of iron, 15-19
  utility of FDG-PET scanning in lymphoma by WHO classification, 3875-3876
Imatinib mesylate (STI571)
  abnormalities in Ph^- cells of CML patients on imatinib, 1941-1949
  apoptotic synergism between STI571 and SCH66336 on imatinib-sensitive cell line (letter and response), 2070-2071
  Bcr-Abl and LYN kinase in CML cells resistant to, 690-698
  CML myelodysplastic subclones and imatinib therapy (letter), 781
  CNS is sanctuary for leukemic cells in imatinib-treated mice, 5010-5013
  dose escalation can overcome resistance in CML, 473-475
  early MRD analysis during treatment of Ph^+ ALL with, 85-90
  effects of Bcr-Abl on neutrophilic differentiation reversed by, 655-663
  efficacy in idiopathic hypereosinophilic syndrome, 4714-4716.
  for eosinophilic disorders, 3391-3397
  levels of *BAX, MRP-1,* and platelets predict response to imatinib in CML, 2152-2155
  MDR1 gene overexpression confers imatinib resistance in leukemia cell lines, 2368-2373
  molecular response to, following relapse after SCT for CML (letter), 1200-1201 (erratum, 1683)
  in myeloproliferative variant of idiopathic hypereosinophilic syndrome, 4660-4666
  in newly diagnosed patients with Ph^+ CML, 97-100
  normalization of bone marrow vascularity in CML by (letter), 4641-4643
  persistence of $Bcr\text{-}Abl^+$ progenitors in CML in remission after, 4701-4707
  PP1 and CGP76030 inhibit cells expressing imatinib-resistant Bcr-Abl kinases, 664-672
  SAHA enhances imatinib-induced apoptosis of Bcr-Abl–positive leukemia cells, 3236-3239
  sensitivity of Bcr-Abl mutants to, 4611-4614
  severe skin reaction to, in Ph^+ ALL (letter), 2446
  significance of cytogenetic clonal evolution in imatinib-treated CML, 3794-3800
  sustained complete remission in patient with refractory AML, 2960-2962
  telomere length in peripheral blood granulocytes after treatment of CML with (letter), 375-376
Immune thrombocytopenic purpura (ITP)
  CD40/CD154 blockade in, 621-623
  effects of B7-blocking agent and/or CsA on induction of T-cell anergy in chronic ITP, 2721-2726
  and *Helicobacter pylori* in children (letter), 1660
  IVIG induces dose-dependent amelioration of ITP in rodents (letter and response), 1658-1659
  monoclonal IgG can ameliorate immune thrombocytopenia in murine ITP, 3708-3713
Immunobiology
  A1 is a growth-permissive T-cell survival factor, 2679-2685
  activation of influenza virus–specific T cells by plasmacytoid DCs, 3520-3526
  activity of adenosine on human DCs, 3985-3990
  age-related changes in B lymphopoiesis, 576-584
  AID expression in CLL B cells, 4029-4032
  AID in B-cell non-Hodgkin lymphomas, 3574-3580
  alloantigen-specific suppression of mixed leukocyte reactions by DCs, 3325-3333
  allograft resistance in cytotoxic-deficient hosts, 3991-3999
  antileukemic activity of allorestricted cytotoxic T cells, 1007-1014
  antiviral CD8 T cell function in chronic viral infection, 226-235
  Artemis mutations in radiosensitive SCID patients, 1446-1452
  autoimmune complexes in serum and therapeutic amounts of IVIGs (letter), 1660-1662
  B-cell transformation, Csk, and glycolipid-enriched microdomains, 1874-1881
  BCR/ABL alters NK function and acquisition of KIRs, 3527-3533
  cAMP inhibits Ras and Rap1 activation in T cells, 998-1006
  CCR7 ligands induce endocytosis in mature DCs, 4923-4929
  CD4 on human peripheral blood neutrophils, 4452-4456
  CD40/CD154 blockade in ITP, 621-623
  $CD56^{bright}$ NK cells link adaptive and innate immunity, 3052-3057
  CD57 expression defines replicative senescence and apoptosis of $CD8^+$ T cells, 2711-2720
  cell death induced by granzyme C, 3093-3101
  cell regulation by acquired MHC class II:peptide complexes, 2704-2710
  chaperone-rich cell lysate activates DCs and elicits antitumor immunity, 4485-4491
  chromatin remodeling at human *IL-12(p35)* locus, 4894-4902
  complement-mediated lysis by anti-CD20 mAb, 1045-1052
  contributions of TNF and LT cytokines to DC development, 1477-1483
  CTLA-4 in normal and leukemic hematopoietic cells, 202-209

cytoskeletal and functional defects in DCs from CML patients, 3560-3567
DC dysfunction and infection in HIV, 4505-4511
DC precursor populations of mouse blood, 1453-1459 (erratum, 3364)
DCs overexpressing CD95L elicit allospecific T-cell responses, 1469-1576
degenerate specificity of HTLV-1–specific T cells, 3074-3081
dexamethasone-induced apoptosis of thymocytes, 585-593
differential CD52 expression by myeloid DC subsets, 1422-1429
differential chemokine expression in peripheral blood T cells, 216-225
down-regulation of HLA-DR by human CMV protein pp65, 4870-4877
exogenous stress proteins enhance immunogenicity of apoptotic tumor cells, 245-252
factors affecting antibody levels after allogeneic SCT, 3319-3324
Fcγ receptor transmembrane domains, 4479-4484
G-CSF increases CD123^{hi} blood DCs with altered CD62L and CCR7 expression, 2314-2317
gene expression profile in human leukocytes, 3509-3513
gene expression profiling of plasma cells, 4013-4021
gene therapy and humoral immune response in mice, 2551-2556
generation of DCs from mouse embryonic stem cells, 3501-3508
generation of low-toxicity IL-2 fusion proteins devoid of vasopermeability activity, 4853-4861
genetics of thrombocytopenic SLE, 992-997
glycosylation-dependent inhibition CLA expression, 602-610
granzyme M expression in NK-cell, γδ-T cell, and intestinal T-cell lymphomas, 3590-3593
high AID expression in poor-prognosis CLL, 4903-4908
histone deacetylase inhibitors, 1430-1438
HLA A*2402–restricted EBV-specific CD8$^+$ T cells, 1460-1468
HSP receptor CD91 in HIV-1–infected nonprogressors, 4000-4004
hTERT extends life span of CD4$^+$ T cells, 4512-4519
ICSBP retrovirus transduction rescues DC development, 961-969
IL-4 variant associated with apoptosis, 3102-3105
IL-7 expands T cells in normal and SIV-infected nonhuman primates, 2294-2299
IL-12 immunotherapy of A20 lymphoma, 568-575
IL-12 reversal of CD28 loss in senescent CD4$^+$ T cells, 3543-3549
IL-15 effects on HIV-specific CD8$^+$ T cells, 1024-1029
IL-15 is essential mediator of peripheral NK-cell homeostasis, 4887-4893
immunodominant MAGE-3 CD4 epitopes, 1038-1044
in vivo induction of CD4$^+$/CD25$^+$ regulatory T cells, 4862-4869
internalization of apoptotic cells by splenic marginal zone DCs, 611-620
IVIGs induce B-cell differentiation and IgG secretion, 3065-3073
LF 15-0195 enhances activation-induced T-cell death, 194-201
LFA-1 required for retention of effector CD8 T cells in mouse lungs, 4916-4922
liposomal clodronate for murine autoimmune hemolytic anemia, 594-601
LIR9, an activating receptor in monocytes, 1484-1486
Mac-1 in FcR–mediated immunity to melanoma, 253-258
macrophage- and DC-dependent regulation of B-cell proliferation requires BAFF, 4464-4471
malaria targeting by biscFv, 2300-2306
mast cell activation induced by major basic protein and regulated by membrane SCF, 1898-1904
mast cell–derived TNFα induces macrophage recruitment in cutaneous granulomas, 210-215
mast cells produce IL-25, 3594-3596
mechanisms of action of rituximab in non-Hodgkin's lymphomas, 949-954
β_2-microglobulin inhibits generation of DCs, 4005-4012
MIP-1α and MIP-1β mediate immunity, 807-814
MIP-1α triggers signaling cascades in MM cells, 3568-3573
modified myeloid DCs induce anergic and regulatory T cells, 3581-3589
mutual inactivation of CD4 T cells and tumor cells, 4472-4478
overexpressed *V1-69* genes in unmutated CLL not related to aging process, 3082-3084
p38 MAPK involvement in thymocyte development, 970-976
PECAM-1–driven antiapoptotic signal in CD34$^+$ cells, 186-193
PML does not regulate MHC class I in human cells, 3514-3519
profiling of CD44-stimulated human B cells, 2307-2313
promoter IV of class II transactivator gene essential for positive selection of CD4$^+$ cells, 3550-3559
Rab27a mutations in Griscelli syndrome, 2736-2742
rapamycin induced p27^{KIP1}-mediated apoptosis in DCs, 1439-1445
rapamycin inhibits DC mobilization and function, 4457-4463
reconstitution of NK cell receptor repertoire after *HLA*-matched BMT, 3730-3740
regulation of HTLV-I binding protein in T cells during immune activation, 3085-3092
regulation of TCR Dβ1 promoter by KLF5, 4492-4499
RNA-transfected DCs induce myeloma-specific cytotoxic T cells, 977-982
role of IFN-γ–producing CD4$^+$ T cells in protection against CMV disease, 2686-2692
role of IKK2 and NIK in DC antigen presentation, 983-991
S1P is novel inhibitor of T-cell proliferation, 4909-4915
sensitivity of naive T cells to Fas engagement, 4022-4028
SPAN-Xb in hematologic malignancies, 955-960
Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development, 1015-1023
STAT activation by type I IFN differential therapy for erythroleukemia, 2727-2735
Syk and Rac regulation of Akt-dependent cell survival, 236-244
T-cell repopulation despite thymus irradiation after SCT for MM, 1891-1897
T cells produce interferonlike cytokine limitin, 178-185
TCL1 in plasmacytoid DCs and CD4$^+$CD56$^+$ blastic tumors of skin, 5007-5009
TCR, pTα, and RAG-1 in T-ALL, 2693-2703
TCR$^-$ veto cells in D^d-ζ transgenic mice, 4520-4528
tolerance induction to mammalian blood group–like carbohydrate antigen, 2318-2320
Toll-like receptor function in human naive and memory B cells, 4500-4504
transcriptional regulation of β_2-microglobulin, 3058-3064
tumor rejection by single-chain Fv-CD28/TCR-ζ engineered T cytotoxic T cells (*see Blood* 100:3155-3163, November 1, 2002) (erratum), 3808
ubiquitin inhibits TNF-α response to endotoxin, 1882-1890
V(D)J diversification during intraclonal B-cell differentiation, 1030-1037
VEGF inhibits T-cell development, 4878-4886
Immunodeficiency. *See also* Human immunodeficiency virus type 1
Artemis mutations in radiosensitive SCID patients, 1446-1452
CD45 minigene corrects CD45 deficiency in mice, 849-855
disruption of homeostatic chemokines and DCs by SIV, 1684-1691
nonmalignant late effects after allogeneic SCT, 3373-3385
novel class of CD34$^-$ cells that give rise to SCID-repopulating cells, 869-876
T-cell turnover in SIV-infected rhesus monkeys, 1213-1219
Immunoglobulin (Ig). *See also* Intravenous immunoglobulin
combined V_H3-21 and V_λ2-14 gene use in CLL, 4952-4957
IgV_H genes in t(11;14)lymphoma with mantle cell features, 4975-4981
IVIGs induce B-cell differentiation and IgG secretion, 3065-3073
MM with t(4;14)(p16;q32) translocation maintains *IGH/MMSET* fusion transcript, 2374-2376
molecular heterogeneity in mantle cell lymphoma defined by use of V_H genes, 4042-4046
monoclonal IgG can ameliorate immune thrombocytopenia in murine ITP, 3708-3713
prognostic impact of unmutated V_H gene status after SCT for CLL, 2049-2053
T-cell epitopes in MM immunoglobulin, 4930-4936
t(11;14)(q13;q32) in IgM, IgE, and nonsecretory MM variants, 1570-1571
t(14;18)(q32;q21) involving *IGH* and *MALT1* in MALT lymphoma, 2335-2339
translocation of IgH locus in MM detected by immuno-FISH (letter), 1653
V_H gene analysis in mantle cell lymphoma, 4047-4054

V_H gene mutational status and CD38 expression in CLL, 1087-1093
V_H gene mutations define transformation from MGUS to MM, 4137-4139
VL genes affect presentation and outcome in light chain–associated amyloidosis, 3801-3808
Immunophenotyping
CD163/HbSR as marker of monocytic lineage in AML (letter), 3755-3756
evidence of leukemia after induction therapy predicts relapse of AML, 3398-3406
MRD in adolescent and adult ALL, 4695-4700
in patients with DLBCL, 78-84
Immunosuppression
and autologous SCT in refractory Crohn disease, 2064-2066
efficacy of 2-CDA in refractory factor VIII inhibitors in persons without hemophilia, 943-945
11-year follow-up of ATG/cyclosporin A in aplastic anemia, 1236-1242
histone deacetylase inhibitors, 1430-1438
immunosuppressive drugs, BMT, and costimulation blockade, 2886-2893
LF 15-0195 enhances activation-induced T-cell death, 194-201
Immunotherapy
anti-CD20 vs. anti-CD45 antibodies for radioimmunotherapy of B-cell lymphomas, 2340-2348
bioluminescence to monitor lymphoma growth and treatment efficacy, 640-648
HB22.7 has lymphomacidal properties and augments efficacy of radioimmunotherapy, 3641-3647
IL-12 immunotherapy of A20 lymphoma, 568-575
immunomagnetic selection of low-affinity nerve growth factor-positive T cells, 476-484
IVIG inhibits DC maturation and function, 758-765
LMP1-specific cytotoxic T cells for adoptive immunotherapy of EBV-associated malignancies, 1905-1912
modified DNA vaccine protects against metastatic neuroblastoma, 649-654
radioimmunotherapy of non-Hodgkin lymphoma, 391-398
target antigen distribution and outcome of adoptive cancer immunotherapy, 766-770
Infection
antiviral CD8 T cell function in chronic viral infection, 226-235
B7-H1 up-regulation in HIV infection is marker of disease progression, 2514-2520
CMV infection after receipt of leukoreduced blood products, 4195-4200
CMV seropositivity associated with mycosis fungoides and Sézary syndrome, 2132-2136
DC dysfunction and infection in HIV, 4505-4511
disruption of homeostatic chemokines and DCs by SIV, 1684-1691
donor CMV status and CMV viremia after SCT, 2067-2069
donor immunization with pneumococcal vaccine and protective responses after SCT, 831-836
granulocyte transfusions and CMV infection (letter and response), 5091-5092
Helicobacter pylori and ITP in children (letter), 1660
hemoglobin digestion and osmotic stability of malaria-infected RBCs, 4189-4194
hepatitis C virus quasispecies in DCs and liver cells, 52-57
HSP receptor CD91 in HIV-1–infected nonprogressors, 4000-4004
IL-15 effects on HIV-specific $CD8^+$ T cells, 1024-1029
increased CMV infection after nonmyeloablative SCT (letter), 2071-2072
late CMV central nervous system disease after SCT, 463-465
late CMV disease and mortality after allogeneic SCT, 407-414
leukocyte reduction and HTLV-I in transfusion recipients (letter and response), 370-371
pathogenic molds in hospital water distribution systems, 2542-2546
primary antifungal prophylaxis in patients with hematologic malignancies, 3365-3372
pure red-cell aplasia due to parvovirus B19 after alemtuzumab therapy (letter), 1654
repression of STAT3 activity by Kaposi sarcoma–associated viral cyclin K, 4070-4077
risk of hepatitis B virus infection by transfusion in Kumasi, Ghana, 2419-2425
role of endothelium in severe sepsis and multiple organ dysfunction syndrome, 3765-3777
role of IFN-γ–producing $CD4^+$ T cells in protection against CMV disease, 2686-2692
role of neutrophil β2 integrins in murine *Anaplasma phagocytophila*, 3257-3264
transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment, 2426-2433
ubiquitin inhibits TNF-α response to endotoxin, 1882-1890
Inflammation
CD47 and platelet adhesion on inflamed endothelium under flow, 4836-4843
Egr-1 regulation of TF and inflammatory mediators in mouse endotoxemia model, 3940-3947
hepcidin is putative mediator of anemia of, 2461-2463
increased by lysozyme M deficiency, 2388-2392
inflammatory effects of HMGB1 on endothelial cells, 2652-2660
role of placental growth factor in, 560-567
synthesis of GILZ by macrophages, 729-738
transgenic sickle mice have vascular inflammation, 3953-3959
Inflammatory bowel disease, $p47^{phox}$ pseudogenes and (letter), 3337
Inhibitor of apoptosis (IAP), expression in neutrophils, 1164-1171
Insulin, induction of PAI-1 gene in rat hepatocytes by, 907-914
Integrins
αIIb calcium-binding domain mutations and αIIbβ3 biogenesis, 2268-2276
c-Kit and integrin-directed migration in mast cells, 4725-4732
$\alpha_{IIb}\beta_3$ in collagen-induced platelet aggregation, 2646-2651
rFVIIa enhances $\alpha_{IIb}\beta_3$-deficient platelet adhesion, 1864-1870
role of neutrophil β2 integrins in murine *Anaplasma phagocytophila*, 3257-3264
survival pathway induced by integrin in B cells, 1118-1127
Tyr143Hisα_{IIb} mutation abolishes $\alpha_{IIb}\beta_3$ function for soluble ligands, 3485-3491
urokinase-type plasminogen activator/$\alpha_M\beta_2$ interactions, 1582-1590
Intercellular adhesion molecule (ICAM)
ICAM-directed vascular targeting of antithrombotic agents, 3977-3984
novel secreted isoform of ICAM-4, 1790-1797
Interferon consensus sequence-binding protein (ICSBP)
ICSBP retrovirus transduction rescues DC development, 961-969
role in development of murine $CD8\alpha^+$ DCs, 305-310
Interferon (IFN)
arsenic/IFN reverses two gene networks in HTLV-1 cells, 4576-4582
IFN-α induces myeloblastin expression and specific T-cell response in CML, 259-264
IFN-γ switches monocyte differentiation from DCs to macrophages, 143-150
rituximab for mixed cryoglobulinemia resistant to IFN-α, 259-264
role of IFN-γ–producing $CD4^+$ T cells in protection against CMV disease, 2686-2692
SCF inhibits IFNγ-induced apoptosis by up-regulation of FLIP, 1324-1328
STAT activation by type I IFN differential therapy for erythroleukemia, 2727-2735
Interferon regulatory factor 8 (IRF-8). *See* Interferon consensus sequence-binding protein
Interleukin-1, mechanism of fibrate down-regulation of IL-1–stimulated CRP expression in hepatocytes, 545-551
Interleukin-2
chemokine–cytokine allogeneic antitumor vaccine for neuroblastoma, 1718-1726
generation of low-toxicity IL-2 fusion proteins devoid of vasopermeability activity, 4853-4861
Syk and Rac regulation of Akt-dependent cell survival, 236-244
Interleukin-3
induction of apoptosis in IL-3–dependent hematopoietic cell lines, 4958-4965
and SCF in Hodgkin disease (letter), 376-377
Interleukin-4
IL-4 variant associated with apoptosis, 3102-3105
total lymphoid irradiation preconditioning enriches for IL-4–producing $CD4^+$ cells, 2024-2032
Interleukin-5, constitutive IL-5 overexpression induces extramedullary hematopoiesis in spleen, 863-868
Interleukin-6, paracrine interactions of basic FGF and IL-6 in MM, 2775-2783
Interleukin-7
CD4 T-cell reconstitution after CD34 cell transplantation in monkeys improved by, 4209-4218
IL-7 expands T cells in normal and SIV-infected nonhuman primates, 2294-2299

retrovirus-mediated IL-7 expression in leukemic DCs generated from AML, 2184-2190
T-cell transduction by IL-7–displacing lentiviral vectors, 2167-2174
Interleukin-8
in PF4 inhibition of hematopoiesis, 4687-4694
platelets activation induced by antibodies to, 1419-1421
serum amyloid A induces IL-8 secretion, 1572-1581
Interleukin-10
synthesis of GILZ by macrophages, 729-738
and TGF-β induce $CD4^+CD25^-$ T cells to acquire regulatory function, 5076-5083
Interleukin-12
chromatin remodeling at human *IL-12(p35)* locus, 4894-4902
IL-12 immunotherapy of A20 lymphoma, 568-575
reversal of CD28 loss in senescent $CD4^+$ T cells by, 3543-3549
Interleukin-15
effects on HIV-specific $CD8^+$ T cells, 1024-1029
essential mediator of peripheral NK-cell homeostasis, 4887-4893
Interleukin-17, promotion of angiogenesis and tumor growth by, 2620-2627
Interleukin-18, donor pretreatment with IL-18 attenuates acute GVHD and preserves graft-versus-leukemia effects, 2877-2885
Interleukin-25, mast cells production of, 3594-3596
Intravenous immunoglobulin (IVIG)
autoimmune complexes in serum and therapeutic amounts of IVIGs (letter), 1660-1662
DC maturation and function inhibited by, 758-765
induction of dose-dependent amelioration of ITP in rodents (letter and response), 1658-1659
IVIGs induce B-cell differentiation and IgG secretion, 3065-3073
IQGAP2 in thrombin-induced platelet cytoskeletal reorganization, 3021-3028
IRF-8 (interferon regulatory factor 8). *See* Interferon consensus sequence-binding protein
Iron
clinical consequences of iron overload in hemochromatosis homozygotes, 3351-3358
combined pyridoxal isonicotinoyl hydrazone analog and deferoxamine chelation treatment, 4172-4179
cytokine-mediated regulation of iron transport in monocytes, 4148-4154
deferiprone and hepatic fibrosis (letter and response), 5089-5091
duodenal iron in *Hfe* knock-out mice, 3316-3318
hepatocellular injury and transfusional iron overload during desferrioxamine therapy, 91-96
HFE Cys282Tyr mutation as necessary but not sufficient cause of hereditary hemochromatosis, 3347-3350
human CMV US2 affects antigen presentation and iron homeostasis, 2858-2864
interactions between transferrin receptor and transferrin receptor 2, 2008-2014
iron accumulation in ALAS2-deficient erythroblasts, 1188-1193
iron status indicators (letter), 372-373
iron transport by *Nramp2*/DMT1, 3699-3707
IronChip analysis of cellular iron metabolism, 3690-3698
lack of hepatic fibrosis with deferiprone in beta-thalassemia (*see Blood* 100:1566-1569, September 1, 2002) (erratum), 2460
mitochondrial ferritin in sideroblastic anemias, 1996-2000
MRI evaluation of myocardial iron during iron chelation therapy, 4632-4639
noninvasive measurement of, 15-19
quantitative assessment of body iron, 3359-3364
safety of iron gluconate vs. iron dextran (letter), 3756-3757
UbcH5A up-regulation in hereditary hemochromatosis, 3288-3293
Ischemia/reperfusion injury, antithrombin reduces renal injury in rats, 3029-3036
ITP. *See* Immune thrombocytopenic purpura
IVIG. *See* Intravenous immunoglobulin

Jak1 deficiency and *Abelson*-induced B-cell tumor formation, 4937-4943
JMML. *See* Juvenile myelomonocytic leukemia
JunB
effects of C/EBPα and PKCδ on JunB expression and monocytic differentiation, 3885-3892
methylated *JunB* in CML, 3205-3211
overexpression in primary CTCL, 1513-1519
ras and *junB* activation drive *CD11c* expression in HCL, 4033-4041
Juvenile myelomonocytic leukemia (JMML)
DLI for relapse after SCT, 1713-1714
leukemic potential of doubly mutant *Nf1* and W^v hematopoietic cells, 1984-1986

K-652 cells, SAM-1 erythroid cell line derived from (letter) (*see Blood* 100:3435, November 1, 2002) (erratum), 2088
Kaposi sarcoma–associated herpesvirus. *See* Human herpesvirus 8
Kidney
antithrombin reduces ischemia/reperfusion-induced renal injury in rats, 3029-3036
late-onset X-linked sideroblastic anemia after hemodialysis, 4623-4624
nephrotic syndrome after allogeneic BMT for NK cell leukemia/lymphoma, 4219-4221
Killer immunoglobulin-like receptors (KIRs), *BCR/ABL* alters NK function and acquisition of, 3527-3533
Kininogen deficiency, molecular defects of Fitzgerald trait, 4430-4436
KIRs. *See* Killer immunoglobulin-like receptors
kit
c-Kit and integrin-directed migration in mast cells, 4725-4732
c-kit inhibition does not alter *NF1* leukemia, 1984-1986
kit ligand in fetal hemoglobin reactivation in adult life, 2826-2832
signaling of Asp814Val c-*kit* activating mutant, 1094-1102
sustained complete remission after imatinib in patient with $c\text{-}Kit^+$ AML, 2960-2962
KLF5. *See* Krüppel-like factor 5
KRN5500 mediates cytotoxicity in B-CLL cells, 4547-4550
Krüppel-like factor 5 (KLF5), regulation of TCR Dβ1 promoter by, 4492-4499

L-selectin, up-regulation of CXCR4 in lymphocytes by, 4245-4252
Lactadherin, inhibition of blood coagulation by, 2628-2636
Lactate dehydrogenase (LDH), estimating cell membrane alteration after drug treatment by LDH release (letter and response), 2894-2895
Lactoferrin gene expression, chromatin immunoprecipitation studies of C/EBPα and C/EBPε and CDP/cut in, 3460-3468
LAD. *See* Leukocyte adhesion deficiency
Laminin isoform–specific adhesion and migration of hematopoietic progenitors, 877-885
Langerhans cell histiocytosis (LCH), expression of CCR6 and CCR7 in, 2473-2475
Latent membrane protein (LMP), therapeutic LMP1 vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma, 3150-3156
LCH. *See* Langerhans cell histiocytosis
LDH. *See* Lactate dehydrogenase
LDL. *See* Low-density lipoprotein
Lentiviral vectors
CD4-cell–specific, 3416-3423
IFN-β scaffold attachment region and chicken β-globin insulator in, 4717-4724
multiple copy integration in NON/SCID repopulating cells, 1284-1289
phenotypic correction of β-thalassemia after lentiviral-mediated transfer of γ-globin gene, 2175-2183
rescue from murine model of Cooley anemia by gene therapy, 2932-2939
T-cell transduction by IL-7–displacing lentiviral vectors, 2167-2174
transduction of B cells with, 1727-1733
transduction of thalassemic cells, 104-111
Leukemia. *See also* specific types
CTLA-4 in normal and leukemic hematopoietic cells, 202-209
DHA enhances arsenic trioxide–mediated apoptosis in arsenic trioxide–resistant leukemia, 4990-4997
G3139 and chemotherapy for refractory or relapsed acute leukemia, 425-432
GATA1 mutatgenesis and Down syndrome leukemogenesis, 4298-4300
GATA1 mutations in transient leukemia and acute AMKL of Down syndrome, 4301-4304
GATA1 mutations in transient leukemia and AMKL in Down syndrome, 4301-4304
glycosphingolipid expression in acute nonlymphocytic leukemia, 711-721
leukemic potential of doubly mutant *Nf1* and W^v hematopoietic cells, 1984-1986
mast cell (blood work), 789
monoglycerides induce apoptosis in leukemic cells, 292-294
nephrotic syndrome after allogeneic BMT for NK cell leukemia/lymphoma, 4219-4221
oncogenic activation of MLL by forkhead family proteins, 633-639
pathogenesis of *MLL* fusion gene leukemia, 3229-3235
role of AML1-ETO in leukemogenesis, 624-632
STAT proteins in, 2940-2954

transplantation of unrelated-donor CD34+ cells in pediatric leukemia, 1630-1636
WT1 assay to predict and manage relapse after allogeneic SCT in acute leukemia, 1698-1704
Leukocyte adhesion deficiency (LAD)
novel genetic LAD results in impaired leukocyte arrest on vascular endothelium, 4437-4445
novel mutation in GDP-fucose transporter gene in LADII, 1705-1712
Leukocytes
alloantigen-specific suppression of mixed leukocyte reactions by DCs, 3325-3333
gene expression profile in, 3509-3513
leukocyte reduction and HTLV-I in transfusion recipients (letter and response), 370-371
LSSIG is novel murine leukocyte-specific GPCR, 1185-1187
recombinant PSGL-1 inhibits leukocyte rolling by selectins in vivo, 3249-3256
LF 15-0195, enhancement of activation-induced T-cell death by, 194-201
LFA-1. *See* Lymphocyte function–associated antigen-1
Limitin, T cells produce interferonlike cytokine, 178-185
Lipid rafts, complement-mediated lysis by anti-CD20 mAb correlates with segregation into, 1045-1052
Lipopolysaccharide. *See* Endotoxin
LIR9, an activating receptor in monocytes, 1484-1486
Liver
acute sickle cell hepatopathy as contraindication for percutaneous liver biopsy, 101-103
characterization of fetal liver stroma, 2973-2982
cyclophosphamide metabolism, liver toxicity, and mortality after SCT, 2043-2048
deferiprone and hepatic fibrosis (letter and response), 5089-5091
development of hepatocyte-like cells in livers of mice after SCT, 4201-4208
hematopoietic capacity of connexin43 wild-type and knock-out fetal liver cells, 2996-2998
hepatitis C virus quasispecies in DCs and liver cells, 52-57
hepatocellular injury and transfusional iron overload during desferrioxamine therapy, 91-96
induction of PAI-1 gene by insulin in rat hepatocytes, 907-914
lack of hepatic fibrosis with deferiprone in beta-thalassemia (*see Blood* 100:1566-1569, September 1, 2002) (erratum), 2460
liver sieve and gene therapy (letter and response), 3338-3339
mechanism of fibrate down-regulation of IL-1–stimulated CRP expression in hepatocytes, 545-551
nonmalignant late effects after allogeneic SCT, 3373-3385
spur-cell hemolytic anemia in severe alcoholic cirrhosis (blood work), 3
LMO2 gene, PAR domain transcription factor regulates human expression of, 4757-4764
LMP. *See* Latent membrane protein
LOH. *See* Loss of heterozygosity
Loss of heterozygosity (LOH), within *MLL* in childhood ALL (letter and response), 4222-4223
Low-density lipoprotein (LDL)
erythropoiesis from acetyl LDL incorporating endothelial cells at preliver stage, 4733-4738
oxidized LDL triggers HIF-1α accumulation, 4847-4849
oxidized phospholipids in oxidized LDL down-regulate thrombomodulin, 4765-4774
Low-density lipoprotein receptor–related protein deficiency (LRP), elevated plasma factor VIII in murine model of, 3933-3939
LRP. *See* Low-density lipoprotein receptor–related protein deficiency
LSSIG is novel murine leukocyte-specific GPCR, 1185-1187
LT. *See* Lymphotoxin
Lung
epidemiology and etiology of transfusion-related acute lung injury, 454-462
idiopathic pneumonia syndrome in absence of donor MIP-1α after allogeneic BMT, 3714-3721
LFA-1 required for retention of effector CD8 T cells in mouse lungs, 4916-4922
nonmalignant late effects after allogeneic SCT, 3373-3385
Lupus anticoagulants, and risk of thrombosis in antiphospholipid syndrome, 1827-1832
Lymphocyte function–associated antigen-1 (LFA-1), required for retention of effector CD8 T cells in mouse lungs, 4916-4922
Lymphocytes. *See also* B cells; T cells
adherence to dermal endothelium in GVHD, 771-778
CCR7-mediated lymphocyte homing and tyrosine kinase activation, 38-44
host stem cells selectively reconstitute missing lymphoid lineages, 4347-4354
L-selectin stimulation up-regulates CXCR4 in, 4245-4252
Lymphoma
A20, IL-12 immunotherapy of, 568-575
AID in B-cell non-Hodgkin lymphomas, 3574-3580
AIDS-related, EPOCH for, 4653-4659
anti-CD20 vs. anti-CD45 antibodies for radioimmunotherapy of B-cell lymphomas, 2340-2348
bioluminescence to monitor lymphoma growth and treatment efficacy, 640-648
Burkitt, SSRIs signal apoptosis in, 3212-3219
cardiac lymphoma mimicking myxoma presenting with embolic stroke, 4708-4710
cell cycle deregulation in B-cell lymphomas, 1220-1235
CHOP vs. CNOP in elderly patients with lymphoma, 3840-3848
cutaneous T-cell
alemtuzumab in mycosis fungoides/Sézary syndrome, 4267-4272
CD158k/p140/KIR3DL2 polymorphisms in Sézary patients (letter), 1203
CMV seropositivity associated with mycosis fungoides and Sézary syndrome, 2132-2136
functional expression of CCR3 in CD30+ CTCL, 1487-1493
γδ T-cell phenotype and survival in, 3407-3412
JUNB overexpression in, 1513-1519
diffuse large B-cell
BCL6 mutations disrupt its negative autoregulation in DLBCL, 2914-2923
genetic analysis of CD5+ lymphoma, 699-702
HGAL predicts survival in, 433-440
immunophenotyping in patients with, 78-84
impact of rituximab plus CHOP on bcl-2–associated drug resistance in geriatric patients, 4279-4284
transformation of follicular lymphoma to, 3109-3117
follicular
grade 3, predictor of inferior survival in, 2363-2367
three cytogenetic subgroups in grade 3B of, 1149-1154
transformation to DLBCL, 3109-3117
genomically complex lymphomas and *MYC* inactivation, 2797-2803
granzyme M expression in NK-cell, γδ-T cell, and intestinal T-cell lymphomas, 3590-3593
HB22.7 has lymphomacidal properties and augments efficacy of radioimmunotherapy, 3641-3647
Hodgkin
BCL3 expression differentiates ALCL from, 2789-2796
BCL6 rearrangements in, 706-710
c-Rel protein accumulation in, 3681-3686
cell-cycle and apoptosis deregulation in Hodgkin and Reed-Sternberg cells, 681-689
IL-3 and SCF in (letter), 376-377
lost B-cell identity of Hodgkin and Reed-Sternberg cells of, 1505-1512
nodular sclerosing, prognostic grading of, 4063-4069
rituximab for relapsed CD20+ lymphoma, 420-424
rituximab in lymphocyte-predominant Hodgkin disease, 4285-4289
therapeutic LMP1 vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma, 3150-3156
IgV$_H$ genes in t(11;14) lymphoma with mantle cell features, 4975-4981
lymphoblastic, allogeneic vs. autologous BMT for, 2476-2482
MALT1 deregulation in B-cell non-Hodgkin lymphoma, 4539-4546
mantle cell
alemtuzumab plus rituximab in relapsed and refractory lymphoid malignancies, 3413-3415
molecular heterogeneity in, 4042-4046
sequestration of p27^{Kip1} in, 3181-3187
V_H gene analysis in, 4047-4054
MDS and AML after autotransplantation for, 2015-2023
mechanisms of action of rituximab in non-Hodgkin's lymphomas, 949-954
mucosa-associated lymphoid tissue (MALT)
nongastric, 2489-2495
t(11;18)(q21;q21) in *Helicobacter pylori*–negative gastric MALT lymphoma, 2547-2550
t(14;18)(q32;q21) involving *IGH* and *MALT1* in, 2335-2339
nephrotic syndrome after allogeneic BMT for NK cell leukemia/lymphoma, 4219-4221
primary CNS, expression of BCA-1 in, 815-821

primary effusion
gene expression profiling of AIDS-related PEL, 4115-4121
inhibition of STAT3 signaling in, 1535-1542
remission by AZT-mediated inhibition of NF-κB, 2321-2327
primary mediastinal large B-cell, *FIG1* gene activation in, 2756-2761
radioimmunotherapy of non-Hodgkin lymphoma, 391-398
rituximab for CNS lymphomas: targeting leptomeningeal compartment, 466-468
splenic marginal zone, 2464
T-cell lymphomas and plasma cell tumors in NPM-ALK transgenic mice, 1919-1927
utility of FDG-PET scanning in lymphoma by WHO classification, 3875-3876
Lymphoproliferative disease, prognostic significance of impaired recovery of EBV-specific T cells after SCT, 4290-4297
Lymphotactin, chemokine–cytokine allogeneic antitumor vaccine for neuroblastoma, 1718-1726
Lymphotoxin (LT), contributions of TNF and LT cytokines to DC development, 1477-1483
LYN kinase, in CML cells resistant to STI571, 690-698
Lysosomal storage disease
cappucino is a component of BLOC-1, 4402-4407
murine xenotransplantation model of MPSVII, 2054-2063
Lysozyme M deficiency increases inflammation, 2388-2392

M-CSF. *See* Macrophage colony-stimulating factor
mAb. *See* Monoclonal antibodies
Mac-1, in FcR–mediated immunity to melanoma, 253-258
Macrophage colony-stimulating factor (M-CSF), transgenic mice with a CSF-1R reporter gene, 1155-1163
Macrophage inflammatory protein 1 (MIP-1)
AML-1A and AML-1B regulation of MIP-1α expression in MM, 3778-3783
idiopathic pneumonia syndrome in absence of donor MIP-1α after allogeneic BMT, 3714-3721
MIP-1α and MIP-1β mediate immunity, 807-814
MIP-1α triggers signaling cascades in MM cells, 3568-3573
MIP-1α–binding heparan sulfate oligosaccharide supports long-term culture-initiating cells, 2243-2245
Macrophages
human pro-B cells that give rise to NK cells, T cells and, 4313-4321
IFN-γ switches monocyte differentiation from DCs to, 143-150
macrophage- and DC-dependent regulation of B-cell proliferation requires BAFF, 4464-4471
mast cell–derived TNFα induces macrophage recruitment in cutaneous granulomas, 210-215
synthesis of GILZ by, 729-738
MAGE-3 CD4 epitopes, immunodominant, 1038-1044
Magnetic resonance imaging (MRI)
evaluation of myocardial iron during iron chelation therapy, 4632-4639
noninvasive measurement of iron, 15-19
Major basic protein, activation of mast cells by, 1898-1904
Major histocompatibility complex (MHC)
cell regulation by acquired MHC class II:peptide complexes, 2704-2710
PML does not regulate MHC class I in human cells, 3514-3519
promoter IV of class II transactivator gene essential for positive selection of $CD4^+$ cells, 3550-3559
Malaria
aberrant development of *Plasmodium falciparum* in hemoglobin CC red cells, 3309-3315
CCR5 deficiency decreases susceptibility to cerebral malaria, 4253-4259
glycophorin·C is receptor for PfEBP-2, 4628-4631
hemoglobin digestion and osmotic stability of malaria-infected RBCs, 4189-4194
heparan sulfate on endothelial cells mediates binding of malaria-infected erythrocytes, 2405-2411
malaria-parasitized erythrocytes and hemozoin generate hydroxy fatty acids, 722-728
malaria targeting by biscFv, 2300-2306
PfEMP1 peptide inhibits and reverses cytoadherence of *Plasmodium falciparum*, 331-337
RSP-2 in adhesion of malaria-infected erythrocytes to endothelial cells and placenta, 5025-5032
Src-family kinase signaling modulates *Plasmodium falciparum* adhesion, 2850-2857
MALT lymphoma. *See* Mucosa-associated lymphoid tissue lymphoma
MALT1, deregulation in B-cell non-Hodgkin lymphoma, 4539-4546
Mantle cell lymphoma
alemtuzumab plus rituximab in relapsed and refractory lymphoid malignancies, 3413-3415
molecular heterogeneity in, 4042-4046
sequestration of $p27^{Kip1}$ in, 3181-3187
V_H gene analysis in, 4047-4054
MAPK. *See* Mitogen-activated protein kinase
Mast cells
activation induced by major basic protein and regulated by membrane SCF, 1898-1904
c-Kit and integrin-directed migration in, 4725-4732
effect of mouse strain and *MITF* mutation on decrease of skin mast cells, 1344-1350
G-protein–coupled receptor signaling in Syk-deficient neutrophils and, 4155-4163
IL-25 production by, 3594-3596
mast cell leukemia (blood work), 789
mast cell–derived TNFα induces macrophage recruitment in cutaneous granulomas, 210-215
SgIGSF: new MITF-dependent mast-cell adhesion molecule, 2601-2608
Matrix metalloproteinases (MMPs), membrane-type MMP-mediated angiogenesis in fibrin-collagen matrix, 1810-1817
MDR1 gene, overexpression confers imatinib resistance in leukemia cell lines, 2368-2373
MDS. *See* Myelodysplastic syndrome
Measles viruses display antibody against CD38, 2557-2562
Megakaryocytes
polyploidization associated with functional gene amplification, 541-544
RUNX1 and GATA-1 cooperation in megakaryocytic differentiation, 4333-4341
stromal inhibition of megakaryocytic Rap1 signaling, 1744-1751
TSP2 required for normal platelet formation and function, 3915-3923
VEGF potentiates maturation of, 1316-1323
MEIS1
induction of AML by *NUP98-HOXD13* in concert with *Meis1*, 4529-4538
and PBXs regulate transcription of PF4 gene, 4748-4756
Melanoma, Mac-1 in FcR–mediated immunity to, 253-258
Mercaptopurine, dexamethasone vs. prednisone and oral vs. intravenous mercaptopurine for ALL, 3809-3817
Methionine, cobalamin deficiency with and without neurologic abnormalities, 3302-3308
2-Methoxyestradiol (2ME2)
free radical stress and drug sensitivity in CLL, 4098-4104
identification of 2ME2-modulated genes in MM cells, 3606-3614
MGUS. *See* Monoclonal gammopathy of undetermined significance
MHC. *See* Major histocompatibility complex
Microarray
profiling of CD44-stimulated human B cells, 2307-2313
transcript profiling using microarray and serial analysis of gene expression, 2285-2293
β_2-Microglobulin
inhibition of DC generation by, 4005-4012
transcriptional regulation of, 3058-3064
Microphthalmia transcription factor (MITF), SgIGSF: new MITF-dependent mast-cell adhesion molecule, 2601-2608
Minimal residual disease (MRD)
in adolescent and adult ALL, 4695-4700
early MRD analysis during imatinib treatment of Ph^+ ALL, 85-90
kinetics of MRD and chimerism in CML patients after SCT, 469-472
WT1 assay to predict and manage relapse after allogeneic SCT in acute leukemia, 1698-1704
MIP-1. *See* Macrophage inflammatory protein 1
MITF. *See* Microphthalmia transcription factor
MITF gene, effect of mouse strain and *MITF* mutation on decrease of skin mast cells, 1344-1350
Mitogen-activated protein kinase (MAPK)
MAPK control of granule mobilization in human neutrophils, 3240-3248
MAPK signaling and hematologic malignancies, 4667-4679
p38 MAPK involvement in thymocyte development, 970-976
p38 MAPK mediates procoagulant response during endotoxemia, 4446-4448
targeting p38 MAPK inhibits MM cell growth in bone marrow milieu, 703-705
Mixed cryoglobulinemia
treatment with rituximab, 3818-3826
type II, efficacy and safety of rituximab in, 3827-3834

MLL gene
Ara-C sensitivity in *MLL* gene-rearranged infant ALL, 1270-1276
LOH within *MLL* in childhood ALL (letter and response), 4222-4223
mutation of *ATM* gene in childhood ALL with *MLL* gene rearrangement, 3622-3627
oncogenic activation forkhead family proteins, 633-639
pathogenesis of *MLL* fusion gene leukemia, 3229-3235
MM. *See* Multiple myeloma
MMM. *See* Myelofibrosis with myeloid metaplasia
MMPs. *See* Matrix metalloproteinases
Molds in hospital water distribution systems, 2542-2546
Monoclonal antibodies (mAb)
agranulocytosis unresponsive to growth factors after rituximab (letter), 4225-4226
alemtuzumab in mycosis fungoides/Sézary syndrome, 4267-4272
alemtuzumab plus rituximab in relapsed and refractory lymphoid malignancies, 3413-3415
anti-C3b(i) mAb enhances complement activation and rituximab killing of $CD20^+$ cells, 1071-1079
anti-CD20 vs. anti-CD45 antibodies for radioimmunotherapy of B-cell lymphomas, 2340-2348
anti-CD45–mediated cytoreduction for SCT, 2434-2439
CML myelodysplastic subclones and imatinib therapy (letter), 781
complement-mediated lysis by anti-CD20 mAb, 1045-1052
differential response to AML cells to gemtuzumab ozogamicin, 4589-4597
dose escalation of imatinib can overcome resistance in CML, 473-475
efficacy and safety of rituximab in type II mixed cryoglobulinemia, 3827-3834
fludarabine with concurrent vs. sequential rituximab in B-CLL, 6-14
gemtuzumab ozogamicin for relapsed pediatric AML, 3868-3871
imatinib for eosinophilic disorders, 3391-3397
imatinib reverses effects of Bcr-Abl on neutrophilic differentiation, 655-663
impact of rituximab plus CHOP on bcl-2–associated drug resistance in geriatric DLBCL, 4279-4284
mechanisms of action of rituximab in non-Hodgkin's lymphomas, 949-954
molecular response to imatinib following relapse after SCT for CML (letter), 1200-1201 (erratum, 1683)
PP1 and CGP76030 inhibit cells expressing imatinib-resistant Bcr-Abl kinases, 664-672
pure red-cell aplasia due to parvovirus B19 after alemtuzumab therapy (letter), 1654
reduced-intensity SCT with alemtuzumab (letter), 779-780
rituximab for acquired factor VIII inhibitors (letter and response), 3753-3755
rituximab for CNS lymphomas: targeting leptomeningeal compartment, 466-468
rituximab for pediatric autoimmune hemolytic anemia, 3857-3861
rituximab for relapsed $CD20^+$ Hodgkin lymphoma, 420-424
rituximab in lymphocyte-predominant Hodgkin disease, 4285-4289
SAHA enhances imatinib-induced apoptosis of Bcr-Abl–positive leukemia cells, 3236-3239
significance of cytogenetic clonal evolution in imatinib-treated CML, 3794-3800
sustained complete remission after imatinib in patient with refractory AML, 2960-2962
treatment of mixed cryoglobulinemia with rituximab, 3818-3826
Monoclonal gammopathy of undetermined significance (MGUS), V_H gene mutations define transformation from MGUS to MM, 4137-4139
Monocytes
cytokine-mediated regulation of iron transport in monocytes, 4148-4154
effects of C/EBPα and PKCδ on JunB expression and monocytic differentiation, 3885-3892
Gp96 binds to neutrophils and monocytes and stimulates effector functions, 2810-2815
IFN-γ switches monocyte differentiation from DCs to macrophages, 143-150
LIR9, an activating receptor in, 1484-1486
Monoglycerides induce apoptosis in leukemic cells, 292-294
MPD. *See* Myeloproliferative disorder
MPS. *See* Mucopolysaccharidoses
MRD. *See* Minimal residual disease
MRI. *See* Magnetic resonance imaging
MRP-1, levels of *BAX, MRP-1*, and platelets predict response to imatinib in CML, 2152-2155
Mucopolysaccharidoses (MPS), murine xenotransplantation model of MPSVII, 2054-2063
Mucosa-associated lymphoid tissue (MALT) lymphoma
nongastric, 2489-2495
t(11;18)(q21;q21) in *Helicobacter pylori*–negative gastric MALT lymphoma, 2547-2550
t(14;18)(q32;q21) involving *IGH* and *MALT1* in, 2335-2339
Multiple myeloma (MM)
AML-1A and AML-1B regulation of MIP-1α expression in, 3778-3783
antimyeloma activity of proteasome inhibitor PS-341, 1530-1534
antisense Bcl-2 potentiates apoptosis in drug-resistant myeloma cells, 4105-4114
arsenic trioxide–induced apoptosis in myeloma cells, 4078-4087
CD40 induces MM cell migration, 2762-2769
curcumin down-regulates NF-κB and IκBα kinase in MM cells, 1053-1062
downstream effectors of oncogenic ras in MM cells, 3126-3135
gene expression profiling of MM and pathogenesis of disease, 4998-5006
gene expression profiling of plasma cell differentiation and, 1128-1140
graft versus myeloma and chromosome 13 deletion in (letter), 1201-1202
identification of 2ME2-modulated genes in MM cells, 3606-3614
idiotype vaccination reduces clonal tumor B cells, 4607-4610
metaphase cytogenetic abnormalities and survival in, 3849-3856
MIP-1α triggers signaling cascades in MM cells, 3568-3573
MM tumor progression in murine model is multistage and dynamic process, 3136-3141
oncolytic measles viruses display antibody against CD38, a myeloma cell marker, 2557-2562
paracrine interactions of basic FGF and IL-6 in, 2775-2783
PS-341 potentiates sensitivity of MM cells to chemotherapy, 2377-2380
R115777 in hematologic malignancies, 1692-1697
RANKL and osteoprotegerin in myeloma bone disease, 2094-2098
recurrent genomic aberrations in MM, 4569-4575
RNA-transfected DCs induce myeloma-specific cytotoxic T cells, 977-982
SOCS-1 hypermethylation in, 2784-2788
SPAN-Xb in hematologic malignancies, 955-960
subset with t(4;14)(p16;q32) translocation maintains *IGH/MMSET* fusion transcript, 2374-2376
survival not improved after high-dose therapy in, 2144-2151
T-cell epitopes in MM immunoglobulin, 4930-4936
T-cell repopulation despite thymus irradiation after SCT for, 1891-1897
t(4;14)(p16;q32) is adverse prognostic factor in, 1520-1529
t(11;14)(q13;q32) in IgM, IgE, and nonsecretory MM variants, 1570-1571
targeting p38 MAPK inhibits MM cell growth in bone marrow milieu, 703-705
telomerase and telomere length in, 4982-4989
translocation of IgH locus detected by immuno-FISH (letter), 1653
V_H gene mutations define transformation from MGUS to, 4137-4139
Multiple organ dysfunction syndrome, role of endothelium in severe sepsis and, 3765-3777
Multiple sclerosis, increased adhesiveness of $CD8^+$ T cells in brain venules in, 4775-4782
Muscle
AAV-mediated factor IX gene transfer to muscle in hemophilia B, 2963-2972
angiostatin inhibits HGF in endothelial and smooth muscle cells, 1857-1863
Myc
genomically complex lymphomas and *MYC* inactivation, 2797-2803
oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors, 1950-1955
Mycosis fungoides. *See also* Cutaneous T-cell lymphoma
alemtuzumab in Sézary syndrome and, 4267-4272
CMV seropositivity associated with Sézary syndrome and, 2132-2136
Myeloblastin, IFN-α induces myeloblastin expression and specific T-cell response in CML, 259-264
Myelodysplastic syndrome (MDS)
and AML after autotransplantation for lymphoma, 2015-2023
AML1 mutations in radiation- and therapy-related MDS/AML, 673-680

ATG efficacy and toxicity in anemic patients with, 2156-2158
with bone marrow eosinophilia or basophilia, 3386-3390
decitabine treatment of hematopoietic malignancies (letter and response), 4644-4646
DNA methylation inhibitors and reversal of transcriptional silencing (letter and response), 1656-1658
G-CSF inhibits cytochrome *c* release in, 1080-1086
with isolated del(5q) chromosome abnormality (blood work), 3346
mitochondrial DNA mutations in, 3118-3125
reduced PKB/Akt and ERK phosphorylation in, 1172-1180
unrelated cord blood transplantation for adults with advanced MDS, 4711-4713
Myelofibrosis
GATA1 expression in CD34$^+$ progenitors in (letter and response), 5087-5089
R115777 in hematologic malignancies, 1692-1697
Myelofibrosis with myeloid metaplasia (MMM)
B and T cell clonal involvement in, 1981-1983
combination low-dose thalidomide and prednisone for, 2534-2541
Myeloid cells
chromatin immunoprecipitation studies of C/EBPα and C/EBPε and CDP/cut in lactoferrin gene expression, 3460-3468
G-CSF–induced expansion of myeloid progenitor cells, 2584-2590
GABP, Sp1, and RAR activate CD18 transcription in, 311-317
impaired granulocytopoiesis in chronic idiopathic neutropenia and apoptosis of myeloid progenitor cells, 2591-2600
live erythroid and myeloid cells in β-globin ECFP x lysozyme EGFP mice, 903-906
oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors, 1950-1955
risk factors for thromboembolic complications in essential thrombocythemia (letter), 783-784
Myeloproliferative disorder (MPD), endogenous retroviral sequence fused to FGFR1 kinase in 8p12 MPD, 286-288
MYH11 real-time RT-PCR for rapid identification of *CBFB-MYH11*–positive AML (letter), 5085-5086
Myocardium
MRI evaluation of myocardial iron during iron chelation therapy, 4632-4639
myocardial fibrosis in mice with factor IX overexpression, 1871-1873
risk of combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles for myocardial infarction, 3037-3041
Myosin, as stabilizer of fibrin during clot dissolution, 4380-4386

Nasopharyngeal carcinoma, therapeutic LMP1 vaccine for EBV-associated Hodgkin disease and, 3150-3156
Natural killer (NK) cells
BCR/ABL alters NK function and acquisition of KIRs, 3527-3533
CD56^{bright} NK cells link adaptive and innate immunity, 3052-3057
human pro-B cells that give rise to macrophages, T cells and, 4313-4321
IL-15 is essential mediator of peripheral NK-cell homeostasis, 4887-4893
novel myeloid-like NK cell progenitor in human UCB, 3444-3450
reconstitution of NK cell receptor repertoire after *HLA*-matched BMT, 3730-3740
Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development, 1015-1023
T-cell large granular lymphocyte cells express activating killer cell receptors, 3198-3204
total lymphoid irradiation preconditioning enriches for IL-4–producing CD4$^+$ cells, 2024-2032
Neoplasia
abnormalities in Ph$^-$ cells of CML patients on imatinib, 1941-1949
acadesine activates AMPK and induces apoptosis in B-CLL cells, 3674-3680
albumin protects B-CLL cells from chlorambucil- and radiation-induced apoptosis, 3174-3180
AML1/MTG8 gene suppression supports myeloid differentiation of t(8;21)-positive leukemic cells, 3157-3163
AML1 mutations in radiation- and therapy-related MDS/AML, 673-680
anti-C3b(i) mAb enhances complement activation and rituximab killing of CD20$^+$ cells, 1071-1079
anti-CD20 vs. anti-CD45 antibodies for radioimmunotherapy of B-cell lymphomas, 2340-2348
antimyeloma activity of proteasome inhibitor PS-341, 1530-1534
antisense Bcl-2 potentiates apoptosis in drug-resistant myeloma cells, 4105-4114
APL model with FLT3 mutation is responsive to retinoic acid and SU11657, 3188-3197
arsenic/IFN reverses two gene networks in HTLV-1 cells, 4576-4582
arsenic trioxide–induced apoptosis in myeloma cells, 4078-4087
asparagine synthetase in t(12;21)$^+$ pediatric ALL, 2743-2747
ATRA induces CD52 expression in APL, 1977-1980
BCL3 expression differentiates ALCL from Hodgkin disease, 2789-2796
BCL6 rearrangements in Hodgkin lymphoma, 706-710
Bcr-Abl and LYN kinase in CML cells resistant to STI571, 690-698
bioluminescence to monitor lymphoma growth and treatment efficacy, 640-648
C/EBPs repress leukemic phenotype of AML, 1141-1148
c-Rel protein accumulation in Hodgkin lymphoma, 3681-3686
cancer in Fanconi anemia (letter), 2072-2073
CD40 induces MM cell migration, 2762-2769
CD100/Plexin-B1 interactions in CD5$^+$ B cells, 1962-1969
cell context–specific effects of *BCR-ABL* in hematopoietic progenitors, 4088-4097
cell-cycle and apoptosis deregulation in Hodgkin and Reed-Sternberg cells, 681-689
cell cycle deregulation in B-cell lymphomas, 1220-1235
centrosome aberrations in AML and cytogenetic risk profile, 289-291
cholesterol reduction kills AML cells and sensitizes them to therapeutics, 3628-3634
CNS is sanctuary for leukemic cells in imatinib-treated mice, 5010-5013
combined V_H3-21 and V_λ2-14 gene use in CLL, 4952-4957
curcumin down-regulates NF-κB and IκBα kinase in MM cells, 1053-1062
cyclin B1 regulates DNA damage–induced apoptosis, 1928-1933
*CYP1A1*2B (Val)* allele in AML patients with *NRAS* mutation, 2770-2774
detection of quiescent leukemic progenitor cells in AML, 3142-3149
DHA enhances arsenic trioxide–mediated apoptosis in arsenic trioxide–resistant leukemia, 4990-4997
differential response to AML cells to gemtuzumab ozogamicin, 4589-4597
DLI as primary therapy for neoplasms (letter and response), 373-374
down-regulation of BRCA1 in BCR-ABL–expressing cells, 4583-4588
downstream effectors of oncogenic ras in MM cells, 3126-3135
E26 leukemia virus converts primitive erythroid cells into multilineage progenitors, 1103-1110
EAF-2, functional homolog of EAF-1, 2355-2362
EB1089 induces apoptosis in B-CLL cells in vitro, 2454-2460
endogenous retroviral sequence fused to FGFR1 kinase in 8p12 MPD, 286-288
enhancement of ATRA-induced cell differentiation by inhibition of calcium accumulation into ER, 3220-3228
Evi3 encodes an EBFAZ-related Krüppel-like zinc finger protein, 1934-1940
expression of ribosomal and translation-associated genes in CLL, 2748-2755
FIG1 gene activation in primary mediastinal large B-cell lymphoma, 2756-2761
fludarabine uptake mechanisms in B-CLL, 2328-2334
free radical stress and drug sensitivity in CLL, 4098-4104
functional expression of CCR3 in CD30$^+$ CTCL, 1487-1493
G-CSF inhibits cytochrome *c* release in MDS, 1080-1086
gene expression profiling of AIDS-related PEL, 4115-4121
gene expression profiling of MM and pathogenesis of disease, 4998-5006
gene expression profiling of plasma cell differentiation and MM, 1128-1140
genetic analysis of CD5$^+$ DLBCL, 699-702
genomically complex lymphomas and *MYC* inactivation, 2797-2803
HB22.7 has lymphomacidal properties and augments efficacy of radioimmunotherapy, 3641-3647
HHV8–encoded viral FLICE inhibitory protein protects against apoptosis via NF-κB activation, 1956-1961
homeodomain-DNA interactions required for HOX11-mediated transformation, 4966-4974
HOX gene expression in PML-RARα^{2b} APL, 1558-1565
identification of 2ME2-modulated genes in MM cells, 3606-3614

idiotype vaccination in MM reduces clonal tumor B cells, 4607-4610
IFN-α induces myeloblastin expression and specific T-cell response in CML, 259-264
IgV$_H$ genes in t(11;14) lymphoma with mantle cell features, 4975-4981
imatinib reverses effects of Bcr-Abl on neutrophilic differentiation, 655-663
induction of AML by *NUP98-HOXD13* in concert with *Meis1*, 4529-4538
induction of apoptosis in IL-3–dependent hematopoietic cell lines, 4958-4965
inhibition of *bcr-abl* gene expression by small interfering RNA, 1566-1569
Jak1 deficiency and *Abelson*-induced B-cell tumor formation, 4937-4943
JUNB overexpression in primary CTCL, 1513-1519
KRN5500 mediates cytotoxicity in B-CLL cells, 4547-4550
late relapses evolve from slow-responding subclones in t(12;21)$^+$ ALL, 3635-3640
leukemic potential of doubly mutant *Nf1* and *W^v* hematopoietic cells, 1984-1986
lost B-cell identity of Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma, 1505-1512
MALT1 deregulation in B-cell non-Hodgkin lymphoma, 4539-4546
MAPK signaling and hematologic malignancies, 4667-4679
MDR1 gene overexpression confers imatinib resistance in leukemia cell lines, 2368-2373
methylated *JunB* in CML, 3205-3211
mitochondrial DNA mutations in MDS, 3118-3125
MM tumor progression in murine model is multistage and dynamic process, 3136-3141
MM with t(4;14)(p16;q32) translocation maintains *IGH/MMSET* fusion transcript, 2374-2376
modified DNA vaccine protects against metastatic neuroblastoma, 649-654
modulation of folate receptor β gene by retinoic acid receptors, 4551-4560
molecular heterogeneity in mantle cell lymphoma, 4042-4046
molecular sequelae of histone deacetylase inhibition in malignant B cells, 4055-4062
monoglycerides induce apoptosis in leukemic cells, 292-294
mutation of *ATM* gene in childhood ALL with *MLL* gene rearrangement, 3622-3627
oncogenic activation of MLL by forkhead family proteins, 633-639
opposing effects of PML and PML-RARα on STAT3 activity, 3668-3673
oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors, 1950-1955
paracrine interactions of basic FGF and IL-6 in MM, 2775-2783
pathogenesis of *MLL* fusion gene leukemia, 3229-3235
PDE4 inhibitors activate mitochondrial apoptotic pathway in CLL, 4122-4130
platelet-endothelial interaction in tumor angiogenesis, 1970-1976
PP1 and CGP76030 inhibit cells expressing imatinib-resistant Bcr-Abl kinases, 664-672
predictor of inferior survival in grade 3 follicular lymphoma, 2363-2367
prognostic grading of nodular sclerosing Hodgkin disease, 4063-4069
PS-341 potentiates sensitivity of MM cells to chemotherapy, 2377-2380
PU.1 inactivation by AML1-ETO in t(8;21) myeloid leukemia, 270-277
rapamycin-induced G_1 arrest in cycling B-CLL cells, 278-285
ras and *junB* activation drive *CD11c* expression in HCL, 4033-4041
recurrent genomic aberrations in MM, 4569-4575
relative risk for radiation-induced AML in mice, 2349-2354
remission of PEL by AZT-mediated inhibition of NF-κB, 2321-2327
repression of STAT3 activity by Kaposi sarcoma–associated viral cyclin K, 4070-4077
resistance of B-CLL cells to DNA damage–induced apoptosis, 4598-4606
role of AML1-ETO in leukemogenesis, 624-632
SAHA enhances imatinib-induced apoptosis of Bcr-Abl–positive leukemia cells, 3236-3239
sequestration of p27^{Kip1} in mantle cell lymphoma, 3181-3187
signaling of Asp814Val c-*kit* activating mutant, 1094-1102
sildenafil and vardenafil induce apoptosis of B-CLL cells, 265-269
SOCS-1 hypermethylation in MM, 2784-2788
splenic marginal zone lymphoma, 2464
SSRIs signal apoptosis in Burkitt lymphoma cells, 3212-3219
SU5614 inhibits FLT3 and induces apoptosis in AML cell lines, 1494-1504
SU11248 is a novel FLT3 inhibitor, 3597-3605
suppression of myeloid transcription factors and STAT induction by AML-specific Flt3 mutations, 3164-3173
survival pathway induced by integrin in B cells, 1118-1127
T-cell epitopes in MM immunoglobulin, 4930-4936
T-cell large granular lymphocyte cells express activating killer cell receptors, 3198-3204
T-cell lymphomas and plasma cell tumors in NPM-ALK transgenic mice, 1919-1927
t(4;14)(p16;q32) is adverse prognostic factor in MM, 1520-1529
t(11;14)(q13;q32) in IgM, IgE, and nonsecretory MM variants, 1570-1571
t(14;18)(q32;q21) involving *IGH* and *MALT1* in MALT lymphoma, 2335-2339
targeting p38 MAPK inhibits MM cell growth in bone marrow milieu, 703-705
TCL1 in plasmacytoid DCs and CD4$^+$CD56$^+$ blastic tumors of skin, 5007-5009
TCR-BV use in B-CLL, 1063-1070
telomerase and telomere length in MM, 4982-4989
tetrocarcin-A–induced ER stress mediates apoptosis in B-CLL cells, 4561-4568
therapeutic LMP1 vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma, 3150-3156
three cytogenetic subgroups in follicular lymphoma grade 3B, 1149-1154
TNF induction involved in interactions with paclitaxel in myeloid leukemia cells, 3648-3657
TRAIL induces apoptosis in Ph$^+$ leukemia cells, 3658-3667
transactivation of fucosyltransferase VII gene by HTLV-1 Tax, 3615-3621
transcriptional regulation of *CBS* in Down syndrome, 1551-1557
transformation of follicular lymphoma to DLBCL, 3109-3117
V_H gene analysis in mantle cell lymphoma, 4047-4054
V_H gene mutational status and CD38 expression in CLL, 1087-1093
YY1 is a myeloid transforming gene interfering with neutrophilic differentiation, 1111-1117
ZAP-70 expression identifies CLL subtype, 4944-4951
Neovascularization. *See also* Angiogenesis
stage of embryonic stem cell differentiation and adult neovascularization, 2675-2678
Neuroblastoma
chemokine–cytokine allogeneic antitumor vaccine for, 1718-1726
metastatic, modified DNA vaccine protects against, 649-654
Neuropilin-1 on hematopoietic cells regulates vascular development, 1801-1809
Neutropenia
agranulocytosis unresponsive to growth factors after rituximab (letter), 4225-4226
chronic idiopathic
impaired granulocytopoiesis in, 2591-2600
serum elastase levels and ELA-2 elastase mutations in (letter), 2898-2899
Neutrophils
C/EBPε and PU.1 regulation of neutrophil and eosinophil gene expression, 3265-3273
caspase inhibition augments cell death in TNF-α–stimulated neutrophils, 295-304
Cb2 induces reversible block in neutrophilic differentiation, 1336-1343
CD4 on human peripheral blood neutrophils, 4452-4456
circulating apoptotic neutrophils in glycogen storage disease type 1b, 5021-5024
expression of IAP in, 1164-1171
G-protein–coupled receptor signaling in Syk-deficient mast cells and, 4155-4163
Gp96 binds to neutrophils and monocytes and stimulates effector functions, 2810-2815
Ikaros regulates differentiation of, 2219-2226
imatinib reverses effects of Bcr-Abl on neutrophilic differentiation, 655-663
impaired neutrophil maturation in truncated G-CSF receptor–transgenic mice, 2990-2995
inhibition of G6P transport in neutrophils results in apoptosis, 2381-2387
in vitro regulation of granulopoiesis by neutrophil elastase, 1752-1758
MAPK control of granule mobilization in human neutrophils, 3240-3248
PECAM-1–dependent neutrophil transmigration, 2816-2825
reduced PKB/Akt and ERK phosphorylation in MDS, 1172-1180
role of apoptosis in control of neutrophil homeostasis in circulation, 739-746

role of neutrophil β2 integrins in murine *Anaplasma phagocytophila*, 3257-3264
TNF-α induces caspase-independent cell death in, 1987-1995
transcription factors during neutrophil differentiation in bone marrow, 4322-4332
two distinct pathways signal F-actin polymerization in, 1181-1184
YY1 is a myeloid transforming gene interfering with neutrophilic differentiation, 1111-1117
NF-κB. *See* Nuclear factor-κB
NF1, leukemic potential of doubly mutant *Nf1* and *W^v* hematopoietic cells, 1984-1986
NIK. *See* Nuclear factor-κB–inducing kinase
Nitric oxide, sensitivity of *Fancc*$^{-/-}$ bone marrow cells to, 3877-3884
S-Nitrosohemoglobin, vasoactivity of, 4408-4415
NK cells. *See* Natural killer cells
Notch
combined effects of *Notch* signaling and cytokines on stem cell differentiation, 1784-1789
regulation of osteoclastogenesis by Notch signaling, 2227-2234
Nramp2/DMT1, iron transport by, 3699-3707
NRAS gene mutation, *CYP1A1*2B (Val)* allele in AML patients with, 2770-2774
Nuclear factor-κB (NF-κB)
in CD40-induced MM cell migration, 2762-2769
curcumin down-regulates NF-κB and IκBα kinase in MM cells, 1053-1062
HHV8–encoded viral FLICE inhibitory protein protects against apoptosis via activation of, 1956-1961
remission of PEL by AZT-mediated inhibition of, 2321-2327
Nuclear factor-κB–inducing kinase (NIK), role of IKK2 and NIK in DC antigen presentation, 983-991
NUP98-HOXD13, induction of AML by, in concert with *Meis1*, 4529-4538
Nur77/NAK-1 regulates TNFα-induced PAI-1 expression, 3042-3048

Ocular complications, nonmalignant late effects after allogeneic SCT, 3373-3385
Osteoclastogenesis
regulation by Notch signaling, 2227-2234
trichostatin A and sodium butyrate suppression of, 3451-3459
Osteoprotegerin (OPG)
and osteosclerosis in mice overexpressing TPO, 2983-2989
and RANKL in myeloma bone disease, 2094-2098
Outcome
of CD34$^+$ peripheral blood SCT in first chronic phase CML, 446-453
early blast clearance is prognostic factor in AML, 64-70
metaphase cytogenetic abnormalities and survival in MM, 3849-3856
POEMS syndrome, 2496-2506
spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in AML, 2125-2131
target antigen distribution and outcome of adoptive cancer immunotherapy, 766-770
VL genes affect presentation and outcome in light chain–associated amyloidosis, 3801-3808
OX40 ligation regulates GVHD and graft rejection after BMT, 3741-3748
Oxidative stress
free radical stress and drug sensitivity in CLL, 4098-4104
hTERT extends life span of CD4$^+$ T cells and confers resistance to apoptosis induced by, 4512-4519
oxidized LDL triggers accumulation of HIF-1α, 4847-4849
peroxiredoxin II and life span of mouse erythrocytes, 5033-5038
Oxygen saturation, nocturnal hypoxemia and painful sickle cell crises in children, 846-848

P-selectin, facilitation of atherosclerosis development by, 2661-2666
P-selectin glycoprotein ligand-1 (PSGL-1)
glycosylation-dependent inhibition of CLA expression, 602-610
N-terminal residues required for P-selectin binding, 552-559
recombinant PSGL-1 inhibits leukocyte rolling by selectins in vivo, 3249-3256
role in increased adhesiveness of CD8$^+$ T cells in multiple sclerosis, 4775-4782
P2Y receptors
$P2Y_1$ and TPα receptors in platelets, 1400-1408
$P2Y_{12}$ in GPVI-mediated Rap1 activation in platelets, 1409-1415
role of extracellular cysteines in $P2Y_{12}$ receptor inactivation, 3908-3914
p14^ARF, *p15^INK4b*, and *p16^INK4a*$ methylation status in CML (letter), 374-375
p27^{Kip1}, sequestration in mantle cell lymphoma, 3181-3187
p38 MAPK
involvement in thymocyte development, 970-976
mediation of procoagulant response during endotoxemia by, 4446-4448
MM cell growth in bone marrow milieu inhibited by targeting of, 703-705
p47^{phox} pseudogenes and inflammatory bowel disease (letter), 3337
p53, inhibition of p53-dependent apoptosis by distinct signaling pathways (*see Blood* 100:3990-4000, December 1, 2002) (erratum), 2114
p57KIP2 methylation in ALL, 4131-4136
Paclitaxel, TNF induction involved in interactions with paclitaxel in myeloid leukemia cells, 3648-3657
PAI-1. *See* Plasminogen activator inhibitor 1
PAR-1. *See* Protease-activated receptor 1
Paroxysmal nocturnal hemoglobinuria (PNH), *PIG-A* gene mutations in aplastic anemia/PNH, 2833-2841
Parvovirus B19 infection, pure red-cell aplasia due to, after alemtuzumab therapy (letter), 1654
Pax5 determines B- vs. T-cell fate, 4342-4346
PBXs and MEIS1 regulate transcription of PF4 gene, 4748-4756
PDE inhibitors. *See* Phosphodiesterase inhibitors
PECAM-1. *See* Platelet endothelial cell adhesion molecule-1
Pediatric hematology
Ara-C sensitivity in *MLL* gene-rearranged infant ALL, 1270-1276
asparagine synthetase in t(12;21)$^+$ pediatric ALL, 2743-2747
central venous line–related thrombosis, 4273-4278
comprehensive banking of sibling donor UCB for children with malignant and nonmalignant disease, 351-357
dexamethasone vs. prednisone and oral vs. intravenous mercaptopurine for ALL, 3809-3817
distinct HLA associations by stroke subtype in children with SCD, 2865-2869
G-CSF and risk of secondary myeloid malignancy after etoposide, 3862-3867
gemtuzumab ozogamicin for relapsed AML, 3868-3871
Helicobacter pylori and ITP in children (letter), 1660
LOH within *MLL* in childhood ALL (letter and response), 4222-4223
long-term complications after childhood SCT for AML, 1611-1619
nocturnal hypoxemia and painful sickle cell crises, 846-848
posterior leukoencephalopathy syndrome and cerebral infarcts associated with acute chest syndrome in SCD, 415-419
prenatal origin of translocations associated with AML (ietter), 4640-4641
rituximab for pediatric autoimmune hemolytic anemia, 3857-3861
thromboembolic events in children with ALL: prednisone vs. dexamethasone, 2529-2533
transplantation of unrelated-donor CD34$^+$ cells in pediatric leukemia, 1630-1636
unrelated donor SCT vs. chemotherapy for pediatric relapsed ALL, 3835-3839
VWF-cleaving protease and *ADAMTS13* mutations in childhood TTP, 1845-1850
PEL. *See* Primary effusion lymphoma
Peripheral blood
CD4 on human peripheral blood neutrophils, 4452-4456
circulating plasma cells as prognostic indicator in amyloidosis, 827-830
cyclophosphamide with lymphocyte-depleted peripheral blood stem cell support for refractory autoimmune thrombocytopenia, 71-77
differential chemokine expression in peripheral blood T cells, 216-225
IL-15 is essential mediator of peripheral NK-cell homeostasis, 4887-4893
outcome of CD34$^+$ peripheral blood SCT in first chronic phase CML, 446-453
peripheral smear in pernicious anemia (blood work), 1668
retroviral transduction efficiency of G-CSF+SCF–mobilized peripheral blood CD34$^+$ cells, 2199-2205
ubiquitin inhibits TNF-α response to endotoxin, 1882-1890
Peroxiredoxin
in erythrocytes, role in detoxifying peroxides (letter and response), 2897-2898
peroxiredoxin II and life span of mouse erythrocytes, 5033-5038
PET. *See* Positron emission tomography
PF4. *See* Platelet factor 4
PfEMP1. *See Plasmodium falciparum* erythrocyte membrane protein 1
PGE. *See* Prostaglandin E

Ph chromosome. *See* Philadelphia chromosome
Phagocytes
Bcl-2 family's regulation of granulocyte survival, 2393-2400
C/EBPε and PU.1 regulation of neutrophil and eosinophil gene expression, 3265-3273
caspase inhibition augments cell death in TNF-α–stimulated neutrophils, 295-304
Cb2 induces reversible block in neutrophilic differentiation, 1336-1343
circulating apoptotic neutrophils in glycogen storage disease type 1b, 5021-5024
cytokine-mediated regulation of iron transport in monocytes, 4148-4154
expression of IAP in neutrophils, 1164-1171
Felic localizes to phagocytic cup, 2804-2809
GABP, Sp1, and RAR activate CD18 transcription in myeloid cells, 311-317
glycosphingolipid expression in acute nonlymphocytic leukemia, 711-721
Gp96 binds to neutrophils and monocytes and stimulates effector functions, 2810-2815
HPK1 negatively regulates PGE_2-induced *fos* gene transcription, 3687-3689
Ikaros regulates neutrophil differentiation, 2219-2226
inhibition of G6P transport in neutrophils results in apoptosis, 2381-2387
leukocyte antiadhesive actions of annexin 1, 4140-4147
ligation of Siglec-8 and induction of eosinophil apoptosis, 5014-5020
LSSIG is novel murine leukocyte-specific GPCR, 1185-1187
lysozyme M deficiency increases inflammation, 2388-2392
malaria-parasitized erythrocytes and hemozoin generate hydroxy fatty acids, 722-728
MAPK control of granule mobilization in human neutrophils, 3240-3248
PECAM-1–dependent neutrophil transmigration, 2816-2825
phagocytic signal transduced by carboxy-terminal region of G-CSF receptor, 4615-4622
recombinant PSGL–1 inhibits leukocyte rolling by selectins in vivo, 3249-3256
reduced PKB/Akt and ERK phosphorylation in MDS, 1172-1180
role for ICSBP in development of murine $CD8\alpha^+$ DCs, 305-310
role of apoptosis in control of neutrophil homeostasis in circulation, 739-746
role of neutrophil β2 integrins in murine *Anaplasma phagocytophila*, 3257-3264
serum amyloid A induces IL-8 secretion, 1572-1581
synthesis of GILZ by macrophages, 729-738
TNF-α induces caspase-independent cell death in neutrophils, 1987-1995
transcription factors during neutrophil differentiation in bone marrow, 4322-4332
transgenic mice with a CSF-1R reporter gene, 1155-1163
two distinct pathways signal F-actin polymerization in neutrophils, 1181-1184
urokinase-type plasminogen activator/$\alpha_M\beta_2$ interactions, 1582-1590
Phenotype. *See also* Immunophenotyping
C/EBPs repress leukemic phenotype of AML, 1141-1148
CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians (letter), 2896-2897
γδ T-cell phenotype and survival in CTCL, 3407-3412
genetics of thrombocytopenic SLE, 992-997
I locus, adult i phenotype, and congenital cataracts, 2081-2088
phenotypic correction of β-thalassemia after lentiviral-mediated transfer of γ-globin gene, 2175-2183
T-cell population phenotypically indistinguishable from $CD3^+$ lymphogranular leukemia (letter), 4643-4644
Philadelphia (Ph) chromosome
abnormalities in Ph^- cells of CML patients on imatinib, 1941-1949
early MRD analysis during imatinib treatment of Ph^+ ALL, 85-90
imatinib in newly diagnosed patients with Ph^+ CML, 97-100
severe skin reaction to imatinib in Ph^+ ALL (letter), 2446
TRAIL induces apoptosis in Ph^+ leukemia cells, 3658-3667
Phosphatidylinositol 3–kinase (PI3K)
in CD40-induced MM cell migration, 2762-2769
in control of EPO-induced erythroid progenitor proliferation, 3436-3443
interaction between VWF and GPIb activates Src kinase in platelets, 3469-3476
Src and PI3K mediate soluble E-selectin–induced angiogenesis, 3960-3968
Phosphodiesterase (PDE) inhibitors
PDE4 inhibitors activate mitochondrial apoptotic pathway in CLL, 4122-4130
sildenafil and vardenafil induce apoptosis of B-CLL cells, 265-269
PI3K. *See* Phosphatidylinositol 3–kinase
PIG-A gene mutations in aplastic anemia/PNH, 2833-2841
PKB. *See* Protein kinase B
PKC. *See* Protein kinase C
PKD. *See* Protein kinase D
PKLR gene, disruption of novel regulatory element causes pyruvate kinase deficiency, 1596-1602
Placental growth factor, role in inflammation, 560-567
Plasma cells
gene expression profiling of, 4013-4021
gene expression profiling of plasma cell differentiation and MM, 1128-1140
as prognostic indicator in amyloidosis, 827-830
T-cell lymphomas and plasma cell tumors in NPM-ALK transgenic mice, 1919-1927
Plasmacytoma, prognostic value of angiogenesis in solitary bone plasmacytoma, 1715-1717
Plasmin, dose-dependent effects of plasmin and tPA on coagulation and hemorrhage, 3002-3007
Plasminogen activator inhibitor 1 (PAI-1)
circadian oscillation of PAI-1 and *4G5G* polymorphism, 1841-1844
induction in rat hepatocytes by insulin, 907-914
Nur77/NAK-1 regulates TNFα-induced PAI-1 expression, 3042-3048
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1), inhibition and reversal of cytoadherence of *Plasmodium falciparum* by, 331-337
Platelet endothelial cell adhesion molecule-1 (PECAM-1)
PECAM-1–dependent neutrophil transmigration, 2816-2825
PECAM-1–driven antiapoptotic signal in $CD34^+$ cells, 186-193
Platelet factor 4 (PF4)
inhibition of hematopoiesis by, 4687-4694
MEIS1 and PBXs regulate transcription of PF4 gene, 4748-4756
Platelets
activation induced by antibodies to IL-8, 1419-1421
CD47 and platelet adhesion on inflamed endothelium under flow, 4836-4843
collagen-induced platelet aggregation, 2646-2651
GPIIb/IIIa-mediated platelet-platelet interaction, 929-936
GPVI polymorphism and platelet response, 4372-4379
interaction between VWF and GPIb activates Src kinase in, 3469-3476
IQGAP2 in thrombin-induced platelet cytoskeletal reorganization, 3021-3028
levels of *BAX, MRP-1,* and platelets predict response to imatinib in CML, 2152-2155
mechanisms and implications of platelet discoid shape, 4789-4796
megakaryocytes require TSP2 for normal platelet formation and function, 3915-3923
overexpression of platelet $P2X_1$ ion channel in transgenic mice, 3969-3976
$P2Y_1$ and TPα receptors in, 1400-1408
$P2Y_{12}$ in GPVI-mediated Rap1 activation in, 1409-1415
PAR-1 polymorphism associated with platelet receptor density and response to SFLLRN, 1833-1840
PKD activation by PKC in, 1392-1399
platelet-endothelial interaction in tumor angiogenesis, 1970-1976
platelet P-selectin facilitates atherosclerosis development, 2661-2666
rFVIIa enhances $\alpha_{IIb}\beta_3$-deficient platelet adhesion, 1864-1870
role for $G\alpha_{i1}$ in mediating platelet aggregation, 4828-4835
role of extracellular cysteines in $P2Y_{12}$ receptor inactivation, 3908-3914
role of intracellular domains of GPIb in controlling adhesive properties of GPIb/V/IX complex, 3477-3484
shear-induced platelet activation and self-association of VWF in suspension, 2637-2645
thrombin activatable fibrinolysis inhibitor in, 4844-4846
transcript profiling using microarray and serial analysis of gene expression, 2285-2293
transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment, 2426-2433
VWF and shear-dependent p125FAK phosphorylation, 4363-4371
PML-RARα
APL model with FLT3 mutation is responsive to retinoic acid and SU11657, 3188-3197

HOX gene expression in PML-RARα^{2b} APL, 1558-1565
opposing effects of PML and PML-RARα on STAT3 activity, 3668-3673
PML does not regulate MHC class I in human cells, 3514-3519
prognostic value of quantitative real-time RT-PCR analysis of PML-RARα mRNA in APL, 2521-2528
Pneumococcal vaccine, donor immunization and protective responses after SCT, 831-836
PNH. *See* Paroxysmal nocturnal hemoglobinuria
POEMS syndrome, 2496-2506
Polycythemia
congenital, *VHL* gene mutations in, 1591-1595
discrimination of polycythemias and thrombocytoses by clonality assays, 3294-3301
hemostasis and coagulation in erythrocytosis, 4416-4422
Positron emission tomography (PET), utility of FDG-PET scanning in lymphoma by WHO classification, 3875-3876
PP1 and CGP76030 inhibit cells expressing imatinib-resistant Bcr-Abl kinases, 664-672
pp65
down-regulation of HLA-DR by human CMV protein pp65, 4870-4877
human CMV immediate-early mRNAemia vs. pp65 antigenemia in SCT recipients, 5053-5060
Prednisone
combination low-dose thalidomide and prednisone for MMM, 2534-2541
vs. dexamethasone and oral vs. intravenous mercaptopurine for ALL, 3809-3817
thromboembolic events in children with ALL: prednisone vs. dexamethasone, 2529-2533
Pregnancy, anti–protein Z antibodies in women with pathologic pregnancies, 4850-4852
Primary effusion lymphoma (PEL)
gene expression profiling of AIDS-related PEL, 4115-4121
inhibition of STAT3 signaling in, 1535-1542
remission by AZT-mediated inhibition of NF-κB, 2321-2327
Primary mediastinal large B-cell lymphoma, *FIG1* gene activation in, 2756-2761
Progenipoietin-1, donor pretreatment with, to prevent GVHD after SCT, 2033-2042
Progenitor cells. *See also* Stem cells
CD26/DPPIV mediates G-CSF mobilization in mouse progenitor cells, 4680-4686
cell context–specific effects of *BCR-ABL* in hematopoietic progenitors, 4088-4097
detection of quiescent leukemic progenitor cells in AML, 3142-3149
E26 leukemia virus converts primitive erythroid cells into multilineage progenitors, 1103-1110
expansion of umbilical cord progenitor cells by human telomerase catalytic subunit–transfected stromal cells, 532-540
function of *bcl-x* promoter in erythroid progenitors, 2235-2242
G-CSF–induced expansion of myeloid progenitor cells, 2584-2590
G-protein signaling in mobilization of, 4739-4747
human cord blood CD34$^+$Pax-5$^+$ B-cell progenitors, 3424-3430
impaired granulocytopoiesis in chronic idiopathic neutropenia and apoptosis of myeloid progenitor cells, 2591-2600
laminin isoform–specific adhesion and migration of, 877-885
novel myeloid-like NK cell progenitor in human UCB, 3444-3450
PI3K in control of EPO-induced erythroid progenitor proliferation, 3436-3443
SCF inhibits apoptosis in erythroid progenitors by up-regulation of FLIP, 1324-1328
stem cell and progenitor defects in Sca-1/Ly-6A–null mice, 517-523
VL30 promoter directs sustained activity in erythroid progenitors, 1798-1800
Prognosis
CD38 expression in CLL patients at risk of disease progression, 1262-1269
circulating CD20 in CLL is of prognostic significance, 2507-2513
circulating plasma cells as prognostic indicator in amyloidosis, 827-830
early blast clearance is prognostic factor in AML, 64-70
HGAL predicts survival in large B-cell lymphoma, 433-440
high AID expression in poor-prognosis CLL, 4903-4908
high *EVI1* expression predicts poor survival in AML, 837-845
prognostic grading of nodular sclerosing Hodgkin disease, 4063-4069
prognostic impact of unmutated V_H gene status after SCT for CLL, 2049-2053
prognostic significance of impaired recovery of EBV-specific T cells after SCT, 4290-4297
prognostic value of angiogenesis in solitary bone plasmacytoma, 1715-1717
prognostic value of quantitative real-time RT-PCR analysis of PML-RARα mRNA in APL, 2521-2528
significance of cytogenetic clonal evolution in imatinib-treated CML, 3794-3800
survival not improved after high-dose therapy in MM, 2144-2151
t(4;14)(p16;q32) is adverse prognostic factor in MM, 1520-1529
Prostaglandin E (PGE), HPK1 negatively regulates PGE_2-induced *fos* gene transcription, 3687-3689
Protease-activated receptor 1 (PAR-1), gene polymorphism associated with platelet receptor density and response to SFLLRN, 1833-1840
Proteasome inhibitor PS-341, antimyeloma activity of, 1530-1534
Protein 4.1R, regulation of expression of, 4164-4171
Protein C
activated (APC)
APC alters cytosolic calcium flux in brain endothelium, 4797-4801
chromosome 18 locus influences APC resistance and thrombosis susceptibility, 163-167
EFG2 in protein S and APC cofactor activity, 1416-1418
exosite-dependent regulation of factor VIIIa by, 4802-4807
endotoxin-induced DIC and cytokine activation in protein C–deficient mice, 4823-4827
fasting plasma total homocysteine and protein C activity in vitro (letter), 2446-2447
Gla domain–mutated hyperactive protein C, 2277-2284
regulation of human endothelial cell protein C receptor gene promoter, 4393-4401
Protein kinase B (PKB), reduced PKB/Akt and ERK phosphorylation in MDS, 1172-1180
Protein kinase C (PKC)
activation of PKD in human platelets by, 1392-1399
effects of C/EBPα and PKCδ on JunB expression and monocytic differentiation, 3885-3892
PKCζ mediated Raf-1/ERK activation by daunorubicin, 1543-1550
Protein kinase D (PKD), activation by PKC in human platelets, 1392-1399
Protein S, EFG2 in protein S and APC cofactor activity, 1416-1418
Protein Z, anti–protein Z antibodies in women with pathologic pregnancies, 4850-4852
Prothrombin
clot structure altered by elevation of, 3008-3013
risk of combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles for myocardial infarction, 3037-3041
PS-341
antimyeloma activity of, 1530-1534
potentiation of sensitivity of MM cells to chemotherapy, 2377-2380
PSGL-1. *See* P-selectin glycoprotein ligand-1
pTα, TCR, and RAG-1 in T-ALL, 2693-2703
PU.1
C/EBPε and PU.1 regulation of neutrophil and eosinophil gene expression, 3265-3273
heterozygous mutations in AML (letter), 2074
inactivation by AML1-ETO in t(8;21) myeloid leukemia, 270-277
Pulmonary hypertension in SCD, cardiac catheterization for, 1257-1261
Pyruvate kinase deficiency, caused by disruption of novel regulatory element in *PKLR*, 1596-1602

Quality of life, nonmalignant late effects after allogeneic SCT, 3373-3385
Quinine-induced immune thrombocytopenia, target for antibodies associated with, 937-942

R115777 in hematologic malignancies, 1692-1697
Rab
differential regulation of CXCR2 trafficking by Rab GTPases, 2115-2124
Rab27a mutations in Griscelli syndrome, 2736-2742
Rac and Syk regulation of Akt-dependent cell survival, 236-244
Radiation therapy
albumin protects B-CLL cells from chlorambucil- and radiation-induced apoptosis, 3174-3180
AML1 mutations in radiation- and therapy-related MDS/AML, 673-680
anti-CD20 vs. anti-CD45 antibodies for radioimmunotherapy of B-cell lymphomas, 2340-2348
antiapoptotic cytokines reduce radiation lethality, 2609-2616

Artemis mutations in radiosensitive SCID patients, 1446-1452
HB22.7 has lymphomacidal properties and augments efficacy of radioimmunotherapy, 3641-3647
in vivo tracking of stem cells transplanted into irradiated or nonirradiated recipients (*see Blood* 100:3545-3552, November 15, 2002) (erratum), 390
radioimmunotherapy of non-Hodgkin lymphoma, 391-398
relative risk for radiation-induced AML in mice, 2349-2354
total lymphoid irradiation preconditioning enriches for IL-4–producing $CD4^+$ cells, 2024-2032
unrelated SCT with reduced conditioning can induce complete chimerism and sustained remissions, 1620-1629
Raf-1, PKCζ mediated Raf-1/ERK activation by daunorubicin, 1543-1550
RAG-1, TCR, and pTα in T-ALL, 2693-2703
RANKL. *See* Receptor activator of nuclear factor-κB ligand
Rap1
cAMP inhibits Ras and Rap1 activation in T cells, 998-1006
$P2Y_{12}$ in GPVI-mediated Rap1 activation in platelets, 1409-1415
stromal inhibition of megakaryocytic Rap1 signaling, 1744-1751
Rapamycin
G_1 arrest in cycling B-CLL cells induced by, 278-285
inhibition of DC mobilization and function by, 4457-4463
RAR. *See* Retinoic acid receptor
Ras
cAMP inhibits Ras and Rap1 activation in T cells, 998-1006
CD13/APN is an endothelial target of, 1818-1826
downstream effectors of oncogenic ras in MM cells, 3126-3135
hematologic effects of inactivating *Rce1*, 2250-2252
ras and *junB* activation drive *CD11c* expression in HCL, 4033-4041
RBCs. *See* Red blood cells
Rce1, hematologic effects of inactivation of, 2250-2252
Receptor activator of nuclear factor-κB ligand (RANKL), and osteoprotegerin in myeloma bone disease, 2094-2098
Red blood cells (RBCs)
aberrant development of *Plasmodium falciparum* in hemoglobin CC red cells, 3309-3315
acidic and neutral sialidase in erythrocytes of patients with diabetes (letter), 2071
activation of BCAM/Lu-dependent sickle (SS) RBC adhesion, 3281-3287
association of CD47 with Rh and erythrocyte cytoskeleton, 1194-1199
band 3–based macrocomplex of proteins in membrane of, 4180-4188
clinical consequences of iron overload in hemochromatosis homozygotes, 3351-3358
cobalamin deficiency with and without neurologic abnormalities, 3302-3308
combined pyridoxal isonicotinoyl hydrazone analog and deferoxamine chelation treatment, 4172-4179
complement receptor 1 inhibitors in transfusion therapy, 5046-5052
discrimination of polycythemias and thrombocytoses by clonality assays, 3294-3301
disruption of novel regulatory element in *PKLR* causes pyruvate kinase deficiency, 1596-1602
distinct HLA associations by stroke subtype in children with SCD, 2865-2869
duodenal iron in *Hfe* knock-out mice, 3316-3318
erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis, 4625-4627
erythropoiesis from acetyl LDL incorporating endothelial cells at preliver stage, 4733-4738
fetal hemoglobin reactivation in adult life, 2826-2832
globin loci in pufferfish and humans, 2842-2849
glycophorin C is receptor for PfEBP-2, 4628-4631
hemoglobin digestion and osmotic stability of malaria-infected RBCs, 4189-4194
hemostasis and coagulation in erythrocytosis, 4416-4422
heparan sulfate on endothelial cells mediates binding of malaria-infected erythrocytes, 2405-2411
HFE Cys282Tyr mutation as necessary but not sufficient cause of hereditary hemochromatosis, 3347-3350
HK Utrecht: mutation associated with hexokinase deficiency and hemolytic anemia, 345-347
human CMV US2 affects antigen presentation and iron homeostasis, 2858-2864
hypoxic up-regulation of erythroid ALAS2, 348-350
ICA-17043 prevents sickled red blood cell dehydration, 2412-2418
induction of fetal hemoglobin by apicidin, 2001-2007
interactions between transferrin receptor and transferrin receptor 2, 2008-2014
involvement of ABC7 in heme biosynthesis, 3274-3280
iron accumulation in ALAS2-deficient erythroblasts, 1188-1193
iron transport by *Nramp2*/DMT1, 3699-3707
IronChip analysis of cellular iron metabolism, 3690-3698
locus control region dependency on β-globin intron-2, 1603-1610
malaria-parasitized erythrocytes and hemozoin generate hydroxy fatty acids, 722-728
mitochondrial ferritin in sideroblastic anemias, 1996-2000
mutations in murine erythroid α-spectrin gene, 325-330
new and old integral proteins of human erythrocyte membrane (letter and response), 3751-3753
nucleolar localization of RPS19 protein in Diamond-Blackfan anemia, 5039-5045
peroxiredoxin II and life span of mouse erythrocytes, 5033-5038
PfEMP1 peptide inhibits and reverses cytoadherence of *Plasmodium falciparum*, 331-337
PIG-A gene mutations in aplastic anemia/PNH, 2833-2841
pure red-cell aplasia due to parvovirus B19 after alemtuzumab therapy (letter), 1654
red cell skeleton protein 4.2 interacts with CD47, 338-344
regulation of expression of protein 4.1R isoforms, 4164-4171
ribosomal protein S19 expression during erythroid differentiation, 318-324
role of erythrocyte peroxiredoxin in detoxifying peroxides (letter and response), 2897-2898
RSP-2 in adhesion of malaria-infected erythrocytes to endothelial cells and placenta, 5025-5032
Scianna antigens expressed by ERMAP, 752-757
spleen-facilitated vesiculation and hemoglobin loss from erythrocytes, 747-751
Src-family kinase signaling modulates *Plasmodium falciparum* adhesion, 2850-2857
stroke risk in siblings with SCD, 2401-2404
transgenic sickle mice have vascular inflammation, 3953-3959
UbcH5A up-regulation in hereditary hemochromatosis, 3288-3293
VHL gene mutations in congenital polycythemia, 1591-1595
Reed-Sternberg cells
cell-cycle and apoptosis deregulation in Hodgkin cells and, 681-689
lost B-cell identity of Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma, 1505-1512
c-Rel protein accumulation in Hodgkin lymphoma, 3681-3686
Relapse
alemtuzumab plus rituximab in relapsed and refractory lymphoid malignancies, 3413-3415
DLI for JMML relapsing after SCT, 1713-1714
G3139 and chemotherapy for refractory or relapsed acute leukemia, 425-432
gemtuzumab ozogamicin for relapsed pediatric AML, 3868-3871
immunophenotypic evidence of leukemia after induction therapy predicts relapse of AML, 3398-3406
late relapses evolve from slow-responding subclones in $t(12;21)^+$ ALL, 3635-3640
molecular response to imatinib following relapse after SCT for CML (letter), 1200-1201 (erratum, 1683)
rituximab for relapsed $CD20^+$ Hodgkin lymphoma, 420-424
unrelated donor SCT vs. chemotherapy for pediatric relapsed ALL, 3835-3839
WT1 assay to predict and manage relapse after allogeneic SCT in acute leukemia, 1698-1704
Remission
early blast clearance is prognostic factor in AML, 64-70
long-term complications after childhood SCT for AML in first remission, 1611-1619
of PEL by AZT-mediated inhibition of NF-κB, 2321-2327
persistence of Bcr-Abl^+ progenitors in CML in remission after imatinib, 4701-4707
Retinoic acid receptor (RAR)
GABP, Sp1, and RAR activate CD18 transcription in myeloid cells, 311-317
modulation of folate receptor β gene by, 4551-4560
Retroviral vectors
gene therapy for hemophilia B, 3924-3932

gene therapy for Wiskott-Aldrich syndrome, 2159-2166
integration in preferred genomic targets of bone marrow–repopulating cells, 2191-2198
long-term results of the first ADA gene therapy trial, 2563-2569
macrophage-specific, gene therapy of ApoE-deficient mice using, 485-491
retroviral-mediated Fancc expression enhances repopulating ability of *Fancc*$^{-/-}$ stem cells, 1299-1307
retrovirus-mediated IL-7 expression in leukemic DCs generated from AML, 2184-2190
side effects of retroviral gene transfer into hematopoietic stem cells, 2099-2114
transduction efficiency of G-CSF+SCF–mobilized peripheral blood CD34$^+$ cells, 2199-2205
Reverse transcription–polymerase chain reaction (RT-PCR)
MYH11 real-time RT-PCR for rapid identification of *CBFB-MYH11*–positive AML (letter), 5085-5086
prognostic value of quantitative real-time RT-PCR analysis of PML-RARα mRNA in APL, 2521-2528
RH blood group, association of CD47 with Rh and erythrocyte cytoskeleton, 1194-1199
Ribosomal protein S19 expression during erythroid differentiation, 318-324
Ring surface protein 2 (RSP-2), in adhesion of malaria-infected erythrocytes to endothelial cells and placenta, 5025-5032
Rituximab
for acquired factor VIII inhibitors (letter and response), 3753-3755
agranulocytosis unresponsive to growth factors after (letter), 4225-4226
anti-C3b(i) mAb enhances complement activation and rituximab killing of CD20$^+$ cells, 1071-1079
for CNS lymphomas: targeting leptomeningeal compartment, 466-468
concurrent with or sequential to fludarabine in B-CLL, 6-14
efficacy and safety in type II mixed cryoglobulinemia, 3827-3834
impact of rituximab plus CHOP on bcl-2–associated drug resistance in geriatric DLBCL, 4279-4284
in lymphocyte-predominant Hodgkin disease, 4285-4289
mechanisms of action in non-Hodgkin's lymphomas, 949-954
for pediatric autoimmune hemolytic anemia, 3857-3861
plus alemtuzumab in relapsed and refractory lymphoid malignancies, 3413-3415
for relapsed CD20$^+$ Hodgkin lymphoma, 420-424
treatment of mixed cryoglobulinemia with, 3818-3826
RNA
human CMV immediate-early mRNAemia vs. pp65 antigenemia in SCT recipients, 5053-5060
inhibition of *bcr-abl* gene expression by small interfering RNA, 1566-1569
prognostic value of quantitative real-time RT-PCR analysis of PML-RARα mRNA in APL, 2521-2528
RNA-transfected DCs induce myeloma-specific cytotoxic T cells, 977-982
Rosmarinic acid, inhibition of TCR signaling by, 3534-3542
Roxifiban-associated thrombocytopenia, antibody testing reduces incidence of, 58-63
RPS19 protein, nucleolar localization in Diamond-Blackfan anemia, 5039-5045
RSP-2. *See* Ring surface protein 2
RT-PCR. *See* Reverse transcription–polymerase chain reaction
RUNX1 and GATA-1 cooperation in megakaryocytic differentiation, 4333-4341

S1P. *See* Sphingosine 1-phosphate
SAHA. *See* Suberoylanilide hydroxyamic acid
Sca-1. *See* Stem cell antigen–1
SCD. *See* Sickle cell disease
SCF. *See* Stem cell factor
SCH66336, apoptotic synergism between STI571 and SCH66336 on imatinib-sensitive cell line (letter and response), 2070-2071
Scianna antigens expressed by ERMAP, 752-757
SCID. *See* Severe combined immunodeficiency
SCT. *See* Stem cell transplantation
SDF-1. *See* Stromal cell–derived factor 1
Second malignancy, G-CSF and risk of secondary myeloid malignancy after etoposide, 3862-3867
Selectins
combined anticoagulant and antiselectin treatments prevent DIC, 921-928
L-selectin stimulation up-regulates CXCR4 in lymphocytes, 4245-4252
N-terminal residues in PSGL-1 required for P-selectin binding, 552-559
platelet P-selectin facilitates atherosclerosis development, 2661-2666
recombinant PSGL-1 inhibits leukocyte rolling by selectins in vivo, 3249-3256
Src and PI3K mediate soluble E-selectin–induced angiogenesis, 3960-3968
Selective serotonin reuptake inhibitors (SSRIs), signaling of apoptosis in Burkitt lymphoma cells by, 3212-3219
Serum amyloid A, induction of IL-8 secretion by, 1572-1581
Severe combined immunodeficiency (SCID)
Artemis mutations in radiosensitive SCID patients, 1446-1452
novel class of CD34$^-$ cells that give rise to SCID-repopulating cells, 869-876
Sézary syndrome. *See also* Cutaneous T-cell lymphoma
alemtuzumab in mycosis fungoides and, 4267-4272
CD158k/p140/KIR3DL2 polymorphisms in, 1203
CMV seropositivity associated with mycosis fungoides and, 2132-2136
SgIGSF: new MITF-dependent mast-cell adhesion molecule, 2601-2608
Sialic acid binding immunoglobulin-like lectin 8 (Siglec-8), and induction of eosinophil apoptosis, 5014-5020
Sialidase, acidic and neutral, in erythrocytes of patients with diabetes (letter), 2071
Sickle cell disease (SCD)
activation of BCAM/Lu-dependent sickle (SS) RBC adhesion, 3281-3287
acute sickle cell hepatopathy as contraindication for percutaneous liver biopsy, 101-103
cardiac catheterization for pulmonary hypertension in, 1257-1261
distinct HLA associations by stroke subtype in children with, 2865-2869
ICA-17043 prevents sickled red blood cell dehydration, 2412-2418
nocturnal hypoxemia and painful sickle cell crises in children, 846-848
posterior leukoencephalopathy syndrome and cerebral infarcts associated with acute chest syndrome in children with, 415-419
related UCB transplantation in thalassemia and, 2137-2143
stroke risk in siblings with, 2401-2404
transgenic sickle mice have vascular inflammation, 3953-3959
Sideroblastic anemia, X-linked, after hemodialysis, 4623-4624
Siglec-8. *See* Sialic acid binding immunoglobulin-like lectin 8
Signal transducers and activators of transcription (STAT)
donor pretreatment with IL-18 attenuates acute GVHD via STAT6 and preserves graft-versus-leukemia effects, 2877-2885
inhibition of STAT3 signaling in PEL, 1535-1542
LSSIG is novel murine leukocyte-specific GPCR induced by STAT3 activation, 1185-1187
opposing effects of PML and PML-RARα on STAT3 activity, 3668-3673
repression of STAT3 activity by Kaposi sarcoma–associated viral cyclin K, 4070-4077
STAT activation by type I IFN differential therapy for erythroleukemia, 2727-2735
STAT proteins in leukemias, 2940-2954
STAT5a required for eosinophil differentiation of cord blood–derived CD34$^+$ cells, 134-142
suppression of myeloid transcription factors and STAT induction by AML-specific Flt3 mutations, 3164-3173
Signal transduction
CD40 induces MM cell migration, 2762-2769
in collagen-induced platelet aggregation, 2646-2651
G-protein signaling in stem cell mobilization, 4739-4747
inhibition of p53-dependent apoptosis by distinct signaling pathways (*see Blood* 100:3990-4000, December 1, 2002) (erratum), 2114
interaction between VWF and GPIb activates Src kinase in platelets, 3469-3476
intracellular domains of CXCR4 in SDF-1–mediated signaling, 399-406
MAPK signaling and hematologic malignancies, 4667-4679
MyD88 pathway in endothelial activation by antiphospholipid antibodies, 3495-3500
p38 MAPK mediates procoagulant response during endotoxemia, 4446-4448
PECAM-1–driven antiapoptotic signal in CD34$^+$ cells, 186-193
phagocytic signal transduced by carboxy-terminal region of G-CSF receptor, 4615-4622
PI3K in control of EPO-induced erythroid progenitor proliferation, 3436-3443

regulation of osteoclastogenesis by Notch signaling, 2227-2234
signaling of Asp814Val c-*kit* activating mutant, 1094-1102
Src and PI3K mediate soluble E-selectin–induced angiogenesis, 3960-3968
Src-family kinase signaling modulates *Plasmodium falciparum* adhesion, 2850-2857
STAT proteins in leukemias, 2940-2954
stromal inhibition of megakaryocytic Rap1 signaling, 1744-1751
two distinct pathways signal F-actin polymerization in neutrophils, 1181-1184
Sildenafil and vardenafil induce apoptosis of B-CLL cells, 265-269
Simian immunodeficiency virus (SIV), IL-7 expands T cells in normal and SIV-infected nonhuman primates, 2294-2299
Single nucleotide polymorphism (SNP)–based quantitation of hematopoietic chimerism after allogeneic SCT, 363-369
SIV. *See* Simian immunodeficiency virus
SLE. *See* Systemic lupus erythematosus
Smad proteins
in cellular response to hypoxia, 2253-2260
role of phospho-Smad2/3 in HL-60 cell differentiation, 498-507
Smad5 gene disruption and high-proliferative potential precursors during embryonic hematopoiesis, 124-133
SNP. *See* Single nucleotide polymorphism
SOCS. *See* Suppressor of cytokine signaling
Sodium butyrate and trichostatin A suppress osteoclastogenesis, 3451-3459
Solitary bone plasmacytoma, prognostic value of angiogenesis in, 1715-1717
Sp1
GABP, Sp1, and RAR activate CD18 transcription in myeloid cells, 311-317
regulation of human endothelial cell protein C receptor gene promoter by Sp1 binding sites, 4393-4401
SPAN-Xb in hematologic malignancies, 955-960
Spectrin, mutations in murine erythroid α-spectrin gene, 325-330
Sphingosine 1-phosphate (S1P), novel inhibitor of T-cell proliferation, 4909-4915
Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development, 1015-1023
Spleen
constitutive IL-5 overexpression induces extramedullary hematopoiesis in, 863-868
internalization of apoptotic cells by splenic marginal zone DCs, 611-620
spleen-facilitated vesiculation and hemoglobin loss from erythrocytes, 747-751
splenic marginal zone lymphoma, 2464
Src kinase
interaction between VWF and GPIb activates Src kinase in platelets, 3469-3476
role in dexamethasone-induced apoptosis of thymocytes, 585-593
Src and PI3K mediate soluble E-selectin–induced angiogenesis, 3960-3968
Src-family kinase signaling modulates *Plasmodium falciparum* adhesion, 2850-2857
SSRIs. *See* Selective serotonin reuptake inhibitors
STAT. *See* Signal transducers and activators of transcription
Stem cell antigen–1 (Sca-1), stem cell and progenitor defects in Sca-1/Ly-6A–null mice, 517-523
Stem cell factor (SCF)
fetal hemoglobin modulation during erythropoiesis, 492-497
and IL-3 in Hodgkin disease (letter), 376-377
mast cell activation induced by major basic protein and regulated by membrane SCF, 1898-1904
retroviral transduction efficiency of G-CSF+SCF–mobilized peripheral blood $CD34^+$ cells, 2199-2205
SCF inhibits IFNγ-induced apoptosis by up-regulation of FLIP, 1324-1328
Stem cell transplantation (SCT)
anti-CD45–mediated cytoreduction for, 2434-2439
autologous SCT in refractory Crohn disease, 2064-2066
cyclophosphamide metabolism, liver toxicity, and mortality after, 2043-2048
cyclophosphamide with lymphocyte-depleted peripheral blood stem cell support for refractory autoimmune thrombocytopenia, 71-77
development of hepatocyte-like cells in livers of mice after, 4201-4208
DLI for JMML relapsing after, 1713-1714
donor CMV status and CMV viremia after, 2067-2069
donor immunization with pneumococcal vaccine and protective responses after, 831-836
donor pretreatment with progenipoietin-1 to prevent GVHD, 2033-2042
engineering CD19-specific human cytotoxic T lymphocytes, 1637-1644
factors affecting antibody levels after allogeic SCT, 3319-3324
human CMV immediate-early mRNAemia vs. pp65 antigenemia in SCT recipients, 5053-5060
IL-7 improves CD4 T-cell reconstitution after CD34 cell transplantation in monkeys, 4209-4218
increased CMV infection after nonmyeloablative SCT (letter), 2071-2072
kinetics of MRD and chimerism in CML patients after, 469-472
late CMV central nervous system disease after, 463-465
late CMV disease and mortality after allogeneic SCT, 407-414
long-term complications after childhood SCT for AML, 1611-1619
MDS and AML after autotransplantation for lymphoma, 2015-2023
molecular response to imatinib following relapse after SCT for CML (letter), 1200-1201 (erratum, 1683)
monitoring CML after nonmyeloablative transplantations (letter and response), 5084-5085
non-T-cell–depleted HLA haploidentical SCT based on feto-maternal microchimerism, 3334-3336
nonmalignant late effects after allogeneic SCT, 3373-3385
nonmyeloablative SCT for CML in first chronic phase, 441-445
outcome of $CD34^+$ peripheral blood SCT in first chronic phase CML, 446-453
prognostic impact of unmutated V_H gene status after SCT for CLL, 2049-2053
prognostic significance of impaired recovery of EBV-specific T cells after, 4290-4297
reactivity of T cells expressing a suicide gene after T-cell–depleted SCT, 1290-1298
reduced-intensity SCT with alemtuzumab (letter), 779-780
SNP-based quantitation of hematopoietic chimerism after allogeneic SCT, 363-369
T-cell repopulation despite thymus irradiation after SCT for MM, 1891-1897
telomere length homeostasis after allogeneic peripheral blood SCT, 358-362
total lymphoid irradiation preconditioning enriches for IL-4–producing $CD4^+$ cells, 2024-2032
transplantation of unrelated-donor $CD34^+$ cells in pediatric leukemia, 1630-1636
unrelated donor SCT vs. chemotherapy for pediatric relapsed ALL, 3835-3839
unrelated SCT with reduced conditioning can induce complete chimerism and sustained remissions, 1620-1629
WT1 assay to predict and manage relapse after allogeneic SCT in acute leukemia, 1698-1704
Stem cells. *See also* Progenitor cells
combined effects of *Notch* signaling and cytokines on stem cell differentiation, 1784-1789
distribution of mesenchymal stem cells after systemic infusion in primates, 2999-3001
G-protein signaling in mobilization of, 4739-4747
generation of DCs from mouse embryonic stem cells, 3501-3508
heterologous cell cooperation in migration, homing, and engraftment of, 45-51
host stem cells selectively reconstitute missing lymphoid lineages, 4347-4354
hyaluronan and biology of, 856-862
intra–bone marrow injection in SCID-repopulating cell assay, 2905-2913
marrow frequency of rat long-term repopulating cells and species body weight, 3431-3435
novel class of $CD34^-$ cells that give rise to SCID-repopulating cells, 869-876
preservation and accumulation of hematopoietic stem cells by HES-1, 1777-1783
reversibility of CD34 expression on human stem cells, 112-118
SCID-repopulating activity of $CD34^-$ cells by intra–bone marrow injection, 2924-2931
side effects of retroviral gene transfer into hematopoietic stem cells, 2099-2114
stage of embryonic stem cell differentiation and adult neovascularization, 2675-2678
stem cell and progenitor defects in Sca-1/Ly-6A–null mice, 517-523
T cell inhibition by mesenchymal stem cells, 3722-3729
transcriptional accessibility in, 383-390
STI571. *See* Imatinib mesylate
Stroke
cardiac lymphoma mimicking myxoma presenting with embolic stroke, 4708-4710

distinct HLA associations by stroke subtype in children with SCD, 2865-2869
risk in siblings with SCD, 2401-2404
Stromal cell–derived factor 1 (SDF-1)
C3a and C3a receptor in stem cell homing responses to, 3784-3793
intracellular domains of CXCR4 in SDF-1–mediated signaling, 399-406
Stromal cells
characterization of fetal liver stroma, 2973-2982
expansion of umbilical cord progenitor cells by human telomerase catalytic subunit–transfected stromal cells, 532-540
inhibition of megakaryocytic Rap1 signaling, 1744-1751
SU5614 inhibits FLT3 and induces apoptosis in AML cell lines, 1494-1504
SU11248 is a novel FLT3 inhibitor, 3597-3605
SU11657, APL model with FLT3 mutation is responsive to retinoic acid and, 3188-3197
Suberoylanilide hydroxyamic acid (SAHA), enhancement of imatinib-induced apoptosis of Bcr-Abl–positive leukemia cells by, 3236-3239
Suppressor of cytokine signaling (SOCS), SOCS-1 hypermethylation in MM, 2784-2788
Survivin, decreased by inhibition of STAT3 signaling in PEL, 1535-1542
Syk
G-protein–coupled receptor signaling in Syk-deficient neutrophils and mast cells, 4155-4163
and Rac regulation of Akt-dependent cell survival, 236-244
Systemic lupus erythematosus (SLE), genetics of thrombocytopenic SLE, 992-997

T-cell receptor (TCR)
inhibition of TCR signaling by rosmarinic acid, 3534-3542
nonmyeloablative conditioning for BMT with bismuth-213–labeled anti-TCRαβ, 5068-5075
regulation of TCR Dβ1 promoter by KLF5, 4492-4499
TCR, pTα, and RAG-1 in T-ALL, 2693-2703
TCR^- veto cells in D^d-ζ transgenic mice, 4520-4528
T-cell receptor–B-variable (TCR-BV) gene, use in B-CLL, 1063-1070
T cells
A1 is a growth-permissive T-cell survival factor, 2679-2685
activation of influenza virus–specific T cells by plasmacytoid DCs, 3520-3526
antileukemic activity of allorestricted cytotoxic T cells, 1007-1014
antiviral CD8 T cell function in chronic viral infection, 226-235
B and T cell clonal involvement in MMM, 1981-1983
bone marrow mesenchymal stem cells inhibit T-cell responses, 3722-3729
cAMP inhibits Ras and Rap1 activation in, 998-1006
CCR4 vs. CCR10 in T_H lymphocyte trafficking, 1677-1683
CD57 expression defines replicative senescence and apoptosis of $CD8^+$ T cells, 2711-2720
DCs overexpressing CD95L elicit allospecific T-cell responses, 1469-1576
degenerate specificity of HTLV-1–specific T cells, 3074-3081
differential chemokine expression in peripheral blood T cells, 216-225
effects of B7-blocking agent and/or CsA on induction of T-cell anergy in chronic ITP, 2721-2726
endothelial induction of CCL21 in T-cell autoimmune diseases, 801-806
engineering CD19-specific human cytotoxic T lymphocytes, 1637-1644
factor VIII-specific T-cell clones in hemophilia A, 1351-1358
γδ T-cell phenotype and survival in CTCL, 3407-3412
glycosylation-dependent inhibition of CLA expression, 602-610
hTERT extends life span of $CD4^+$ T cells, 4512-4519
HTLV receptor is early T-cell activation marker, 1913-1918
human pro-B cells that give rise to macrophages, NK cells and, 4313-4321
IFN-α induces myeloblastin expression and specific T-cell response in CML, 259-264
IL-7 expands T cells in normal and SIV-infected nonhuman primates, 2294-2299
IL-10 and TGF-β induce $CD4^+CD25^-$ T cells to acquire regulatory function, 5076-5083
IL-15 effects on HIV-specific $CD8^+$ T cells, 1024-1029
immunodominant MAGE-3 CD4 epitopes, 1038-1044
immunomagnetic selection of low-affinity nerve growth factor-positive T cells for, 476-484
increased adhesiveness of $CD8^+$ T cells in multiple sclerosis, 4775-4782
in vivo induction of $CD4^+/CD25^+$ regulatory T cells, 4862-4869
LF 15-0195 enhances activation-induced T-cell death, 194-201
LFA-1 required for retention of effector CD8 T cells in mouse lungs, 4916-4922
LMP1-specific cytotoxic T cells for adoptive immunotherapy of EBV-associated malignancies, 1905-1912
modified myeloid DCs induce anergic and regulatory T cells, 3581-3589
mutual inactivation of CD4 T cells and tumor cells, 4472-4478
Pax5 determines B- vs. T-cell fate, 4342-4346
production of interferonlike cytokine limitin by, 178-185
prognostic significance of impaired recovery of EBV-specific T cells after SCT, 4290-4297
proliferation potential of $CD8^+$ T-cell subsets in response to antigen or cytokines, 4260-4266
reactivity of T cells expressing a suicide gene after T-cell–depleted SCT, 1290-1298
regulation of HTLV-I binding protein in T cells during immune activation, 3085-3092
RNA-transfected DCs induce myeloma-specific cytotoxic T cells, 977-982
role of IFN-γ–producing $CD4^+$ T cells in protection against CMV disease, 2686-2692
S1P is novel inhibitor of T-cell proliferation, 4909-4915
sensitivity of naive T cells to Fas engagement, 4022-4028
Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development, 1015-1023
T-cell epitopes in MM immunoglobulin, 4930-4936
T-cell expansion in thymoma with B lymphopenia, 3106-3108
T-cell large granular lymphocyte cells express activating killer cell receptors, 3198-3204
T-cell population phenotypically indistinguishable from $CD3^+$ lymphogranular leukemia (letter), 4643-4644
T-cell repopulation despite thymus irradiation after SCT for MM, 1891-1897
T-cell transduction by IL-7–displacing lentiviral vectors, 2167-2174
T-cell turnover in SIV-infected rhesus monkeys, 1213-1219
total lymphoid irradiation preconditioning enriches for IL-4–producing $CD4^+$ cells, 2024-2032
tumor rejection by single-chain Fv-CD28/TCR-ζ engineered T cytotoxic T cells (*see Blood* 100:3155-3163, November 1, 2002) (erratum), 3808
VEGF inhibits development of, 4878-4886
TCL1, in plasmacytoid DCs and $CD4^+CD56^+$ blastic tumors of skin, 5007-5009
TCR. *See* T-cell receptor
TCR-BV. *See* T-cell receptor–B-variable gene
Telomerase reverse transcriptase (hTERT), life span of $CD4^+$ T cells extended by, 4512-4519
Telomere length
homeostasis after allogeneic peripheral blood SCT, 358-362
in peripheral blood granulocytes after imatinib treatment of CML (letter), 375-376
and telomerase in MM, 4982-4989
Testicular proteins, SPAN-Xb in hematologic malignancies, 955-960
Tetrocarcin-A–induced ER stress mediates apoptosis in B-CLL cells, 4561-4568
TF. *See* Tissue factor
TFPI. *See* Tissue factor pathway inhibitor
TGF-β. *See* Transforming growth factor-β
Thalassemia
hemoglobin H disease, 791-800
lack of hepatic fibrosis with deferiprone in (*see Blood* 100:1566-1569, September 1, 2002) (erratum), 2460
lentiviral transduction of thalassemic cells, 104-111
phenotypic correction of β-thalassemia after lentiviral-mediated transfer of γ-globin gene, 2175-2183
related UCB transplantation in SCD and, 2137-2143
rescue from murine model of Cooley anemia by gene therapy, 2932-2939
Thalidomide, combination low-dose thalidomide and prednisone for MMM, 2534-2541
Theileria parva, B-cell transformation, Csk, and glycolipid-enriched microdomains, 1874-1881
Therapeutic trials
alemtuzumab in mycosis fungoides/Sézary syndrome, 4267-4272
augmentation of UCB transplantation with ex vivo–expanded UCB cells, 5061-5067

cardiac catheterization for pulmonary hypertension in SCD, 1257-1261
CHOP vs. CNOP in elderly patients with lymphoma, 3840-3848
combination low-dose thalidomide and prednisone for MMM, 2534-2541
cyclophosphamide with lymphocyte-depleted peripheral blood stem cell support for refractory autoimmune thrombocytopenia, 71-77
dexamethasone vs. prednisone and oral vs. intravenous mercaptopurine for ALL, 3809-3817
DLI for JMML relapsing after SCT, 1713-1714
efficacy and safety of rituximab in type II mixed cryoglobulinemia, 3827-3834
EPOCH for AIDS-related lymphoma, 4653-4659
fludarabine with concurrent vs. sequential rituximab in B-CLL, 6-14
G3139 and chemotherapy for refractory or relapsed acute leukemia, 425-432
gemtuzumab ozogamicin for relapsed pediatric AML, 3868-3871
human CMV immediate-early mRNAemia vs. pp65 antigenemia in SCT recipients, 5053-5060
imatinib in newly diagnosed patients with Ph^+ CML, 97-100
R115777 in hematologic malignancies, 1692-1697
radioimmunotherapy of non-Hodgkin lymphoma, 391-398
related UCB transplantation in SCD and thalassemia, 2137-2143
rituximab for CNS lymphomas: targeting leptomeningeal compartment, 466-468
rituximab for relapsed $CD20^+$ Hodgkin lymphoma, 420-424
rituximab in lymphocyte-predominant Hodgkin disease, 4285-4289
impact of rituximab plus CHOP on bcl-2–associated drug resistance in geriatric DLBCL, 4279-4284
survival not improved after high-dose therapy in MM, 2144-2151
unrelated cord blood transplantation for adults with advanced MDS, 4711-4713
unrelated donor SCT vs. chemotherapy for pediatric relapsed ALL, 3835-3839

Thrombin
estimating rate of thrombin and fibrin generation during CPB, 4355-4362
factor XIII activation by thrombin depends on FXIIIVal34Leu genotype (letter and response), 371-372
IQGAP2 in thrombin-induced platelet cytoskeletal reorganization, 3021-3028

Thrombin activatable fibrinolysis inhibitor in human platelets, 4844-4846

Thrombocythemia, essential
long-term use of hydroxyurea in young patients with (letter), 3749
risk factors for thromboembolic complications in (letter), 783-784

Thrombocytopenia
after treatment with GP11b/IIIa inhibitors (letter and response), 1655
antibody testing reduces incidence of roxifiban-associated thrombocytopenia, 58-63
CD40/CD154 blockade in ITP, 621-623
cyclophosphamide with lymphocyte-depleted peripheral blood stem cell support for refractory autoimmune thrombocytopenia, 71-77
effects of B7-blocking agent and/or CsA on induction of T-cell anergy in chronic ITP, 2721-2726
genetics of thrombocytopenic SLE, 992-997
Helicobacter pylori and ITP in children (letter), 1660
heparin-induced, in patients treated with subcutaneous unfractionated heparin, 2955-2959
heparin-induced (HIT)
central venous catheters, upper-extremity DVT, and, 3049-3051
how I treat HIT thrombosis, 31-37
in patients treated with subcutaneous unfractionated heparin, 2955-2959
IVIG induces dose-dependent amelioration of ITP in rodents (letter and response), 1658-1659
monoclonal IgG can ameliorate immune thrombocytopenia in murine ITP, 3708-3713
quinine-induced, target for antibodies associated with, 937-942
VWF-cleaving protease and *ADAMTS13* mutations in childhood TTP, 1845-1850

Thrombolysis
dose-dependent effects of plasmin and tPA on coagulation and hemorrhage, 3002-3007
ICAM-directed vascular targeting of antithrombotic agents, 3977-3984
modified Folts model for evaluation of antithrombotics (letter and response), 782-783

Thrombomodulin, down-regulation by oxidized phospholipids in oxidized LDL, 4765-4774

Thrombopoietin (TPO)
effects in early murine yolk sac hematopoiesis, 1329-1335
OPG and osteosclerosis in mice overexpressing TPO, 2983-2989

Thrombosis
antihirudin antibodies after desirudin for thrombosis prophylaxis for hip-replacement surgery, 2617-2619
central venous catheters, upper-extremity DVT, and HIT, 3049-3051
central venous line–related, in children, 4273-4278
chromosome 18 locus influences APC resistance and thrombosis susceptibility, 163-167
combined anticoagulant and antiselectin treatments prevent DIC, 921-928
D-dimer and risk of future venous thrombosis, 1243-1248
discrimination of polycythemias and thrombocytoses by clonality assays, 3294-3301
elevated prothrombin alters clot structure, 3008-3013
endotoxin-induced DIC and cytokine activation in protein C–deficient mice, 4823-4827
erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis, 4625-4627
estimating rate of thrombin and fibrin generation during CPB, 4355-4362
GPIIb/IIIa-mediated platelet-platelet interaction, 929-936
hemostasis and coagulation in erythrocytosis, 4416-4422
how I treat HIT and, 31-37
ICAM-directed vascular targeting of antithrombotic agents, 3977-3984
low TFPI levels increase risk of venous thrombosis, 4387-4392
lupus anticoagulants and risk of thrombosis in antiphospholipid syndrome, 1827-1832
modified Folts model to evaluate new antithrombotics (letter and response), 782-783
overexpression of platelet $P2X_1$ ion channel in transgenic mice, 3969-3976
risk factors for thromboembolic complications in essential thrombocythemia (letter), 783-784
shielding front-strand β3 of VWF A1 domain inhibits its binding to GPIbα, 1375-1383
targeting of collagen-binding site on GPVI and in vivo depletion of receptor, 3948-3952
thromboembolic events in children with ALL: prednisone vs. dexamethasone, 2529-2533
thrombogenicity of β_2-GPI–dependent antiphospholipid antibodies, 157-162
thrombus generation in von Willebrand disease under flow conditions, 915-920

Thrombospondin-2 (TSP2), megakaryocytes require TSP2 for normal platelet formation and function, 3915-3923

Thrombotic thrombocytopenic purpura (TTP)
ADAMTS13 mutation in congenital TTP, 4449-4451
VWF-cleaving protease and *ADAMTS13* mutations in childhood TTP, 1845-1850

Thromboxane A2, in collagen-induced platelet aggregation, 2646-2651

Thromboxane-prostanoid-α (TPα), $P2Y_1$ and TPα receptors in platelets, 1400-1408

Thymocytes
dexamethasone-induced apoptosis of, 585-593
IL-7 expands T cells in normal and SIV-infected nonhuman primates, 2294-2299
p38 MAPK involvement in development of, 970-976

Thymoma with B lymphopenia, T-cell expansion in, 3106-3108

Thyrotropin, mediation of bone marrow production of TNF-α by, 119-123

Tissue factor pathway inhibitor (TFPI), low levels increase risk of venous thrombosis, 4387-4392

Tissue factor (TF), Egr-1 regulation of TF and inflammatory mediators in mouse endotoxemia model, 3940-3947

Tissue plasminogen activator (tPA)
dose-dependent effects of plasmin and tPA on coagulation and hemorrhage, 3002-3007
ICAM-directed vascular targeting of antithrombotic agents, 3977-3984

TNF. *See* Tumor necrosis factor family

Toll-like receptor function in human naive and memory B cells, 4500-4504

tPA. *See* Tissue plasminogen activator

TPα. *See* Thromboxane-prostanoid-α

TPO. *See* Thrombopoietin

TRAIL. *See* Tumor necrosis factor–related apoptosis-inducing ligand

Transcobalamin codon 259 polymorphism designation (letter and response), 3749-3751
Transcription factors. *See also* specific transcription factors
AML-1A and AML-1B regulation of MIP-1α expression in MM, 3778-3783
during neutrophil differentiation in bone marrow, 4322-4332
PAR domain transcription factor regulates human *LMO2* gene expression, 4757-4764
PU.1 inactivation by AML1-ETO in t(8;21) myeloid leukemia, 270-277
Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development, 1015-1023
suppression of myeloid transcription factors and STAT induction by AML-specific Flt3 mutations, 3164-3173
ZBP-89 is a repressor of *CD11b* gene, 894-902
Transferrin receptor and transferrin receptor 2, interactions between, 2008-2014
Transforming growth factor-β (TGF-β) and IL-10 induce $CD4^+CD25^-$ T cells to acquire regulatory function, 5076-5083
Transfusion medicine
CMV infection after receipt of leukoreduced blood products, 4195-4200
complement receptor 1 inhibitors in transfusion therapy, 5046-5052
epidemiology and etiology of transfusion-related acute lung injury, 454-462
granulocyte transfusions and CMV infection (letter and response), 5091-5092
hepatocellular injury and transfusional iron overload during desferrioxamine therapy, 91-96
human blood group I antigen expression, 2870-2876
IVIG inhibits DC maturation and function, 758-765
leukocyte reduction and HTLV-I in transfusion recipients (letter and response), 370-371
monoclonal IgG can ameliorate immune thrombocytopenia in murine ITP, 3708-3713
MRI evaluation of myocardial iron during iron chelation therapy, 4632-4639
risk of hepatitis B virus infection by transfusion in Kumasi, Ghana, 2419-2425
transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment, 2426-2433
Transplantation. *See also* Bone marrow transplantation; Stem cell transplantation
alloantigen-specific suppression of mixed leukocyte reactions by DCs, 3325-3333
augmentation of UCB transplantation with ex vivo–expanded UCB cells, 5061-5067
comprehensive banking of sibling donor UCB for children with malignant and nonmalignant disease, 351-357
donor immunization with pneumococcal vaccine and protective responses after SCT, 831-836
eosinophils and severe GVHD (letter), 2073-2074
IL-10 and TGF-β induce $CD4^+CD25^-$ T cells to acquire regulatory function, 5076-5083
lymphocyte adherence to dermal endothelium in GVHD, 771-778
marrow vs. cord blood for unrelated donor transplantation, 4233-4244
murine xenotransplantation model of MPSVII, 2054-2063
target antigen distribution and outcome of adoptive cancer immunotherapy, 766-770
tolerance induction to mammalian blood group–like carbohydrate antigen, 2318-2320
unrelated cord blood transplantation for adults with advanced MDS, 4711-4713
Trichostatin A and sodium butyrate suppress osteoclastogenesis, 3451-3459
TSP2. *See* Thrombospondin-2
TTP. *See* Thrombotic thrombocytopenic purpura
Tumor necrosis factor (TNF) family
caspase inhibition augments cell death in TNF-α–stimulated neutrophils, 295-304
contributions of TNF and LT cytokines to DC development, 1477-1483
donor T cell–derived TNF required for GVHD and graft-versus-tumor activity after BMT, 2440-2445
intrinsic thyrotropin-mediated pathway of TNF-α production in bone marrow, 119-123
macrophage- and DC-dependent regulation of B-cell proliferation requires BAFF, 4464-4471
mast cell–derived TNFα induces macrophage recruitment in cutaneous granulomas, 210-215
modulation of erythroid cells by TNF, 524-531
Nur77/NAK-1 regulates TNFα-induced PAI-1 expression, 3042-3048
TNF-α induces caspase-independent cell death in neutrophils, 1987-1995
TNF induction involved in interactions with paclitaxel in myeloid leukemia cells, 3648-3657
ubiquitin inhibits TNF-α response to endotoxin, 1882-1890
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), induction of apoptosis in Ph^+ leukemia cells by, 3658-3667
Tyrosine kinase, CCR7-mediated lymphocyte homing and activation of, 38-44

UbcH5A up-regulation in hereditary hemochromatosis, 3288-3293
Ubiquitin, inhibition of TNF-α response to endotoxin, 1882-1890
UCB. *See* Umbilical cord blood
Umbilical cord blood (UCB)
augmentation of UCB transplantation with ex vivo–expanded UCB cells, 5061-5067
comprehensive banking of sibling donor UCB for children with malignant and nonmalignant disease, 351-357
expansion of umbilical cord progenitor cells by human telomerase catalytic subunit–transfected stromal cells, 532-540
human cord blood $CD34^+Pax\text{-}5^+$ B-cell progenitors, 3424-3430
marrow vs. cord blood for unrelated donor transplantation, 4233-4244
novel myeloid-like NK cell progenitor in, 3444-3450
related UCB transplantation in SCD and thalassemia, 2137-2143
STAT5a required for eosinophil differentiation of cord blood–derived $CD34^+$ cells, 134-142
unrelated cord blood transplantation for adults with advanced MDS, 4711-4713
Urokinase-type plasminogen activator, interactions with integrin $\alpha_M\beta_2$, 1582-1590

V1-69 genes, overexpression in unmutated CLL not related to aging process, 3082-3084
Vaccines
chemokine–cytokine allogeneic antitumor vaccine for neuroblastoma, 1718-1726
donor immunization with pneumococcal vaccine and protective responses after SCT, 831-836
idiotype vaccination in MM reduces clonal tumor B cells, 4607-4610
modified DNA vaccine protects against metastatic neuroblastoma, 649-654
therapeutic LMP1 vaccine for EBV-associated Hodgkin disease and, 3150-3156
tumor cell vaccines for metastatic cancer after BMT, 1645-1652
Vardenafil and sildenafil induce apoptosis of B-CLL cells, 265-269
Vascular endothelial growth factor (VEGF)
inhibition of T-cell development by, 4878-4886
modulation of VEGFR-2–mediated endothelial-cell activity by VEGF-C/VEGRF-3, 1367-1374
neuropilin-1 on hematopoietic cells regulates vascular development, 1801-1809
potentiation of megakaryocyte maturation by, 1316-1323
threshold for VEGF in developing endothelial cells, 2261-2267
VEGFR-3 and CD133 identify $CD34^+$ lymphatic/vascular endothelial precursor cells, 168-172
Vasodilator-stimulated phosphoprotein (VASP), cAMP-dependent protein kinase mediates cGMP-induced VASP phosphorylation, 4423-4429
VASP. *See* Vasodilator-stimulated phosphoprotein
VEGF. *See* Vascular endothelial growth factor
VHL gene, mutations in congenital polycythemia, 1591-1595
Virus vectors
adeno-associated virus, factor IX gene transfer to muscle in hemophilia B, 2963-2972
adenoviral
gene therapy and humoral immune response in mice, 2551-2556
high-capacity, gene therapy for hemophilia A using, 1734-1743
lentiviral
CD4-cell–specific, 3416-3423
IFN-β scaffold attachment region and chicken β-globin insulator in, 4717-4724
multiple copy integration in NON/SCID repopulating cells, 1284-1289
phenotypic correction of β-thalassemia after lentiviral-mediated transfer of γ-globin gene, 2175-2183
rescue from murine model of Cooley anemia by gene therapy, 2932-2939

T-cell transduction by IL-7–displacing lentiviral vectors, 2167-2174
transduction of B cells with, 1727-1733
transduction of thalassemic cells, 104-111
oncolytic measles viruses display antibody against CD38, 2557-2562
retroviral
gene therapy for hemophilia B, 3924-3932
gene therapy for Wiskott-Aldrich syndrome, 2159-2166
integration in preferred genomic targets of bone marrow–repopulating cells, 2191-2198
long-term results of the first ADA gene therapy trial, 2563-2569
macrophage-specific, gene therapy of ApoE-deficient mice using, 485-491
retroviral-mediated Fancc expression enhances repopulating ability of *Fancc*$^{-/-}$ stem cells, 1299-1307
retrovirus-mediated IL-7 expression in leukemic DCs generated from AML, 2184-2190
side effects of retroviral gene transfer into hematopoietic stem cells, 2099-2114
transduction efficiency of G-CSF+SCF–mobilized peripheral blood CD34^{+} cells, 2199-2205
VL30 promoter directs sustained activity in erythroid progenitors, 1798-1800
von Willebrand disease (VWD)
Arg760Cys mutation of VWF propeptide cleavage site responsible for new VWD variant, 151-156
thrombus generation under flow conditions in, 915-920
VWD type I, 2089-2093
von Willebrand factor (VWF)
interaction between VWF and GPIb activates Src kinase in platelets, 3469-3476
regions in VWF propeptide and mature VWF that enable normal VWF storage, 1384-1391
and shear-dependent p125FAK phosphorylation, 4363-4371
shear-induced platelet activation and self-association of VWF in suspension, 2637-2645
shielding front-strand β3 of VWF A1 domain inhibits its binding to GPIbα, 1375-1383
von Willebrand factor–cleaving protease (ADAMTS13)
ADAMTS13 mutation in congenital TTP, 4449-4451
desmopressin-induced changes in activity of, 946-948
mutations in childhood TTP, 1845-1850
VWD. *See* von Willebrand disease
VWF. *See* von Willebrand factor
Wiskott-Aldrich syndrome, gene therapy for, 2159-2166
WT1 gene
in murine hematopoiesis, 2570-2574
WT1 assay to predict and manage relapse after allogeneic SCT in acute leukemia, 1698-1704
X-linked sideroblastic anemia after hemodialysis, 4623-4624
YY1 is a myeloid transforming gene interfering with neutrophilic differentiation, 1111-1117
ZAP-70 expression identifies CLL subtype, 4944-4951
Zidovudine (AZT), remission by AZT-mediated inhibition of NF-κB, 2321-2327
Zinc finger proteins
Evi3 encodes an EBFAZ-related Krüppel-like zinc finger protein, 1934-1940
ZBP-89 is a repressor of *CD11b* gene, 894-902

Inside *Blood* segments are not included in this index but are included in on-line searches done at www.bloodjournal.org.